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Abstract
Recent interest has grown in regard to non-invasive testing and oral 
fluid diagnostics. The use of oral fluid allows for a mobile diagnosis 
service that is not restricted to an assigned place allowing for testing 
to be conducted from ‘bedside to roadside’. The development of our 
unique collector Seradate, an oral fluid collection device prototype 
that was designed with the intention of collecting oral fluid that is rich 
in oral mucosal transudate (OMT). OMT is an unique fluid that is 
presented from the gingival crevice and contains serum-based 
compounds. Due to low levels of OMT presence within oral fluid our 
ideas in design were formed on postulated and experimental models 
of inducing the release of OMT. The Seradate was tested alongside 
current marketed oral swabs for its effectiveness in monitoring levels 
of OMT-derived immunoglobulins present within ora! fluid. Further 
validation work was conducted on the monitoring of stress hormones 
and the determination of smoking status. Our findings showed that 
the Seradate was an adequate alternative to current marketed oral 
swabs in the monitoring of oral based constituents and with a few 
minor modifications the Seradate can be used as an alternative to 
current oral swabbing methods.
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Chapter 1
1 Introduction
Medical diagnostics have been used to monitor disease, infection 
immunisation status, hormonal imbalances and drugs using 
various fluid matrices found within the human body. The collection 
of fluid matrices for diagnosis has been simplified into 2 categories 
for the purposes of this thesis invasive collection and non-invasive 
collection. Invasive procedures are physical interventions that 
require breaking of the skin. These procedures are used in the 
collection of blood, cerebral spinal fluid and organ biopsies. The 
procedures can be restrictive in terms of compliance issues, and 
procedures require trained individuals and collection requires a 
clinical setting. Non-invasive procedures may require partial 
intervention by a third party but involve no physical breaking of the 
skin. These procedures include the collection of urine and oral 
swabbing. Non-invasive procedures are mainly self-directed and 
can be done in a more relaxed surrounding with minimal 
supervision.
Recent interest has grown in regard to non-invasive testing and 
oral fluid based diagnostics. The use of oral fluid allows for a 
mobile diagnosis service that is not restricted to an assigned place 
allowing for testing to be conducted from “Bedside to Roadside” 
(Malamud 1997; Humphrey and Williamson 2001; Vyse, Cohen et 
al. 2001; Cameron and Carman 2005; Chiappin, Antonelli et al. 
2007). With recent advancements in computational and analytical 
sciences, oral fluid samples of low sample volume and protein 
concentration can be screened for systemic disease, illicit and 
therapeutic drugs and hormones. Oral fluid testing provides ease 
of access, ease of use, patient confidentiality and acceptability 
(Cordeiro, Turpin et al. 1993; Malamud 1997; Ditto 2003; Cameron 
and Carman 2005). Patient acceptability is with reference to
i
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compliance issues where intravenous collections are problematic 
such as in the elderly, young children, haemophiliacs and venous- 
compromised individuals.
The acceptance of oral fluid as an alternative matrix to blood has 
advanced over the past 20 years. This has been linked to the 
profiling of the oral fluid proteome which is nearing completion, 
and has allowed the discovery of serum based markers within the 
matrix that are presented by oral mucosal transudate (OMT) also 
known as gingival crevicular fluid (GCF). Oral Fluid and its 
constituents have provided a variety of disease markers that are of 
local (Intra-oral) and systemic origin (Streckfus and Bigler 2002; 
Van Nieuw Amerongen, Bolscher et al. 2004; Aurer, Jorgic-Srdjak 
et al. 2005).
2
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1.1 Origins of Oral Fluid and OMT 
Oral Fluid
Oral fluid (whole saliva) is secreted from multiple salivary glands 
within the oral cavity (Figure 1.1 ).This includes major salivary 
gland secretions from the parotid gland, submandibular gland, 
sublingual gland and minor salivary glands that lie beneath the 
oral mucosa (Humphrey and Williamson 2001; Schipper, Loof et 
al. 2007).
Salivary
Glands
Parotid duct
Parotid gland
Masseter muscle
Submandibular 
gland
Tongue
Sublingual gland
Submandibular
duct
Mandible
Figure 1.1 The anatomical positioning of the major salivary glands. The parotid 
gland, the submandibular and sublingual gland. This image was modified from 
McGraw Hill Companies.
The minor salivary glands lie beneath the oral mucosa these 
include the serous von Ebner glands located within the connective 
tissue under the circumvalate papillae and the Blandin-Nuhm 
mucous glands (Humphrey and Williamson 2001).
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The consistency of oral fluid can either be serous or mucous, this 
is dependent on the involvement of specific salivary glands.((This 
is effectively a ratio of gland involvement that is accounted for by 
65%, 23%, 8% to 4% for the submandibular giand, parotid gland, 
Von Ebner gland and sublingual gland secretions in that order 
(Chicharro JL 1998; Hu, Denny et al. 2004; Chiappin, Antonelli et 
al. 2007)).
Secretions from both the submandibular and sublingual salivary 
glands enter the oral cavity through Wharton's duct. The collection 
and evaluation of the secretions from the individual salivary glands 
are useful for the detection of gland-specific pathology caused 
either by infection or obstruction (Mandel 1993; Aps and Martens 
2005). The salivary glands are formed of two specific specialised 
epithelial cell regions: the acinar and ductal regions. The acinar 
region is a hub for protein synthesis and protein secretion. Amino 
acids enter the acinar cells by active transport, and after 
intracellular protein synthesis, the newly formed proteins are 
stored in storage granules until they are released in response to 
secretory stimulation (Kaufman and Lamster 2002; Aps and 
Martens 2005). Acinar fluid secretion can occur by active transport 
of anions into the salivary lumen and the movement of water is 
propagated by an osmotic gradient from interstitial fluid into 
salivary lumen. The acinar fluid is isotonic and formed within local 
vasculature. Acinar cells are permeable to water whereas ductal 
cells are not.
Ductal cells absorb most of the Na+ and Ci' ions from primary 
salivary secretion and secrete small amounts of K+ and HC03‘ and 
some proteins. This modifies the final salivary secretion to be 
Hypotonic (Baum, 1993). Salivary secretion is maintained by the 
autonomic nervous system (parasympathetic and sympathetic).
4
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The signalling mechanism involves the binding of 
neurotransmitters acetylcholine and nor-epinephrine to plasma 
membrane receptors and signal transduction via guanine 
nucleotide-binding regulatory proteins (G-proteins) and activation 
of intracellular calcium signalling mechanisms. There are several 
routes by which serum constituents that are not part of the normal 
salivary composition (i.e. drugs and hormones) can reach saliva 
(Figure 1.2). Within the salivary glands, transfer mechanisms are 
by intracellular routes (passive diffusion) and extracellular routes 
(ultra-filtration). A serum molecule reaching saliva by diffusion 
must cross five barriers: the capillary wall, interstitial space, basal 
cell membrane of the acinus cell or duct cell, cytoplasm of the 
acinus or duct cell, and the luminal cell membrane (Aps and 
Martens 2005).
Blood
Transcellular
Interstitial
Space
Acinus/
Duct
Cell
Saliva
Passive diffusion
Paracellular
Active transport
W
Ultranitration
pH = 7.4 7.0 6.2-7.4
Figure 1.2: The transport of molecules that not part of the normal salivary 
secretion from serum to saliva is transcellular route (passive diffusion and active 
transport) and paracellular route (ultrafiltration) through tight junctions.
(Figure adapted from Haeckel and Hanecke 1996)
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Oral Mucosal Transudate
Oral mucosal transudate (OMT) is also known as gingival 
crevicular fluid (GCF), crevicular fluid (CF) and gingival fluid (GF) 
(Cordeiro, Turpin et al. 1993; Malamud 1997; Ditto 2003; Cameron 
and Carman 2005) (Figure 1.3). It has been termed as an 
inflammatory exudate or interstitial transudate. Both forms exhibit 
slight differences not only in the presence of serum based proteins 
but also elevated levels of albumin and inflammatory cytokines. 
These are linked to localised disease of the gingivae that can 
range from gingivitis to periodontitis (Griffiths 2003).
Crevicular
epithelium
Junctional
epithelium
Saliva
Gingival crevicular fluid 
Junctional epithelium 
Lamina propria 
Blood capillary
Figure 1.3: The flow of gingival fluid by which components of serum can reach 
the dental and epithelial surfaces of the mouth.
(Adapted from Malamud 1997)
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OMT production and release was postulated by Brill and Krasse, 
stating that OMT is an important component of the protective 
mechanisms of the crevicular region of the gingival sulcus (Brill N 
1958). The theory suggested that stimulation of the gingival 
margin was important for the maintenance of gingival health. To 
test this hypothesis of changes in capillary permeability healthy 
gingivae were induced either mechanically using abrasion or 
chemically with histamine. The experiments showed that 
stimulation of the gum surfaces caused an increase in the flow of 
OMT and an increase in vascular permeability. This coincides with 
natural formation of OMT within a clinically healthy gingival 
crevice. Under natural oral conditions the presence of bacterial 
plaque would result in the accumulation of high molecular weight 
molecules creating an osmotic gradient that would induce the 
release of interstitial fluid from the connective tissue to the gingival 
sulcus. This finding was supported by the application of 
phosphate-buffered saline (PBS) containing homologous serum 
albumin on the gum surface causing a 100% increase in the 
volume of OMT produced. In contrast, the application of PBS 
alone caused no such effect (Stoller, Karras et al. 1990).
The theory of OMT being an interstitial transudate was suggested 
by Alfano from the hypothesis postulated by Pashley (Alfano 1974; 
Pashley 1976). The theory suggested that OMT production is 
governed by the passage of fluid from capillaries into the tissues 
as a capillary filtrate and the removal of this fluid by the lymphatic 
system (lymphatic uptake). When the rate of capillary filtrate 
exceeds that of lymphatic uptake, fluid will accumulate as oedema 
and/or leave the area as OMT. It was also postulated that the 
initial fluid produced could simply represent interstitial fluid which 
appears in the crevice as a result of an osmotic gradient. The 
initial pre-inf lam matory fluid was considered to be a transudate,
7
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and on stimulation, this changed to become an inflammatory 
exudate (Tollefsen and Saltvedt 1980; Griffiths 2003).
The levels of OMT protein concentration shown in studies states 
that inflamed or diseased gingivae protein levels are comparable 
to the protein concentration of serum. Further analysis showed 
that proteins were significantly lower in comparison to serum, but 
with a strong co-variation between the proteins studied in the two 
fluids, suggesting that OMT represents an inflammatory exudate of 
serum. Due to the relatively small volume of OMT produced, 
especially in healthy gingivae the protein concentration was similar 
to that of interstitial fluid. This would be consistent with the 
hypothesis by Aifano that the initial fluid accumulation represents a 
transudate of interstitial fluid produced by an osmotic gradient and 
that the later fluid represents a true exudate (Aifano 1974; Griffiths 
2003). The presence of serum constituents in oral fluid are largely 
attributed to OMT outflow. The levels of serum derived proteins 
are associated with gingival health. Oral disease such as gingivitis 
and periodontitis would cause greater inflammation of the gum 
surfaces resulting in OMT that is analogous with serum and not 
interstitial fluid (Griffiths 2003). These findings are seen in 
chronically inflamed gingival tissue as healthy gingivae only 
occasionally responded to these stimuli thus suggesting an 
alternate pathological origin of OMT.
8
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1.2 The functions of oral fluid and the importance of OMT
Our main components of interest in oral fluid are saliva and oral 
mucosal transudate.(Humphrey and Williamson 2001; Chiappin, 
Antonelli et al. 2007). The use of oral fluid as a method of 
diagnosis shows a lower risk of being altered by the patient in 
comparison to urine.
The primary function of oral fluid is a lubricant, so as to keep the 
oral cavity hydrated this helps in the initial stages of digestion, the 
presence of alpha-amylase helps with the initial stages of 
digestion. The protective properties of oral fluid within the oral 
cavity include numerous antimicrobial constituents such as 
statherins that are protease inhibitors and involved in the 
maintenance of tooth enamel mineralisation, mucins are low 
molecular weight proteins that bind to bacteria and viruses to 
ensure oral cavity clearance, the lack of mucins would result in 
oral fluid to lose its resistance and the oral cavity will be more 
susceptible to inflammatory and infectious complications. IgA 
provides further anti-bacterial protection by agglutination to 
bacteria. Its origins are centred in Peyer’s patches, lymphatic cells 
of mucous and tonsils (known collectively as mucosal associated 
lymphoid tissue MALT) and iactoferrin binds to iron ions that are 
vital for bacterial survival. There are additional proteins such as 
histatins and polypeptides all of which exhibit anti- bacterial and 
anti-fungal properties.
Other components present in Oral Fluid include expectorated 
bronchial and nasal secretions, serum and blood derivatives from 
open wounds, viruses, fungi from oral flora, desquamated 
epithelial cells and food debris(Alfano 1974; Messana, Cabras et 
al. 2004; Messana, Inzitari et al. 2008). OMT has an important 
function in the maintenance of antimicrobial defence of the
9
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periodontium and the structural integrity of the junctional 
epithelium. It also acts as mediator in the transport of bacterial 
products within the periodontal environment and the outward 
movement of host derived products. OMT provides a measure of 
host mediated response to microbial plaque and its constituents 
can be analysed to measure transitions from healthy to disease 
status of the gingivae The ability of OMT to present systemic 
serum derivatives is important in measuring links between 
intra/inter oral health and systemic well being (Carneiro, Venuleo 
et al. 2012).
10
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1.3 Collection of oral fluid
The role of oral fluid and its constituents are being studied due to 
its variability between and within individuals. The collection 
procedures dictate the quantity of oral fluid collected; this process 
can be linked to Pavlov’s theory of conditional reflexes. The link 
between innate or conditioned reflex will have a direct influence on 
the volume of oral fluid released but will have no effect on overall 
consistency of fluid collected (Pavlov 1927/1960).
Unlike blood or urine oral fluid can be separated by its individual 
secretions.
Parotid gland secretions are collected with the Carlson-Crittenden 
collector that is placed at the opening of the Stenson duct and held 
in place with suction. Sublingual and submandibular secretions are 
collected using suction or by an aggregator. The secretions of 
individual salivary glands show an increase and decrease of 
particular proteins in relation to exogenous factors such as stress, 
exercise and diurnal effects.
Our focus lies in the collection of oral fluid and OMT; oral fluid can 
be collected as a stimulated sample, unstimulated sample or by an 
oral fluid collection device (OFCD).
Unstimulated oral fluid collection
Unstimulated ora! fluid can be obtained either by the drooling 
method. This is to allow oral fluid to accumulate on the floor of the 
mouth and to drip off the lower lip into a collection tube (Martin 
and Burgen 1962; Mandel 1993; Aps and Martens 2005), or the 
spiting method (expectoration), in which the subject expectorates 
oral fluid into a tube.(Martin and Burgen 1962; Aps and Martens
ii
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2005). Unstimulated oral fluid flow rate is affected by levels of 
hydration, but also by olfactory stimulation, exposure to light, body 
positioning, and seasonal and diurnal factors.
Stimulated oral fluid collection
The collection of stimulated oral fluid involves moving the tongue 
around the oral cavity, pursing of the lips and rubbing of the 
cheeks. The method of stimulation can be enhanced by chewing 
on paraffin wax, rubber bands or chewing gum and the placement 
of an absorbent pad are termed as mechanical stimulation 
methods(Granger,Schwartz et al. 1999; Dawes, Tsang et al. 2001; 
Meurman, Rantonen et al. 2002). Gustatory stimulation of oral fluid 
can also be used by the addition of lemon drops or citric acid on 
the tip of the tongue, the fluid is collected by expectoration, 
drooling, suctioning or swabbing (Granger, Schwartz et al. 1999).
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Oral fluid collection devices
Oral fluid collection devices (OFCDs) were developed to 
standardise and regulate oral fluid collected for its use in 
biomedical research and field-based screening, (Malamud 1997; 
Cameron and Carman 2005). There are a variety of OFCDs 
currently marketed specifically for the collection of oral fluid. The 
collection technique largely uses a swabbing method directed to 
gum surfaces and inner cheek. To achieve a standardised volume 
of oral fluid the collectors use absorbent food safe materials such 
as cotton and specially treated hydrophilic polymers (sintered 
plastics, fibrous polymers) to adequately collect and release oral 
fluid. Once the sample has been collected the collector is placed 
into a tube or vial to avoid user contamination. An antibacterial/ 
antifungal agent can be used for sample stability to prevent the 
actions of bacterial and salivary proteases. The sample is then 
processed for testing purposes. There are countless commercial 
OFCDs, for the purposes of the thesis we will focus on Orasure 
OFCD, Salivette OFCD, Oracol OFCD and Concateno Certus 
OFCD. These devices have been advocated for oral fluid 
collection and the testing for therapeutic drugs, drugs of abuse, 
hormones and vaccine and disease antibodies(Alfano 1974; 
Malamud 1997; Vyse, Cohen etal. 2001; Kidd, Midgleyetal.
2009; Kozaki, Hashiguchi et al. 2009; Aimela, Hidalgo et al. 2011).
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Orasure ora! fluid collection device
The Orasure oral fluid collection device is an FDA approved OFCD 
(Figure 1.4).
Figure 1.4 Orasure oral fluid collection device
The collector is composed of an absorbent cotton pad affixed to 
nylon stick. The pad is treated with a buffered salt solution (pH 
7.2) comprising of 0.1% gelatine, 3.5% sodium chloride, 0.3% 
citric acid, 0.1% potassium sorbate and 0.1% sodium benzoate). 
The pad is positioned between the lower cheek and gums, the 
salts contained within the pad create a hypertonic environment 
allowing transfer of buccal and gingival tissue interstitial fluid to 
migrate across the mucosal surfaces and be collected on the pad. 
The use of gelatine within the pad is to render irreversible binding 
of antibodies to the cotton surface. The pad is kept in place for a 
period of 2-5 minutes to allow for complete saturation and placed 
within a tube containing a preservative solution (0.5% Tween-20, 
0.01% chlorohexidine digluconate) (Cordeiro,Turpin et al.1993; 
Malamud 1997;Cameron and Carman 2005). Various studies were
14
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conducted utilising this collector and have aided greatly in the 
assessment of disease states such HIV, Hepatitis B/C and drugs 
of abuse (Cameron and Carman 2005; Langel.Engblom et al. 
2008; Chang, Cohen et al. 2009).
Salivette
The Salivette was developed by Sarstedt AG & Co, it is an 
absorbent cylindrical collector composed of cotton, polyester or 
polyethylene (figure 1.5). Oral Fluid is collected by placing the 
cylindrical collector under the tongue or against the cheek. Upon 
saturation the collector is placed into a tube for transport prior to 
testing. It uses have been associated with the monitoring of serum 
free cortisol present within oral fluid, unbound cortisol reflects 
actual cortisol levels within the body and is a better indicator than 
its serum counterpart (Krueger, Breunig et al. 1996; Strazdins, 
Meyerkort et al. 2005; Grdschl and Rauh 2006).
Figure 1.5 Salivette collection device
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Oracol
The Oracol saliva collection device was developed by Malvern 
Medical Developments Ltd (figure 1.6). The Oracol test kit has 
been designed to collect OF from patients. The kit consists of an 
absorbent foam swab, its uses have been linked with the 
monitoring antibodies in the detection of HIV, hepatitis A and B, 
mumps and rubella and the assessment of cortisol levels in 
response to stress.(Vyse, Cohen et al. 2001; Morris, Cohen et al. 
2002; Langel, Engblom et al. 2008). The sample is collected either 
by centrifugation or compression of the foam pad.
Figure 1.6 Oracol saliva collection device
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Concateno Certus
The Concateno Certus collection device is composed of an 
absorbent material that is attached to a nylon handle (figure 1.7). 
The device is used in the same manner as the Orasure OFCD. 
The Certus has a distinct difference in comparison to the other 
listed collectors as it has a volume adequacy indicator that is 
incorporated into its handle, that changes from white to blue once 
sufficient oral fluid is collected (approximately 1ml). The collector 
is then placed into a vial containing preservative. The Certus 
OFCD is unique in its processing as it doesn’t use centrifugation 
as its method of extracting collected oral fluid, as the constituents 
within the preservative help to leach out oral fluid compounds. The 
uses of the Concateno Certus have not been listed in the 
literature.
Figure 1.7 Concateno Certus collection device
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1.4 Collection of OMT
OMT collection is a non-invasive procedure and requires dental 
expertise to prevent any trauma to the patient. There are several 
collection techniques that have been employed for the collection of 
OMT each technique has its distinct advantages and 
disadvantages. The techniques can be divided into three methods.
Gingival washing method
The gingival crevice is perfused with an isotonic solution (Hanks’ 
balanced salt solution) of fixed volume. The fluid collected then 
represents a dilution of crevicular fluid and contains both cells and 
soluble constituents such as plasma proteins. The technique can 
be applied to an individual site or group of sites that can divided by 
into 2 groups of healthy and unhealthy gingivae. The sample is 
collected by aspiration. As complete sample collection cannot be 
guaranteed an accurate quantification of OMT volume or 
composition is not possible as a dilution factor of the final collected 
sample cannot be determined (Oppenhei.Fg 1970; Skapski and 
Lehner 1976; Griffiths 2003)
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Capillary tubing and micropipettes
The collection site is dried with cotton rolls, capillary tubes of 
known internal diameter are inserted into the entrance of the 
gingival crevice. OMT from the crevice migrates into the tube by 
capillary action and because the internal diameter is known the 
volume of fluid collected can be accurately determined by 
measuring the distance which the OMT has migrated. This 
technique appears to be ideal as it provides an undiluted sample 
of ‘native’ OMT whose volume can be accurately assessed. 
However, it is difficult to collect an adequate volume of OMT in a 
short period, unless the sites are inflamed and contain large 
volumes of OMT. To collect a reasonable volume of fluid may, in 
some instances, mean that collection times from an individual site 
may exceed 30 minutes and, even then, adequate samples from 
healthy crevices may be impossible to obtain. It is difficult to 
conceive that holding a capillary tube at the entrance to a gingival 
crevice for such lengthy periods ensures an atraumatic collection. 
A further complication of this technique is the difficulty of removing 
the complete sample from the tubing. This requires a jet of air, 
passing a larger fixed volume of a diluting solution through the 
capillary tube or by centrifugation of the tube (Sueda, Bang et al. 
1969; Griffiths 2003).
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Absorbent filter paper strips
This is the most common form of collecting OMT the advantages 
of the technique are that it is quick and easy to use, and can be 
applied to individual sites of interest. The methods of collection are 
divided into two forms the intra-crevicular and extra-crevicular 
technique.
The former involves insertion of the filter strip into the gingival 
crevice, whereas in the latter the filter strip is laid atop of the 
gingival crevice region. The intra-crevicular method is the method 
used most frequently and can be further subdivided depending 
upon whether the strip is inserted just at the entrance of the 
crevice or periodontal pocket (superficial) or whether the strip is 
inserted to the base of the pocket or ‘until minimum resistance is 
felt’ (Deep) (figure 1.8).
Figure 1.8: An illustration of the positioning of paper for the filter paper strip 
method of collection (a) Extra crevicular (b) Intra crevicular (Superficial)
(c) Intra crevicular (Deep). Modified from Griffiths GS 2000.
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In shallow pockets or healthy crevices both intra and extra- 
crevicular method would represent the same volume. The amount 
of OMT collected on a strip can be assessed by the distance the 
fluid had migrated up the strip. This is often taken as a simple 
linear measurement, but a more accurate value is achieved by 
weighing the filter paper before and after collection. (Loe and 
HoImpede.P 1965; Griffiths 2003)
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1.5 The profiling of oral fluid proteins
Oral fluid contains a vast array of proteins that are linked to the 
homeostatic maintenance of the oral cavity. Most proteins and 
peptides present within oral fluid undergo a complex series of 
molecular processes, which ultimately define their structures. The 
onset of these processes occurs at the biosynthetic level within the 
gland, while terminal processing of the protein/peptides takes 
place after secretion into the oral cavity, in the lifetime of a salivary 
protein, four principal phases can be distinguished(Helmerhorst 
and Oppenheim 2007).
• Phase 1 consists of the basic cellular process of protein 
biosynthesis, based on its genetic blueprint
• Phase 2 is characterized by intracellular post-translationai 
modifications prior to secretion of the protein into the ductal 
system.
• Phase 3 consists of modifications incurred during secretion 
and transit through the ductal tree.
• Phase 4 represents extensive modifications to salivary 
proteins after their release into the non-sterile environment 
of the oral cavity. This last phase has profound 
consequences for the proteome of oral fluid, since the 
population of proteins and peptides undergoes continued 
modifications in the time span between entry into and 
clearance from the oral cavity.
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The definition of the oral fluid proteome is therefore highly 
variable, dependent on time and the nature and amounts of agents 
capable of protein/peptide modifications.
The collection of oral fluid and the monitoring of its proteins have 
been of great interest to scientists on mapping the oral fluid 
proteome (oralome). Various studies have been conducted to 
evaluate proteins present within oral fluid. Oral fluid composition is 
subjective to change intra and inter individually, studies have been 
conducted to map protein secretions from individual salivary 
glands and OMT .Oral Fluid proteins are susceptible to 
degradation upon release from the oral cavity, to improve stability 
they are treated with protease inhibitors until they can be 
processed. The maintenance of limiting degradation of collected 
samples in profiling studies is to limit the presentation of degraded 
that would not be present within oral fluid in vivo (Amado, Vitorino 
et al. 2005; Messana, Inzitari et al. 2008).
The profiles of oral fluid proteins have been analysed using 2D gel 
electrophoresis for qualitative measurements and quantitation has 
been conducted using LC/GC mass spectrometry. 2D gel 
electrophoresis is used to screen oral fluid proteins and profiles, its 
limitations lie in presentation of high molecular weight proteins 
such as alpha-amylase and albumin which can lead to smearing 
and distortion of the final profiles and cause inter-variability 
between gel profiles. To eliminate this problem several methods 
have directed to the use of effectively removing these proteins 
from the samples (Amado, Vitorino et al. 2005; Krief, Deutsch et 
al. 2011 ).High molecular weight proteins that are transferred in 
oral fluid that are usually of OMT origin are the systemic 
immunoglobulins and albumin (Hu, Loo et al. 2007).The protein 
content of OMT is signified by the level of insult to the gum 
tissues, within normal gingivae they account for a presence of
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30% of serum based proteins as opposed to a presence of 70 % 
found in periodontic patients. The analysis of GCF proteins and 
markers for disease is usually hindered by the presence of large 
molecular weight proteins such as albumin and immunoglobulins, 
which are presented in oral fluid by OMT Outflow (Carneiro, 
Venuleo et al. 2012).
24
Chapter 1
1.6 Oral fluid and assessment of disease
Oral fluid and systemic disease
Autoimmune disease is defined by a failure in the autoimmune 
system that can lead to organ damage. The difficulty in diagnosis 
lies in the uncertainty of its origin. Sjorgren's syndrome is a 
common chronic, autoimmune disorder characterized by salivary 
and lachrymal gland dysfunction, serologic abnormalities, and 
multiple organ-system changes. Viruses such as HTLV-1 play a 
role in the pathogenesis of disease Sjorgren’s syndrome can be 
divided into primary and secondary forms. The primary form only 
affects lachrymal and salivary tissue and the secondary is linked to 
SLE, rheumatoid arthritis and vasculitis. The effects of Sjorgren’s 
show hypo salivation, causing a decrease in levels of saliva. The 
effects of hyposalia are extenuated on the tongue, mucous 
membranes, causing atrophy to papillae, resulting in drying and 
reddening of the oral mucosa. The biomarkers that are presented 
in blood and oral fluid such as IL-6, TNF-alpha, and a range of 
antibodies have been studied, but this has been largely 
unsuccessful due to a lack of specificity to the presentation of the 
disease. Recent advances in protein chip technology showed 
raised levels of lactoferrin, cystatin C and a decrease in alpha- 
amylase and carbonic anhydrase in Sjorgren’s sufferers. Further 
monitoring of OMT and salivary markers would potentially provide 
a diagnostic guideline for maintenance of this disorder (Kalk, 
Vissink et al. 2002; Chiappin, Antonelii et al. 2007).
Cardiovascular disease is a major cause of death world-wide. 
Markers that are present in oral fluid can be a useful predictor in 
the monitoring of cardiac health. This would be useful in
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postoperative follow-up among patients undergoing cardiovascular 
surgery. Salivary alpha amylase is an ideal marker as studies 
have shown that there is a direct link between raised levels of 
alpha-amylase and heart rate upon the induction of stress. There 
is a positive relationship between sympathetic nervous activity and 
corresponding measurements in alpha-amylase (Putignano, Toja 
et al. 2003)
Oral fluid and viral diseases
In terms of HIV, production of antibodies directed toward specific 
viral protein epitopes, and the development of technologies 
capable of measuring these proteins, have facilitated the use of 
testing for HIV infection in oral fluid. Measuring antibodies directed 
to HIV that are present in oral fluid by ELISA and confirmatory 
western blotting, has shown serum sensitivity and specificity.
Oral fluid can be used to measure p-2- microglobulin and/or 
soluble tumor necrosis factor a-receptor levels, and thus assess 
the disease activity in patients with HIV infection or other chronic 
inflammatory disease states.
In addition to the above determinations, Oral fluid has also been 
used for the measurement of other blood borne viruses including 
Hepatitis C and Hepatitis B (Bull, Kimmance et al. 1989; Malamud 
1997; Vyse, Cohen et al. 2001; Cameron and Carman 2005; 
Landrum, Wilson et al. 2005).
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Oral fluid and oncology
With the anatomical proximity of saliva to both pre-malignant and 
malignant oral neoplasms, oral fluid provides a unique window for 
the screening of these lesions. As a great number of cancers are 
related to inactivity of the p53 suppressor gene, this leads to many 
malignant forms of cancer to develop.
The study of CA-125, a glycoprotein complex that is an often-used 
marker for ovarian cancer was compared by monitoring oral fluid 
concentrations among healthy controls, women with benign 
lesions, and those with ovarian cancer, found a significant 
elevation in CA 125 concentration among those with ovarian 
cancer. This suggests that the use of an oral fluid CA-125 assay 
can provide diagnostic sensitivity and specificity to that of a serum 
based assay.
Studies using different oncologic markers have also demonstrated 
that saliva testing may be useful in breast cancer detection 
measured by elevated levels of CA 15-3 and epidermal growth 
factor (EOF) receptor. The protein product of the oncogene c- 
erbB-2, also known as HER-2/neu, is elevated in the oral fluid of 
women diagnosed with breast cancer. The studies on this oral fluid 
marker are reliable and could ideally be used to monitor levels in 
patients during post-operative follow up (Tabak 2001; Li, St John 
et al. 2004).
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1.7 Oral fluid and drugs of abuse
The use of oral fluid in monitoring of therapeutic and illicit drugs is 
in the process of replacing urine as a non invasive method of 
testing. With the easy passage of free-unbound drugs in oral fluid 
from serum, the monitoring of parental drugs can often be 
monitored with a short space of time from administration, the 
presence of cocaine and amphetamines can be measured in oral 
fluid prior to the availability in serum due to the basic nature of the 
drugs (caused by ion trapping which is dependent on the 
differences of oral fluid pH in comparison to blood) (Bosker 2009). 
The concentration levels of drugs and their metabolites can be 
effectively monitored within hours of administration and over an 
extended period of time that is mainly dependant of the rate of 
metabolism.
Barbiturates are sedatives used to treat convulsions and induce 
anaesthesia, they are subdivided into two groups’ short acting 
amobarbital and long acting phenobarbital, and both are addictive 
drugs and can be used illicitly. Amobarbital levels in oral fluid can 
be measured up to 50 hours post administration (Inaba T 1975 , 
DilliS 1980).
Cannabis is a psychoactive substance taken from Cannabis 
sativa; cannabis enters the body via smoking. Its levels in oral 
fluids are relatively low, which is ascribed to the smoking rather 
than active transport by saliva. In recent studies, it has been 
shown that it is possible to detect cannabis from oral fluid roughly 
30 minutes after passive inhalation (Niedbala RS 2001).
Cocaine is a local anaesthetic and vasoconstrictor present in large 
amounts in the coca plant. In oral fluid, cocaine can be detected 
after all forms of administration, however mainly after smoking and
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intranasal administration. The levels in saliva last roughly one hour 
after intake after which they are reduced to comparable levels 
found in blood (Jufer R 2006, Cone EJ 1997).
Nicotine is an alkaloid found within tobacco products. It is 
metabolized in the liver into cotinine and 3-hydroxycotinine. These 
two metabolites are measured in oral fluid to determine the 
intensity of smoking (and use of tobacco products) (Cone EJ 
2007).
Codeine is a drug used for suppressing pain and coughing, it is 
metabolized by oxidation into morphine. Most often, it is 
administered orally, and can be used in combination with other 
drugs. A dosage of 60-120 mg of codeine is detected in oral fluid 
after 1 hour with a maximum concentration after 1.6-1.7 hours 
(Kim I 2002). The concentration of codeine in oral fluids is 3-4 
times greater than its counterpart in plasma (Shirtcliff and 
Marrocco 2003).
Oral Fluid testing does have disadvantages in drug testing as 
drugs can cause hyposalivation (reducing sample volume) limiting 
sample volume. The concentration levels of drugs are lower in oral 
fluid in comparison to urine and are also open to contamination 
from food and bacteria within the oral cavity (Bosker 2009, Huestis 
2004).
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1.8 Overview
Oral fluid diagnostics and the use of non-invasive oral fluid 
collection devices have been used to monitor antibodies directed 
to viral insult and immunisation but also provide potential 
screening for localised/ systemic disease markers and substance 
abuse. This process can only be furthered by a better 
understanding of all oral fluid constituents and what they can tell 
us.
The developments in oral fluid collection and standardisation will 
help in the development of better screening methods and enable 
us to look for more elusive markers presented with this novel 
unique diagnostic matrix.
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Chapter 2
The development of Seradate: an oral fluid collection device 
2.1 Introduction
Our mission statement was to create a new oral swab that would 
allow collection oral fluid sample of higher OMT content to existing 
OFCDs. The name of our collector was termed Seradate; this was 
a combination of the words serum and transudate. These would 
be the components on interest that would be collected.
Normal oral fluid collection is conducted by drooling saliva into a 
tube; this method of collection is variable and user dependant. By 
using an OFCD oral fluid collections can be standardised for their 
use in assessments conducted in routine clinical, field-based and 
experimental applications.
Post sample collection procedures are also important as the oral 
fluid samples contain a valuable number of testable proteins, 
these are at risk of degradation by the presence of bacterial and 
saliva based proteases(Streckfus and Bigler 2002; Chevalier, Hirtz 
et al. 2007; Schipper, Loof et al. 2007). The effects of degradation 
and post sample processing of oral fluid will be reviewed in 
chapter 4.
There are numerous OFCDs and their individual methods of 
collection have shown properties of concentrating oral fluid 
samples prior to testing (Vyse, Cohen et al. 2001; Chevalier, Hirtz 
et al. 2007; Kozaki, Hashiguchi et al. 2009). Samples collected by 
an OFCD also appear less viscous and turbid in comparison to 
drooled oral fluid, making the testing of the fluid easier and 
reducing volume related errors in pipetting. The standardisation 
and collection of oral fluid has been investigated in literature,
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systematic reviews by Crouch et al have highlighted a necessity 
for the standardisation of volume of oral fluid collected to remove 
ambiguity in final concentration of compounds in the collected 
samples (Crouch 2005).
Oral fluid is composed mainly of water and protein (the proteins 
present are composed of salivary based proteins, OMT and oral 
flora). Advances in proteomics and oral fluid protein profiling, have 
shown that OMT based markers can be successfully used in 
monitoring disease states within the body. The level of OMT 
outflow in normal healthy gingiva is relatively low and its levels are 
of serum transudate levels. An elevation in OMT and its protein 
content is evident in inflamed and periodontally challenged 
gingivae. In order to collect a sample of higher OMT protein 
content, we aim to use theories outlined in the literature that will 
exhibit a mixture of 2 definitions of OMT properties that are serum 
transudate and inflammatory exudate.
As the field of non-invasive testing is a platform for cost-effective 
screening at a large scale, it has a potential use for field based 
medicine and in low maintenance medical clinics. Marketed 
OFCDs use a method of collection, that involves swabbing of the 
gum surfaces and removal of the collector once saturated. The 
OFCD construct in its simplest form is a pad that is affixed to a 
plastic handle. The collectors vary in size and shape and their 
application is uniform.
The absorbent materials of OFCDS are subjected to a battery of 
tests that include their suitability to be placed in the oral cavity, 
and to collect and release oral fluid and its measurable 
compounds. The composition of the materials range from simple 
cotton based materials to laser treated sintered plastics. All
32
Chapter 2
materials used show hydrophilic properties and have a high affinity 
for absorption and release of water and oral fluid alike. The 
suitability of the placement of the material within the oral cavity 
comes under user compliance; the material should not be too hard 
or abrasive in nature that may result in injury. The materials used 
all share an ability to absorb and release oral fluid, but the extent 
of release is usually governed by effective processing of the 
sample after collection and also the sensitivity of the oral fluid 
assay used. The retention of oral fluid in the material after 
processing may limit the availability of unbound proteins for 
testing.
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2.2 Aims
The aims are to show the development of the Seradate OFCD 
from early concepts to working prototype. Each stage of 
development will be discussed and the reasons that led to the final 
development of the Seradate OFCD prototype.
The absorbent materials for the swabbing function of the Seradate 
will be reviewed. The materials all underwent tests for their ability 
to collect and release fluids and also their final fluid retention.
To simulate the collection of OMT-rich oral fluid, the materials 
were tested for collection and release of IgG of known 
concentration. IgG is predominantly present in low quantity in oral 
fluid and is regarded as a surrogate marker for OMT. The levels of 
IgG retention within each of the tested materials provides a 
percentage of un-testable content trapped within the material.
A questionnaire comparing the Seradate against current OFCDs 
will be used to show user compliance and highlight any potential 
limiting factors in the prototype OFCD.
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2.3 Section A: Design and prototyping Seradate
Prerequisites of Seradate collection device
In order to create an OFCD that would fulfil the needs of adequate 
OMT-rich fluid collection, certain prerequisites were established as 
a guideline to completing our goal of creating an OFCD.
Simplicity
The collector should be self-explanatory for its intended use. The 
simplicity of design dictates its use as an oral applicator. The final 
design of Seradate should aim to achieve this.
Patient acceptability
The collector should be patient friendly and marketed as a non- 
invasive means of collection. The acceptance of the OFCD by the 
end user is of great importance.
Ergonomic design
The collector should be streamlined for its manner of use. The 
collector should not have any unnecessary attachments and its 
size and shape should adequately fit within the mouth of an adult.
Aesthetics
The collector should be pleasing to the eye as it is a potential 
commercial property. This point shares its basis with patient 
acceptability. The OFCD should be non-threatening and should be 
visually directive of its non-invasive use.
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Health and hygiene
The collector should be sterile and absorbent materials used 
should be inert and of food safe quality. This is of paramount 
importance as with all medically related instruments, it should 
conform to basic hygiene.
Sample volume
The collector should collect a greater volume of OMT that is 
comparable to commercially available OFCDs. This is a potential 
marketing point. As OFCDs provide easier and less messy method 
of collection, the level of fluid collected is a lot lower in comparison 
to its invasive counter parts. By collecting a greater volume, this 
will reduce the requirement for repeat testing or secondary sample 
collection.
Sample integrity
Post collection the OFCD should be stored appropriately prior to 
analysis. Sample integrity will be reviewed in more detail in 
chapter 5. Oral fluid sample storage conditions post collection is a 
key component, if left in non-standardized conditions this often 
results in sample degradation.
Low production cost
The cost of production should be low as possible to improve 
commercial viability of the OFCD. An overall lower production cost 
would yield a greater profit should the OFCD be marketed.
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Seradate: Stage 1 concepts 
The toothbrush concept
The initial concept of the Seradate resembled that of a standard 
toothbrush. The design was chosen to induce familiarity to the 
user and its proposed use would be self-explanatory (figure 2.1). 
The functional use of a toothbrush is to clean the surface of the 
teeth by a rubbing/ abrasion method. This procedure could 
potentially be mimicked to induce partial trauma to the gum 
surfaces to promote the release of OMT, this form of collection is 
currently used by many OFCDs (such as Orasure and Oracol).
The toothbrush handle shows aesthetic and ergonomic design this 
would allow the collector to be held comfortably within the oral 
cavity during sampling. The design of the toothbrush is ideally 
suited for an OFCD but resembles the properties of current 
marketed devices. The manner of oral fluid collection would be 
similar to that of Orasure and Oracol OFCD.
Figure 2.1 The toothbrush concept. The conventional head has been replaced 
by an absorbent pad. The handle will help induce familiarity with oral fluid 
collection.
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The suction concept
The toothbrush concept could be supplemented with suction; this 
could potentially promote the uptake of a sample volume that is far 
greater than that achievable by swabbing. The limitations of 
swabbing are sample volume collected is dictated by the amount 
of material used. The Integration of this method with abrasion of 
the gum surfaces could increase OMT release and allow a greater 
final sample volume to be collected (figure 2.2). The level of 
suction required for the procedure would be variable and 
subjected on an individual basis this would include age and 
current gum health. The methods of suction that can be used 
would include manual suction by hand pump or automatic suction 
using a motorised pump (similar to that used in an electronic 
toothbrush). The collected sample can then be siphoned into a 
separate container.
Figure 2.2 A motorized addition to the toothbrush concept in figure 3.1. The 
handle is hollow to allow easy passage of collected oral fluid that can be 
siphoned into a separate container.
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Stage 1 design
The stage 1 design for the prototype resembled the concept below 
(figure 2.3). The proposed use of suction and hand pump would 
not be viable for on-field screening, and the additional cost of the 
unit would greatly reduce its potential marketable value. The 
design would therefore mimic that of current marketed OFCDs, 
thus giving it the ability to collect an oral fluid sample that exhibits 
OMT properties. As the compound of interest is OMT a more site 
specific design would be better suited to the collection of OMT, a 
new concept would be required that would help induce the release 
of OMT and its effective collection.
Figure 2.3 Prototype design for Seradate OFCD
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Seradate: Stage 2 concepts 
The dual mouth guard concept
The outflow of OMT is localized around the gingival crevice and its 
surrounding surfaces. This led to the suggestion of shell-like 
construct to cover the teeth and gums, as OMT is present in all 
oral fluid samples its final concentration is lowered by saliva 
dilution. The closest similarity to this idea is seen in the dual mouth 
guard, this covers both the upper and lower portions of the gums. 
This will enable collection from two sites by a single collection, 
thus reducing the requirement for multiple sample collection for 
testing purposes. The primary function of the mouth guard is to 
protect the mouth in occasions of blunt trauma induced by various 
sporting activities including boxing, football etc. The mouth guard 
encloses the teeth and gums from the rest of the oral cavity. The 
isolation of a region within the oral cavity would permit specific 
collection resultant in enriched OMT collection. The manner of 
collection will involve the mastication process (biting down) on the 
mouth guard surface against the teeth and gums, to induce mild 
trauma to the gingival surfaces, leading to the release of OMT.
The size of the dual mouth guard would affect the collection 
purposes with potential user mediated contamination. To make 
use of this concept a selected portion of the oral cavity would be 
targeted and not the entire oral cavity. The two suggested regions 
of placement were the front teeth and the molar/premolar region. 
The regions were chosen to maximise both comfort and ease of 
use. The final area for collector placement was decided to enclose 
the molar/premolar region as this would be more comfortable to 
the user.
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Stage 2 design
The design was constructed with the aid of Russell Bland 
(freelance designer).The design has taken its inspiration from the 
dual mouth guard concept (figure 2.4). The measurements for the 
device head were taken from different sets of dentures provided 
by the University of Liverpool Dental School. Accurate 
measurements were made using callipers to find approximate 
dimensions of the sampling head to allow comfortable placement 
in the mouth. The handle design was taken from the toothbrush 
to induce familiarity and features a separation point. This is 
required to separate the head into an adequate tube minimising 
contamination of the collected sample and also protects against 
contact via other uses.
Figure 2.4 Stage 2 Seradate design
Patent number GB 0802710.4 (schematic drawn by Russell Bland)
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The proposed composition materials for the device are two 
separate parts. The head portion would be composed of a flexible 
soft hydrophilic treated polymer either in the form a sintered plastic 
or fibre (polyethylene, polyurethane, polyolefin) as this would be 
the point of primary contact for the capturing OMT. The texture 
and consistency of the material would be evaluated to ensure 
comfort to the user. The composition of the exterior portion would 
use a hydrophobic treated polymer sintered plastic or fibre 
(polyethylene, polyurethane, polyolefin) to repel any excess saliva 
produced within the oral cavity.
The head of the device has an H-shaped design to accommodate 
both the upper and lower gums to allow for greater sample 
collection.
The Inner head portion
The inner head portion would feature protrusions for the following 
reasons (figure 2.5)
Figure 2.5 An outline of the head of the stage 2 Seradate
1. An increase in surface area to contact area ratio between 
the gum surfaces and the absorbent pad. To expose 
material to the gum surface in a shorter period of time.
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2. The protrusions would allow for adhesion via contact of 
teeth to the surrounding material. This has the benefit of 
ensuring that the device shows minimal lateral movement 
and will allow standardised use amongst a variety of users.
3. The protrusions will engage the gingival surface through the 
actions of biting. This stimulation will lead to the release of 
OMT.
The head of the device is composed of an upper and lower 
portion. To allow samples to be taken from both upper and lower 
portions of the oral cavity reducing the need of multiple samples to 
be taken. The cross-section of the device has a bite plate to 
engage the gingival sulcus of the buccal cavity and is composed of 
a hydrophilic polymer.
Stage 2 prototype
The final design was made into a prototype using a composite of 
high density polyethylene. It was evident that even with the 
relevant dimensions being made available from a variety of 
dentures taken from a normal adult mouth; the head of the 
construct was too large and cumbersome to be easily placed 
within the oral cavity in a comfortable manner, as both upper and 
lower gum surfaces were engaged, this limited its proposed use. 
One of the main flaws of the design was not taking into 
consideration the opening of the mouth, as the head of the 
collector only took into account average sizes of teeth and gum 
surfaces. The concept of a dual mouth-guard is promising and 
may work if the size of the head is reduced.
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Seradate: Stage 3 concepts 
Mouth guard concept revisited
Using the concept described at stage 2, the idea of shielding the 
area of collection was retained (region specific for OMT collection) 
and the design concepts were re-drafted in collaboration with the 
Department of Engineering at the University of Liverpool (two 
students from the school of engineering and design were recruited 
and supervised throughout this procedure). This produced a 
design that could be finally tested. Figure 2.6 shows how the idea 
of using mastication and abrasion was re-assessed. The idea was 
shifted from targeting the upper and lower gums surfaces to 
focussing on the lower gum region to allow for greater comfort and 
access of the collector within the oral cavity, the stages of design 
can be seen in figures 2.7 and 2.8.
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Chapter 2
Stage 3 Design
The collection site of the Seradate would use the lower (inferior) 
gum surface as its main area of sample collection. As the 
proposed method of collection involves both abrasion and 
mastication the shielding on the Seradate head would reduce 
further dilution of the collected sample by saliva (figure 2.9).
ABC
Figure 2.9 Seradate stage 3 design. (A )Longitudinal view (B) Anterior View (C) 
Posterior View. The designs were produced using ProEngineer software (By 
Abadur Rohman and Matt Wilson. University of Liverpool
The targeted regions of the lower gums would provide adequate 
shielding from parotid secretions that would be released upon 
inducing the mastication process. The handle design was altered 
to allow more flexibility in the handling of the collector as the rigid 
nature of the original design would not allow easy manipulation of 
the collector once placed into the oral cavity.
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Stage 3 Prototype
The prototype of the Seradate was made out of flexible 
polyurethane to allow for easier biting action (Figure 2.10).
Figure 2.10 The final images of Seradate collection device
The collector was manufactured by MNL (Malcolm Nicholls 
Limited). The mechanism of action would be to bite down on the 
head to cause the lateral sides of the collector to protrude outward 
when pressure is applied and contract when pressure is released 
this continuous agitation of the gum surface would lead to partial 
abrasion of the gum surfaces and facilitate the release of OMT. 
The proposed movement of the device head would form a 
temporary capsule around the gum region of interest and the 
absorbent interface would be shielded from parotid secretions, this 
would reduce OMT dilution of the final collected sample. The 
handle design was changed from the initial toothbrush handle to 
accommodate for flexibility. The absorbent material was placed 
under the lips of the device. The Seradate prototype was tested 
alongside current marketed OFCDs for its ability to collect and 
release oral fluid (chapter 3) and its ability to release oral fluid 
components (Chapter 3, 5, 6).
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2.4 Section B: Seradate absorbent materia! tests
Having developed a testable prototype we looked at various 
materials that could be adequately placed within the oral cavity 
that are able to collect and release oral fluid. The test materials 
used in our assessment were obtained from Porex (Germany) and 
Filtrona Fibertec (Germany) (Table 2.1). The materials chosen for 
use were specifically engineered for oral fluid collection and all 
showed characteristics of wicking. Wicking is also known as 
Capillary attraction, or capillarity, it is the ability of a fluid to flow 
through narrow spaces without the assistance of, and in opposition 
to external forces such as gravity. This occurs because of inter- 
molecular attractive forces between the fluid and solid surrounding 
surfaces and is a combination of surface tension (which is caused 
by cohesion within the liquid) and adhesive forces between the 
fluid and material causing the fluid to rise.
Each of the test materials were laser treated to induce optimal 
hydrophilic properties.
The tested materials were sintered polyethylene and polyolefin. 
Sintered plastics are characterized by high purity, uniformity and 
stability; this lowers its chances of falling apart in the mouth. 
Sintered plastics can formed to specific pore sizes which would be 
very useful in oral fluid collection, so as to reduce sample 
concentration errors.
Polyolefin are fiber-based materials that do not provide specific 
porosity as witnessed in sintered plastics. Polyolefin are not as 
coarse and softer in comparison to sintered plastics and can be 
more easily molded to fit specific shapes.
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Each of the materials was tested for their ability in the retention 
and release of water/saliva and their final percentage retention 
after processing. To test the materials for monitoring oral markers 
each material was also tested for the uptake and release of IgG (A 
surrogate marker for OMT).
Material Composition Comfort* Supplier
BNW 1 Bonded polyolefin fibres 
hydrophilic surface finish
Good Filtrona
Fibertec
BNW 2 Bonded polyolefin fibres 
hydrophilic surface finish
Good Filtrona
Fibertec
D3527G D3727g bi-component
Hydrophilic Nylon/ PET
Good Filtrona
Fibertec
XS-1 1.5 mm thick 20-60 pm 
hydrophilic sintered plastic
Poor Porex
XS-2 1.0 mm thick 20-60 pm
hydrophilic sintered plastic
Poor Porex
XS-3 1.0 mm thick 40-100 pm
hydrophilic sintered plastic
sheet
Poor Porex
XMF-1 sintered plastic sheet Poor Porex
T3 sintered plastic sheet Poor Porex
Table 2.1 Absorbent materials tested for use in the Seradate OFCD prototype. 
*The level of comfort was measured via placement in mouth.
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2.4.1 Materials & methods used to test materials
Standardising absorbent materials used
To standardize our testing of the absorbent materials, each tested 
material was cut to measure 3cm*3cm square, the thickness of 
each material accounted for and material was weighed (dry 
weight). The materials were placed individually into 10 ml of 
distilled water to ensure complete saturation and final-weight 
recorded (final mass). The time period allowed for complete 
saturation was approximately 2 minutes; this was to ensure that all 
materials tested were fully saturated. The volume collected was 
determined as follows
Volume collected (pi) = Final mass (pg) - Dry weight (pg)
The percentage of distilled water/oral fluid retained in tested 
materials
Alongside volume collection, each material was tested for 
water/oral fluid retention. The saturated materials were spun down 
via centrifugation and weighed (final weight).The final retention 
was expressed as a percentage. The level of retention of fluid in 
the material was calculated as follows:
The percentage of water retained (%) = Final weight (mg)
Dry Weight (mg) *100
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Total IgG released by the tested materials
To measure the levels of IgG released by the test materials, the 
sample materials were placed in a pool of known concentration of 
IgG (150 ng/ml) for a period of 2 minutes. The concentration of 
IgG released by each material was measured using Human IgG 
Elisa Quantitation Kit Bethyl Laboratories Inc (Montgomery, USA) 
according to manufacturer’s instructions. 96 well High Bind flat 
bottomed plates (Costar Corning Lifesciences, UK) were coated 
with goat anti-human affinity antibody (Primary Antibody, Bethyl 
laboratories Inc, USA) The number of wells used was determined 
by assay standards, controls and the total number of samples 
tested (either duplicate or triplicate). 1 pi of capture antibody 
diluted with 100ul of coating buffer (0.05 M Carbonate-Bicarbonate 
Sigma Aldrich, UK) administered to each test well. The plate 
incubated at 21 °C for 60 minutes or overnight at 4°C.
The coating buffer was removed by a 3 step wash using a Tecan 
Columbus plate washer (Austria) with PBS 0.05% Tween 20. Each 
step of the wash involves washing of the wells and aspirating the 
wells, this process is repeated a total of three times within the 2- 
step wash process, the plates are then dried by tapping onto blue 
roll. 200 pi of blocking solution (Phosphate buffered saline, 1% 
BSA, pH 8.0) was added to each well. The plate was incubated for 
60 minutes at 37°C. After incubation the blocking solution was 
removed by 3 step wash (as previously described).
The assay standards used human serum as reference (final serum 
concentration 1000 ng/ml according to manufacturer’s guidelines). 
100 pi of sample diluent (Phosphate buffered saline 1% BSA, 
0.05% Tween 20, pH 8.0) was added to each well. 100 pi of dilute 
standard was added to the first well, mixed and 100 pi removed
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and added to the second well, the process was repeated for the 
next 7 wells. This produced a standard curve ranging from 
1000 ng/ml - 7.8 ng/ml. Oral fluid samples were added these were 
diluted to optimal concentration to specific wells (1:100 dilution 
from neat). The plates were then incubated at 21 °C for 60 
minutes.
The samples were removed by 5 - step wash (This is a similar 
process to the 3 step wash). Secondary HRP detection antibody 
was added to each test well, this was diluted from stock 
(1:50,000).100 pi of secondary HRP-detection antibody was 
added to each well and the plate incubated for 60 minutes. After 
Incubation the secondary HRP-detection antibodies were removed 
using a 5 - step wash and 100 pi 3, 3’, 5, 5’-Tetramethylbenzidine 
(TMB, Sigma Aldrich, UK) was added to each well. The plate was 
sealed, covered and placed on a rotating platform for colour 
development. The development time was between 5-10 minutes, 
the reaction was stopped by adding 100 pi 4N H2SO4 to each test 
well. The plate was analysed at 450 nm on a spectrophotometer 
(J Bio LP 400). The sample Immunoglobulin concentrations were 
calculated from a standard curve using Microsoft Excel (for a 
detailed list of materials used please refer to appendix B).
The percentage of IgG retained within the tested materials
To compare the levels of IgG retention within the tested materials, 
the percentage of retention was calculated.
The percentage of IgG retained (%) = original concentration (ngml)
final concentration(ngnnl) *100
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2.4.2 Assessment of materials used in the Seradate
Standardising absorbent materials used
The materials collected different volumes of distilled water (figure 
2.11). A significant increase in collection was seen with D3727g in 
comparison to all tested materials which collected 4000pl. 
Marginal significance was expressed between BNW1 and BNW 2. 
XMF-1 each collects approximately 2000 pi - 2500 pi.
Each BNW 1, BNW2 and XMF-1 showed a significant increase in 
collection in comparison to XS-1, XS-2, XS-3 and T3. The test 
materials XS-1, XS-2, XS-3 and T3 these showed marginal 
significant collection each collecting an average of 500 pi.
5000 n
4000 -
3000 -
2000 -
1000 -
BNW1 BNW2 D327G XS-1 XS-2 XS-3 XMF-1 T3
Figure 2.11 The volume of H20 collected by various novel biomaterials. The 
volume collected was measured in pi. The SEM was too small to be seen in the 
chart, n =5
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The percentage of distilled water retained in tested materials
The materials retained different percentages of distilled water 
(figure 2.12). D3727g and XS-1 showed significant retention at 
approximately 4% in comparison BNW 1, BNW2, XS-2 XS-3 and 
XMF-1. BNW 1, BNW2, XS-2 XS-3 and XMF-1all showed 
comparable retention levels of approximately 2%. T3 showed the 
most significant retention in comparison to all tested materials at 
approximately 30%. This is a range of 7.5 -15 fold increase in 
comparison to its tested counterparts.
BNW1 BNW2 D327G XS-1 XS-2 XS-3 XMF-1 T3
Figure 2.12 The percentage of H20 retained within biomaterials The error bars 
show +SEM. n =5
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Testing materials for collection of oral fluid
The materials collected different volumes of oral fluid (figure 2.13). 
A significant increase in collection was seen with D3727g in 
comparison to all tested materials which collected 4000 pi. 
Marginal significance was expressed between BNW1 and BNW 2. 
XMF-1 each collects approximately 2000 pi- 2500 pi. Each 
BNW 1, BNW2 and XMF-1 showed a significant increase in 
collection in comparison to XS-1, XS-2, XS-3 and T3. The test 
materials XS-1, XS-2, XS-3 and T3 these showed marginal 
significant collection each collecting an average of 500 pi.
5000 -i
4000 -
3000 -
2000 -
1000 -
BNW1 BNW2 D327G XS-1 XS-2 XS-3 XMF-1 T3
Figure 2.13 The volume of oral fluid collected by various novel biomaterials. The 
volume collected was measured in pi. The SEM was too small to be seen in the 
chart, n =5
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The percentage of oral fluid retained in tested materials
The materials retained different percentages of oral fluid (figure 
2.14). D3727g and XS-1 showed significant retention at 
approximately 4% in comparison BNW 1, BNW2, XS-2 XS-3 and 
XMF-1. BNW 1, BNW2, XS-2 XS-3 and XMF-1all showed 
comparable retention levels of approximately 2%. T3 showed the 
most significant retention in comparison to all tested materials at 
approximately 30%. This is a range of 7.5 -15 fold increase in 
comparison to its tested counterparts.
BNW1 BNW2 D327G XS-1 XS-2 XS-3 XMF-1 T3
Figure 2.14 The percentage of Oral Fluid retained within the materials The error 
bars show +SEM. n =5
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Total IgG released by the tested materials
The total IgG released by each material from the original 
concentration of 150 ng/ml was assessed (figure 2.15). BNW-1, 
D3727G and XS-2 released marginally significant levels of IgG 
*100 ng/ml, and were significantly higher in comparison to BNW-2, 
XS-1, XS-3, XMF-1 and T3.
BNW-2, XS-1, XS-3 and XMF-1 released comparable levels of IgG 
~90 ng/ml and were significantly higher in comparison to T3.
T3 released approximately 80 ng/ml of IgG from the initial 
concentration of 150 ng/ml; the material exhibited a significantly 
lower level of release in comparison to all tested materials.
120 n
100 -
BNW1 BNW2 D327G XS-1 XS-2 XS-3 XMF-1 T3
Figure 2.15 Total IgG released from known IgG pooled sample (150ngml). The 
error bars show ±SEM. n =5.
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The percentage of IgG retained within the material
In figure 2.16 the data shows no significant differences between 
D3727g, BNW1 and XS-2 in retaining approximately 30% IgG. 
Marginally significant differences were also seen between BNW2, 
XS-1, XS-3 and XMF-1 in retaining approximately 35% IgG.
T3 expressed the most significant difference in the level of IgG 
retention compared to all materials tested at a retention level of 
50 % IgG.
BNW1 BNW2 D327G XS-1 XS-2 XS-3 XMF-1 T3
Figure 2.16 The total percentage of IgG retained within tested materials. The 
error bars show ±SEM. n =5.
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2.5 Section C: User compliance of Seradate OFCD prototype 
with other collection methods
User compliance is of great importance as OFCDs are marketed 
for their ease and self-directed use. To examine the compliance of 
the Seradate a questionnaire was taken from volunteers within the 
study cohorts to compare the Seradate against other methods of 
oral fluid collection (see appendix for questionnaire and informed 
consent forms).
The questionnaire was subdivided into the following categories
• Aesthetics
• Ease of use
• Comfort
• Overall experience
Each volunteer was also asked to confirm their smoking status 
and dental hygiene schedule.
Each question was assessed on a likert scale of 10 (1= Very poor- 
10 = excellent). A rating of 5 was deemed as user acceptance.
For further feedback on each of the collected methods, volunteers 
were also asked to provide written feedback on each of the 
collection methods to evaluate their overall experience (refer to 
appendix A for questionnaire, informed consent and information 
sheet and appendix C for individual feedback questionnaires)
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Aesthetics
Aesthetics is a measure of first impressions and visually appealing 
aspects of the OFCDs (figure 2.17).
Saliva Orasure Salivette Oracol Seradate Certus OMT
Figure 2.17 Volunteer ratings on aesthetics of oral fluid collection using different 
OFCDs. Rating scale of 1-10. 1 = Very Bad 10=Excellent. Bar height shows 
SEM n=35
Saliva collection functioned as a control. There were no significant 
differences seen between the Orasure, Salivette, Seradate and 
Certus in comparison to the control (drooled saliva) as each 
collection method expressed a level of 6 and higher within the test 
cohort. The Oracol showed a greater level of acceptance at 7 
whilst the collection of OMT by filter strip method was unanimously 
liked overall with a rating of 10. Individual feedback showed that 
14 out of the 35 participants (40%) found saliva collection none
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appealing followed by the Seradate (29%), Orasure (9%) and 
Oracol (9%). There was no dislike of the Certus. As acceptance 
for each of the test methods was set at 5, each of the collection 
methods in terms of aesthetics overall was satisfactory to all 
users.
Ease of use
The ease of use was to check the simplicity of each collection 
procedure after being provided with written and verbal instruction 
(figure 2.18).
Saliva Orasure Salivette Oracol Seradate Certus OMT
Figure 2.18 The rating on ease of use on oral fluid collection using different 
OFCDs. Rating scale of 1-10.1 = Very Bad 10 =Excellent. Bar height shows 
SEM n=35
Saliva collection functioned as a control. There were no significant 
differences seen between the Orasure, Salivette, Seradate and 
Certus in comparison to the control (drooled saliva) as each 
expressed a level of 6 and higher. The Oracol should a greater
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level at 7 whilst the collection of OMT by filter strip method was 
unanimously liked overall with a rating of 10. Individual feedback 
showed that 10 out of 35 participants (29%) found the Seradate 
uncomfortable followed by the saliva collection (14%), Salivette 
(6%), Oracol (6%). There was no dislike of the Certus .As 
acceptance for each of the test methods was set at 5 each of the 
collection methods in terms of ease of use overall was satisfactory 
to all users.
Comfort
The comfort for each collection method was a measure of any pain 
or discomfort derived from each of the collection procedures 
(figure 2.19).
Saliva Orasure Salivette Oracol Seradate Certus OMT
Figure 2.19 The rating on comfort of oral fluid collection. Rating scale of 1-10. 
1= Very Bad 10 =Excellent. Bar height shows SEM n=35
Saliva collection functioned as a control. There were no significant 
differences seen between the Orasure, Salivette, Seradate and
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Certus in comparison to the control (drooled saliva) as each 
expressed a level of 6 and higher. The Oracol should a greater 
level at 7 whilst the collection of OMT by filter strip method was 
unanimously liked overall with a rating of 10. Individual feedback 
showed 13 out of 35 participants found the Seradate 
uncomfortable to use (37%) followed by Salivette (23%), Orasure 
(20%), saliva collection (17%), Certus (14%) and Oracol(6%). As 
acceptance for each of the test methods was set at 5 each of the 
collection methods in terms of comfort was satisfactory to all 
users.
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Overall experience
The overall experience was used a universal measure to 
encompass all previous aspects of the questionnaire and whether 
the participants were willing to do a repeat procedure if the need 
arose (figure 2.20).
Saliva Orasure Salivette Oracol Seradate Certus
Figure 2.20 The rating on overall experience of oral fluid collection. Rating scale 
of 1-10. 1 = Very Bad 10 =Excellent. Bar height shows SEM n=35
Saliva collection functioned as a control. There were no significant 
differences seen between the Orasure, Salivette, Seradate and 
Certus in comparison to the control (drooled saliva) as each 
expressed a level of 6 and higher. The Oracol should a greater 
level at 7 whilst the collection of OMT by filter strip method was 
unanimously liked overall with a rating of 10. Individual feedback 
showed that 10 out of the 35 participants disliked the overall 
experience of using the Oracol (29%) followed by saliva collection 
(23%), Salivette (14%), Orasure (14%), Certus (9%) and Seradate 
(3%).As acceptance for each of the test methods was set at 5
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each of the collection methods in terms of overall experience was 
satisfactory to all users.
Feedback for collection procedures
Individual feedback was taken from each test individual and 
summarised (table 2.2). As the questionnaire showed that the 
OMT collection procedure (both inter and intra crevicular 
collections) was unanimously accepted as the collection method of 
choice. Its disadvantages lay in the requirement of a dentist for 
collection.
Drooled saliva served as the control for the study, this was 
commended on its ease of collection but was least liked and 
deemed unpleasant in comparison all other methods of collection.
Orasure OFCD was commended of ease of use and comfort when 
placed into the mouth; however the salty after taste was slightly 
unpleasant but not scrutinized.
Salivette OFCD was commended on easy positioning in the oral 
cavity (superior or inferior to the tongue). It did have an unpleasant 
after taste and collector did feel awkward in the mouth.
Oracol OFCD was commended on its ease of use and comfort. It 
did leave a slight aftertaste but was not unpleasant.
Seradate OFCD was commended on being comfortable around 
the gums; the collector was stated as too large for some 
volunteers and slight discomfort felt by one user. The pads if 
smaller would have fit better within the construct.
Certus OFCD was commended on its aesthetics, it looked good 
and in particular its volume adequacy indicator, its overall ease of
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use and comfort, also the handle of the collector was too rigid and 
the absorbent material was too hard.
Method of 
collection
Advantages Disadvantages
OMT
collection
Ease of collection
No discomfort felt
Could not feel insertion of 
filter paper strip
Requires a dentist
Drooled
Saliva
Ease of collection Aversion to spitting
Being able to see collected 
saliva
Unpleasant
Orasure Ease of collection
Comfortable in mouth
Self directed
'Salty' after taste in mouth
Salivette Easily positioned in oral 
cavity (Superior/ Inferior to 
tongue)
After taste was unpleasant. 
Awkward feeling when 
placed in mouth.
Ora col Ease of use
Very comfortable
Slight After Taste
Seradate Comfortable around the 
gums
Too large
Pads fall into mouth
Slight discomfort
Certus Highly aesthetic design { 
volume adequacy indicator 
was commended)
Ease of use
Comfortable
Handle is too rigid
Pad material is too hard
Table 2.2 The Advantages and disadvantages of methods of collection
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2.6 Discussion
The development of the Seradate
The early stage in the development of Seradate was to create a 
collector that resembled an OFCD currently available on the 
market. The design of a toothbrush and the method of collection 
were taken from that used in an oral swab. This would allow for a 
sample to be collected that would show OMT-rich oral fluid 
collection. This method is well established as a toothbrush and an 
OFCD. The marketability for such a device would be poor, as 
many commercial collectors boast the same function; this would 
not be a valuable addition to the oral fluid collector market. What 
was required was a unique method of oral fluid collection that will 
use established collection methods as a basis and to improve the 
collection of OMT-rich oral fluid.
The stage 2 design was based on the findings stated by Crouch et 
al that sample collection itself requires standardisation and the 
levels of oral fluid collected can affect the test outcomes from a 
variety of validation tests (Crouch 2005). This led to suggest that 
the ability to collect a greater volume of oral fluid would allow the 
one sample collection to provide enough fluid for multiple tests and 
further validation applications. The stage 2 designs used this 
information taking into account a currently used oral interface (the 
mouth guard), and this was an ideal concept as it provided all the 
advantages that were required to collect a sample that was OMT- 
rich. The guarding elements of the design would be used to shield 
the gums from the external oral cavity and any salivary interaction, 
making the collector site specific for OMT collection. The design 
initially targeted both the upper and lower portions of the gums to
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efficiently collect two samples at the same time; this was to lower 
overall screening time that may require multiple collections.
The design itself had its limitations as both the upper and lower 
gums were targeted for interaction; this limited the biting 
mechanism that could be used to increase OMT outflow. The 
stage 3 designs collectively assessed the findings from stages 1 
and 2 and merged the 2 concepts to form an OMT mediated oral 
fluid collector. The idea of using the toothbrush handle was 
removed due to the unique mechanism of collection used. The 
targeting of the lower gums allowed for the device to be easily 
placed within the oral cavity and the additional curved coronal 
region provided an easy biting point.
The prototype incorporated two forms of collection into its test 
design this included the abrasion motion and the biting motion.
The dual functions of the Seradate were proposed to facilitate an 
increase in OMT outflow by causing mild trauma to the surfaces of 
the gingivae.
Seradate absorbent materials
The materials used for the Seradate collection head were tested 
for their hydrophilic properties, ability to collect and release water/ 
oral fluids while exhibiting minimal retention and overall comfort for 
placement within the oral cavity.
Each of the tested materials showed a high affinity for both oral 
fluid and distilled water, this was the first experiment conducted to 
measure the speed of complete saturation (data not shown).
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The tested materials were a mixture of polyolefin and sintered 
plastics. Each material was individually assessed for its 
acceptability (Table 2.1).From our findings the shortlisted materials 
for use in the Seradate were BNW-1 (polyolefin), D3727g 
(polyolefin) and XS-2 (sintered plastic). Each material met the 
requirements for use within the Seradate but as D3727g exhibited 
a greater volume uptake of H2O and oral fluid in comparison to 
BNW-1 and XS-2 this material was selected for the Seradate.
D3727g showed the appropriate properties that were suited for our 
collector. The material could be easily molded and was 
comfortable enough to be placed within the oral cavity. It also 
showed a high uptake and release of tested fluids, with a low 
retention of testable proteins (IgG).
XS-2 was a sintered plastic and as the Seradate used both 
abrasion and mastication as a method of collection this would 
cause excessive trauma to the gum surfaces (resulting in 
bleeding) and therefore nullify its application as an appropriate 
OFCD. The potential uses for XS-2 would be as a complimentary 
collector that is placed on the gum surface to allow transfer of fluid 
by capillary action.
Site specific applications of wicking based materials such as 
sintered plastics require to be assessed further for their 
appropriate use in intra oral dentai examinations.
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User compliance questionnaire
To measure user compliance of our tested OFCDs, we looked at 
the following parameters
• Aesthetics
• Ease of use
• Comfort
• Overall Experience
The results shown previously were taken from a cohort of male 
and female participants.
Aesthetics
Aesthetics was used a measure of first impressions on its visual 
aspects and not on its direct application. Our findings showed that 
each collection method was deemed acceptable against our cut­
off. There was no significant difference between the Orasure, 
Salivette, Seradate and Certus in comparison to the control 
(drooled saliva). Oracol showed a significantly higher value in 
comparison to OFCDs, OMT collection was significantly higher in 
comparison to all collection methods.
Drooled saliva collection was highlighted as the least aesthetic as 
participants were able to see their own drooled saliva. This could 
be averted in future collections by having the participants drool 
into opaque containers. The Oracol was commended on its 
simplistic design (like a lolly pop).
The design of the Certus was commented on as having the best 
look in particular the window for the adequacy indicator and the 
overall design of the construct was highlighted.
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Ease of use
Ease of use was to check the simplicity of each collection 
procedure after being given both written and verbal instruction.
The collection methods were assessed for their ease of use and 
each method was deemed acceptable by our cohort. There was a 
universal acceptance for the collection of OMT (both intra and 
extra-crevicular collection) conducted by the dentist. There was no 
significant difference between the Orasure, Salivette, Seradate 
and Certus in comparison to the control (drooled saliva). Oracol 
showed a significantly higher value in comparison to OFCDs, OMT 
collection was significantly higher in comparison to all collection 
methods. Oracol was commended on its overall ease of use.
Comfort
The comfort level for each collection method was a measure of 
any pain or discomfort derived from each of the collection 
procedures. Each of the collection methods was deemed 
acceptable as they fell above our cut off. There was no significant 
difference between the Orasure, Salivette, Seradate and Certus in 
comparison to the control (drooled saliva). Oracol showed a 
significantly higher value in comparison to OFCDs, OMT collection 
was significantly higher in comparison to all collection methods.
OMT collection was commended on the feeling of no discomfort, 
each of the collection methods were commended on particular 
aspects of comfort. The Seradate was commended on being 
comfortable around the gums, however the size of head was 
commented on being too large and the inserted absorbent material 
was too large causing it to fall out of the applicator. The Oracol 
was commended for its pleasant material texture.
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Overall experience
The overall experience was used as universal measure to 
encompass all previous aspects of the questionnaire and whether 
the participants were willing to do a repeat procedure if the need 
arose. Each of the collection methods was deemed acceptable as 
they fell above our cut off (5 and above). There was no significant 
difference between the Orasure, Salivette, Seradate and Certus in 
comparison to the control (drooled saliva). Oracol showed a 
significantly higher value in comparison to OFCDs, OMT collection 
was significantly higher in comparison to all collection methods.
The collection of OMT was unanimously agreed on as the best 
overall experience, the cohort agreed that the procedure was very 
simple and pain free. The experience of drooling saliva was least 
liked and was commented on as being unpleasant. The Orasure, 
Oracol and Salivette were commended on collection method 
however each of the collectors showed a distinct after taste that 
was mildly unpleasant. All participants did comment that 
regardless of this factor they would be happy to use the collector 
again in the future. The Certus was credited for its overall design 
as an applicator and especially its volume adequacy indicator; its 
drawbacks were highlighted in terms of its rigidity of the absorbent 
material. The Seradate was commended on its material use and 
comfort upon placement in the mouth in particular the gum 
surfaces. Contraindications were that the head of the applicator 
was too large and a reduction in the size of the absorbent material 
would have overall enhanced the experience.
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Closing comments
As the design of the Seradate was a working prototype it still has a 
lot of scope for development and taking into account the 
constructive criticism it could be used as a potentially marketed 
OFCD in the future.
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Chapter 3
An evaluation of oral fluid collection devices and their use in 
point of care diagnostics
3.1 Introduction
The collection of oral fluid is an attractive alternative matrix to 
serum for use in medical diagnostics and screening. There are 
many methods by which oral fluid is collected and for the purposes 
of this thesis we want to evaluate a group of OFCDs against 
Seradate our prototype OFCD. Each of the OFCDs will be 
evaluated for its ability to monitor Immunoglobulins IgA, IgG, IgM 
and cotinine.
OFCDs and immunoglobulins
The purpose of collecting the immunoglobulins in oral fluid are its 
uses as a surrogate marker for OMT are well established within 
the literature (Malamud 1997). Dimeric Salivary- IgA (S-lgA) is 
predominantly produced by the parotid and submandibular glands 
and is found in higher titre in oral fluid, the concentration of IgG 
and IgM are considerably lower in comparison; this is due to their 
presence being associated to OMT outflow. The collected levels of 
IgG and IgM are often masked in oral fluid samples, due to 
dilution, (de Almeida et al 2008, Childers et al 2003). A ratio of 
IgG: IgA levels is a useful indicator to mark the presence of OMT 
to oral fluid based immunoglobulins when they are presented in 
collected oral fluid.
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OFCDs and monitoring disease
OFCDs have been used to diagnose various blood borne diseases 
and vaccination status these include HIV/Hepatitis B and C, the 
presence of viral infection can be detected by antibodies against 
the virus and their presence in collected samples provide an 
adequate monitoring method that can be comparable to values 
monitored in serum. (Nokes et al 1998, Nurkka et al 2003, Vyse et 
al 2001, Yacoubian et al 2006).
OFCDs and monitoring drugs/hormones
OFCDs are also used to monitor levels of therapeutic drugs, illicit 
drugs, hormone monitoring and provide concentration levels of 
unconjugated free-drugs and hormones that are present in blood 
circulation (Malamud 1997) (Cameron and Carman 2005) (Vyse, 
Cohen et al. 2001; Shirtcliff and Marrocco 2003)
The monitoring of therapeutic and illicit drugs has been associated 
with oral fluid testing with a wide range of analytical methods 
currently available. The methods of analysis include initial 
quantitative screening by immunoassay (ELISA) and confirmatory 
analysis is conducted by mass spectrometry or western blotting. 
This is particularly valuable in low compliance groups which 
include the elderly, young children, haemophiliacs and venous 
compromised individuals
One use of drug monitoring in oral fluid has been to evaluate 
smoking status and daily smoking habits. This can be done by 
measuring cotinine levels (a breakdown product of nicotine). 
Smoking has been linked to various diseases and government 
initiatives to promote smoking cessation; cotinine testing is 
employed as a deterrent for smoking relapse. Smoking and
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disease are inter-related the establishment of smoking status is of 
great use for clinical assessment. With the use of non-invasive 
OFCD screening methods it is relatively simple to measure 
smoking more accurately than by individual admission. As 
smoking is dictated by levels of nicotine presence this has a 
relative short half-life of 2-4 hours. Its main metabolites are 
cotinine and Nicotine N-Oxide. Cotinine is a lot more stable with a 
half-life of around 16-24 hours in vivo (Jacob iii, Yu et al. 2011) its 
approximate levels of collection can be measured via 
immunoassay and secondary confirmation of cotinine can be 
conducted using Liquid Chromatography (LC) or Gas 
Chromatography-Mass Spectrometry (GC-MS).
Factors affecting OFCD collection
The volume of oral fluid collected is of importance when related to 
the availability of adequate samples for testing. The volume of fluid 
collected has a direct consequence on the dilution of compounds 
present within the fluid. As many OFCDs claim adequate volumes 
of collection, the Concateno Certus collector has introduced a 
method of standardising the collected sample by inserting a 
volume adequacy indicator (approximately 1 ml). The limitations of 
unknown volume collection affect the final concentration of 
compounds within an oral fluid sample; this sample is diluted 
further in OFCDs that use a preservative solution. The assumption 
of sample volume will affect the final concentration values of the 
collected test analytes. The possibility of retention of oral proteins 
within the absorbent material should also be taken into 
consideration (Holm-Hansen 2004,Crouch 2005).
The onset of clinical implications such as Xerostomia (dry mouth) 
can affect the levels of oral fluid collected; this is associated to
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anxiety prior to sample collection or from dehydration. Current 
methods stipulate the use of the OFCD for a period of 2-5 minutes 
to amend this, but this doesn’t take into account physiological and 
mental effects induced by the collection procedure (Aps et al 2005, 
Drummer 2008).
The diurnal nature of oral fluid and inter and intra variability seen 
in collection doesn’t allow for standardisation of proteins available 
in oral fluid. Precautions should therefore be taken when 
comparing data taken at different time sets.
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3.2 Aims
Our aims are to compare the Seradate against various marketed 
OFCDs which include the Orasure, Salivette, Oracol and 
Concateno Certus. As our interest in oral fluid resides on the 
collection of OMT based constituents, we will look at each of the 
OFCDs ability to release IgG (our surrogate marker for OMT) from 
a pooled sample of known concentration of IgG. As oral fluid 
Immunoglobulin levels are variable, a set of standards will be used 
to measure IgG levels of pure OMT (GCF) against OFCDs with 
drooled unstimulated oral fluid as control. Pure OMT will be 
collected using the filter paper strips the methods of collection 
used will be intra-crevicular and extra-crevicular.
As the samples will be collected in the same time period, an 
assessment in sample collection will also be conducted to account 
for variation in levels of IgG and cotinine measured. This will help 
establish whether oral stimulation can return to normal with a short 
resting period after each sample is collected.
The ability of the Seradate and OFCDs to release oral fluid 
compounds will be measured by monitoring the collection and 
release of IgG/IgM/lgA and cotinine. As OFCDs and drooled oral 
fluid samples, show a mixture of antibody content, the IgG: IgA 
ratio will also be measured. The order of collection of samples will 
also be tested to assess for bias within the study. The study was 
conducted on group of student volunteers aged between 18-30, 
composed of a mixture of male and female students that are 
smokers and non-smokers (ethical permission was granted by the 
University of Liverpool ethics committee see appendix A)
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3.3 Materials & Methods
A comparison in voiume of oral fluid collected by OFCDs
The volume of collected oral fluid by an OFCD is a required 
assessment for availability of sample for testing procedures as 
described by Crouch et al (Crouch 2005). The volume of oral fluid 
collected was measured by placing each OFCD in a pooled 
sample of Oral Fluid (10ml) for a period of 2 minutes or until fully 
saturated. Before centrifugation, the volume of the released fluid 
from the device was measured using the following method
Total volume of oral fluid = Saturated weight of OFCD (g) 
collected (ml) - Dry weight of OFCD (g)
The volume of oral fluid retained by OFCDs
The volume of Oral fluid retained within each collector after 
centrifugation, is an indication of the level of sample that is not 
available for testing. To measure the retention of oral fluid in the 
OFCDs, the collectors were centrifuged and weighed (final 
weight). The following equation was used
The percentage of Oral fluid retained (%) = Final Weight (mg)
Dry Weight (mg) * 100
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Assessing the retention of igG/igM/igA in OFCDs
Measuring immunoglobulin concentration
Human IgG/IgM and IgA quantitation kit (Bethyl Laboratories, 
Montogomery, USA) were used according to manufacturer’s 
instructions. 96 well High Bind flat bottomed plate (Costar Corning 
Lifesciences, UK) were coated with goat anti-human affinity 
antibody (Primary Antibody, Bethyl Laboratories Inc, USA) The 
number of wells used were determined by assay standards, 
controls and the total number of samples tested (either duplicate 
or triplicate). 1 pi of capture antibody was diluted with 100 pi of 
coating buffer (0.05 M Carbonate-Bicarbonate Sigma Aldrich, UK) 
administered to each test well. The plate was incubated at 21°C 
for 60 minutes or stored overnight at 4°C.
The coating buffer was removed by a 3 - step wash using a Tecan 
Columbus plate washer (Austria) with PBS 0.05% Tween 20. Each 
step of the wash involved washing of the wells and aspirating the 
wells, this process was repeated a total of three times within the 
2-step wash process, the plates were dried by tapping onto blue 
roll. 200 pi of blocking solution (Phosphate buffered saline, 1% 
BSA, pH 8.0) was added to each well. The plates were incubated 
for 60 minutes at 37°C. After incubation the blocking solution was 
removed by 3 step wash (as previously described).
A set of assay standards were made using human serum as 
reference (final serum concentration 1000 ng/ml according to 
manufacturer’s guidelines). 100 pi of sample diluent (Phosphate 
buffered saline 1 % BSA, 0.05% Tween 20, pH 8.0) was added to 
each well. 100 pi of dilute standard was added to the first well, 
mixed and 100 pi removed and added to the second well, the 
process was repeated for the next 7 wells. This produced a 
standard curve ranging from 1000 ng/ml - 7.8 ng/ml. Oral fluid
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samples were then added these were diluted to optimal 
concentration (1:100 dilution from neat) to specific wells. The 
plates were then incubated at 21°C for 60 minutes. The samples 
were removed by 5 step wash (This is a similar process to the 3 
step wash). Secondary HRP detection antibody was added to 
each test well, this was diluted from stock (1:50,000). 100 pi of 
secondary HRP-detection antibody was added to each well and 
the plate incubated for 60 minutes. After Incubation the secondary 
HRP-detection antibodies were removed using a 5-step wash and 
100 pi 3, 3’, 5, 5’-Tetramethylbenzidine (TMB. Sigma Aldrich) was 
added to each well. The plate was sealed, covered and placed on 
a rotating platform for colour development. The development time 
was between 5-10 minutes, the reaction was stopped by adding 
100 pi 4N H2SO4 to each test well. The plate was analysed at 
450 nm on a spectrophotometer (J Bio LP 400). The sample 
Immunoglobulin concentrations were calculated from a standard 
curve using Microsoft Excel (For a detailed list of materials used 
please refer to appendix B).
Assessing the retention of IgG in OFCOs
A comparison between OFCDs was made using oral fluid that was 
spiked with a known concentration of IgG (60 ng/ml). Each 
collector was tested in 5 repetitions to account for any differences 
in IgG retained. Each device was immersed within the pooled 
sample for 2 minutes before being centrifuged. The amount of IgG 
retained by each device was calculated by subtracting the final 
concentration measured from the initial pooled concentration. The 
Value of retention was then calculated as a percentage.
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The percentage of IgG retention 
= Original pooled sample/Final Collected sample * 100
Collection procedures for OFCDs and OMT 
Unstimulated oral fluid
Volunteers were asked to drink and swill water in their mouths 
prior to drooling. The volunteers would then allow saliva to drip 
from lower lip with no additional stimulation into a 25ml universal 
tube (Sarstedt, Germany). The collected saliva varied between 
1.5 ml - 4 ml. Samples were aliquot into 1.5 ml microfuge tubes 
(Eppendorf, UK) and centrifuged at 8000g for 5 minutes to remove 
any cellular or particulate matter. The supernatant was removed 
and 2 pi of protease inhibitor was added to each sample. The 
samples were stored at -80°C until required.
Seradate
Volunteers used the Seradate collection device (University of 
Liverpool, UK) and placed the head of the device just over the 
molars and premolars of the lower jaw. The Seradate uses two 
methods of swabbing
(a) Biting down on the head (mastication motion).
(b) Rubbing the device systematically along the lower gum line 
(agitation motion).
The procedure ranged from 2-5 minutes. The Saturated pad was 
removed and placed into a 15 mi modified centrifuge tube
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(Sarstedt, Germany). The pad was centrifuged at 7500g for 10 
minutes. The supernatant was placed into 1.5 ml microfuge tubes 
(Eppendorf, UK) and 2 pi of protease inhibitor (Roche complete 
protease inhibitor) was added to each sample. The sample was 
stored at-80°C until required fortesting.
Orasure ora! fluid collection device
Volunteers used Orasure collection device (Orasure Technologies 
Inc. Bethlehem.USA) and swabbed around the cheeks and gums, 
leaving it to rest in the upper right cheek for a period of 2 minutes. 
The swab was transferred to a preservative viai. The swab 
centrifuged at 7500g for 10 minutes. The contents were aliquoted 
into 1.5 ml microfuge tubes (Eppendorf, UK). The samples were 
stored at-80°C until required fortesting.
Salivette
Volunteers used Salivette collection device (Sarstedt, Germany) 
and chew the swab for a period of 2 minutes. The swab was 
removed and placed into its housing tube. The swab was 
centrifuged at 7500g for 10 minutes. The supernatant was 
collected and aliquoted into 1.5 mi microfuge tubes (Eppendorf, 
UK) and 2 pi of protease inhibitor (Roche complete protease 
inhibitor, Roche, UK) was added to each sample. The samples 
were stored at”80oC until required fortesting.
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Oracol
Volunteers used the Oracol collection device (Malvern Medical 
Developments, Worcester, UK) and swabbed around the cheeks 
and gums, leaving it to rest in the upper right cheek for a period of 
2 minutes. The swab was transferred to a 15 ml centrifuge tube 
(Sarstedt, Germany). The swab was centrifuged at 7500g for 10 
minutes. The supernatant was aliquoted into 1.5 ml microfuge 
tubes (Eppendorf, UK). 2 pi of protease inhibitor (Roche complete 
protease inhibitor, Roche, UK) was added to each sample. The 
samples were stored at -80°C until required for testing.
Concateno Certus
Volunteers used the Concateno Certus collection device 
(Concateno global drug testing services, London UK) and 
swabbed around the cheeks and gums, leaving it to rest in the 
upper right cheek for a period of 2 minutes. The Swab was 
removed once the volume adequacy indictor turned blue. The 
swab was transferred into a tube containing preservative and 
centrifuged at 7500g for 10 minutes. The content was aliquoted 
into 1.5 ml microfuge tubes (Eppendorf, UK). The samples stored 
at -80°C until required for testing.
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Pure OMT (GCF) collection 
Intra-crevicular OMT collection
Volunteers were asked to rinse their mouths with water. The 
procedure was carried out by Dr Bhavish Patel BDS (VU Mane) 
(GDC Number 74574). Dental rolls were positioned under the 
superior lip to dry area of collection. The area of collection was the 
upper central incisor and upper lateral incisor. The area was 
cleaned with gauze to remove any food matter or supraginvival 
plaque. Filter paper strips (1 cm * 3cm) was placed intra- 
crevicularly into the gingival crevice until mild resistance was felt 
(figure 3.1). The filter paper was then left in place for a period of 1 
minute and removed.
Figure 3.1 An illustration of the positioning of paper for the filter paper strip 
method of collection (a) Extra crevicular (b) Intra crevicular- Superficial (c) Intra 
crevicular- Deep. Modified from Griffiths GS 2000.
To measure the volume collected the filter strip was placed into a 
microfuge tube and weighed. The filter paper after collection was 
placed into the microfuge tube and re-weighed. The sample
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volume collected was worked out by subtraction of final weight 
from initial weight. 300 pi of PBS Tween 0.05% was added to each 
strip and the sample was stored at -86°C. For processing the 
samples were thawed and centrifuged at 7500g for 10 minutes 
and agitated on a roller mixer for 20 minutes. The filter paper was 
then removed and the sample was used for testing.
Extra-crevicular OMT collection
The collection procedure followed similar methodology as Intra- 
crevicular collection. The area of collection was the upper central 
incisor and upper lateral incisor. Filter paper strips (1 cm * 3cm) 
were placed at top of the gingival crevice. The filter paper was left 
in place for a period of 1 minute and removed (see figure 3.1).
To measure the volume collected the filter strip was placed into a 
microfuge tube and weighed. The filter paper after collection was 
placed into the microfuge tube and re-weighed. The sample 
volume collected was worked out by subtraction of final weight 
from initial weight. 300 pi of PBS Tween 0.05% was added to each 
strip and the sample was stored at -868C. For processing the 
samples were thawed and centrifuged at 7500g for 10 minutes 
and agitated on a roller mixer for 20 minutes. The filter paper was 
then removed and the sample was used fortesting.
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Standardisation of IgG coliection for OFCD
To standardise our testing of OFCDs, the same volunteer group 
were used from the OMT collection study. The cohort comprised of 
male and female, smokers and non-smokers. The order of sample 
collection was carried out in a manner to reduce agitation of the 
gum surfaces to lower false results. Each procedure was followed 
by a resting period (approximately 15 minutes) to allow for oral 
fluid composition to re-establish itself.
Measuring cotinine levels in oral fluid
Oral fluid samples collected were assayed for cotinine levels using 
High Sensitivity salivary cotinine assay kit (Salimetrics Europe 
Ltd). All reagents and plates were brought to room temperature.
1X wash buffer was prepared. Serial dilutions of Cotinine standard 
were made in microfuge tubes to create a standard curve ranging 
from 200 ng/ml - 0.8 ng/ml. The Samples were diluted 1:10 in 
sample diluent for smokers and left undiluted for non-smokers.
20 pi of standards, control and sample was placed into an 
appropriate well. 20pl of assay diluents was placed into 2 wells to 
serve as control. Each sample was run in duplicate. The enzyme 
conjugate was diluted 1:300 (with assay diluent). 100 pi of anti­
serum was added into all test wells using a multichannel pipette. 
The plate was covered and placed in an incubator/shaker for 90 
minutes at 37°C.
The test samples underwent a four-step wash 4 (using Tecan 
Columbus Plate Washer, Austria). The plate was Blot dried and 
200 pi of 3, 3’5, 5’ - Tetramethyibenzidine solution into each well. 
The plate was mixed at 500 rpm for 5 minutes and incubated in 
dark for 25 minutes at room temperature (21 °C). 50 pi of stop 
solution was added to each test well and the plate was analysed at
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450 nm on a spectrophotometer (J Bio LP 400). The cotinine 
concentrations of the samples were worked from a standard curve 
using Microsoft Excel.(For a detailed list of materials used please 
refer to appendix B).
OFCDs and monitoring of IgG and cotinine
To assess bias within our order of sample collection, the samples 
were taken on 3 separate occasions. The collection order was as 
follows
• Normal collection order ( Saliva, Orasure, Salivette, Oracoi, 
Seradate, Certus)
• Reverse order* (Certus, Seradate, Oracoi, Salivette, 
Orasure, Saliva)
*= The reverse order was collected twice
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3.4 An assessment of Seradate and OFCDs
Comparing OFCD oral fluid and IgG retention
Each OFCD was tested in 5 repetitions to account for any 
differences in volume retained (Figure 3.2). The Seradate shows a 
significantly higher level of oral fluid collection in comparison to the 
Orasure, Salivette, Oracol and Certus with an approximate uptake 
of 4 ml. The Salivette shows a significantly higher collection of oral 
fluid in comparison to the Orasure, Oracol and Certus (=3.5 ml. 
fluid uptake).The Orasure and Certus show comparable levels of 
oral fluid collection at approximately 1 ml. This value is 
significantly lower in comparison to the Salivette and Seradate, 
and only marginally higher in comparison to Oracol. The Oracol 
showed least volume collected amongst all tested OFCDs at 
approximately 0.8 ml and was significantly lower in comparison to 
the Orasure, Salivette, Seradate and Certus.
Orasure Salivette Oracol Seradate Certus
Figure 3.2 The volume of oral fluid collected after centrifugation from tested 
OFCDs. There are no error bars because the deviation from the mean was too 
small. n=5
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The volume of oral fluid retained by OFCDs
Each collector was tested in 5 repetitions to account for any 
differences in percentage of volume retained within each OFCD 
(see figure 3.3).The Concateno Certus was excluded from this test 
as its methodology doesn’t use centrifugation to release fluid. The 
Salivette and Oracol retained approximately 17% of total oral fluid 
this was significantly higher in comparison to the Orasure and 
Seradate. Orasure retained approximately 10% oral fluid; this was 
significantly lower in comparison to the Salivette and Oracol, but 
only marginally higher in comparison to the Seradate. The 
Seradate retained approximately 2% of the oral fluid and was 
significantly lower in comparison to Orasure, Salivette and Oracol. 
The retention of oral fluid within the tested OFCDs can provide 
answers to final concentrations of proteins presented for testing; 
this can either show an increase due to greater retention of oral 
fluid captured within the material or be caused by entrapping 
proteins within the material.
Orasure Salivette Oracol Seradate
Figure 3.3 The percentage of oral fluid retained in OFCDs. There are no error 
bars because the deviation from the mean was too small. n=5
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Assessing the retention of IgG in OFCDs
Each collector was tested in 5 repetitions to account for any 
differences in percentage of IgG retained within each OFCD (see 
figure 3.4). The Certus retained approximately 55% of the total IgG 
and was significantly higher in comparison to the Orasure, 
Salivette, Oracol and Seradate. The Orasure retained 
approximately 25% of total IgG and was significantly higher in 
comparison to Salivette, Oracol and Seradate. The Seradate 
retained approximately 10% IgG and was significantly higher in 
comparison to Oracol, But significantly lower in comparison to 
Orasure, Salivette and Certus. The Oracol showed least retention 
of IgG at 5% and was significantly lower in comparison to all 
tested OFCDs. The retention of un-testable IgG in each collector 
accounts for 15-30%. The retention of IgG is one parameter that 
can cause invalidation of an oral fluid sample, should the collected 
sample have a low IgG level below cut-off values used in oral fluid 
sample validation.
Orasure Salivette Oracol Seradate Certus
Figure 3.4 The percentage of IgG (60ngml) retained from spiked oral fluid 
samples. There are no error bars because the deviation from the mean was too 
small. n=5
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3.5 Standardisation of IgG collected in oral fluid
A comparison of different OMT collection methods
The collection methods were evaluated by measuring IgG levels 
(figures 3.5 and 3.6). The test cohort was separated into 2 groups 
male and female and also smokers and non-smokers to show any 
differences in OMT collected. Using the intracrevicular method the 
male volunteers gave values marginally higher to the female 
cohort approximately 150 pg/ml in comparison to 125 pg/ml. With 
the intracrevicular method there was no difference between the 
two groups (=80 pg/ml). There were no overall significant 
differences between the two groups.
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Figure 3.5 IgG concentration of pure OMT (GCF) via intra-crevicular and extra-crevicular 
collection methods. Bar show differences between male and female samples. Bar height 
represents the mean value ± SE. n = 20
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Within the smoking cohort, the intra-crevicular collection was 
marginally higher in comparison to the non-smoking cohort 
approximately 130 pg/ml in comparison to 100ug/ml. For the extra- 
crevicular collection the similar trend was witnessed with the 
smokers exhibiting a marginally higher amount of IgG 
approximately 80 pg/ml to 60 pg/ml. There were no overall 
significant differences between the two groups. The participants 
were not subjected to abrasion to gum surfaces and gum health of 
the individuals was assessed by the dentist. Elevations in OMT 
IgG levels would have been seen in compromised groups with a 
range of poor oral health. The two collections showed lower values 
in comparisons to ranges dictated within the literature.
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Figure 3.6 IgG Concentration of pure OMT (GCF) via intra-crevicular and extra- 
crevicular collection methods. Bar show differences between smoker and non smoker 
samples. Bar height represents the mean value ± SE. n = 20
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Standardisation of IgG collection for saliva and OFCD
Comparable values for IgG were seen between the Orasure, 
Seradate and the control (drooled oral fluid » 4 pg/ml), these 
values were significantly higher in comparison to the Salivette 
(«1 pg/ml) and Certus (»1 pg/ml), both of which expressed low 
levels of IgG collection (figure 3.7). The Oracol expressed the 
highest level of IgG released (» 6 pg/ml) and was significantly 
higher in comparison to all tested OFCDs. The low levels of IgG 
released by the Salivette are associated to its method of 
collection, which has lower contact with the gum surfaces.
Male
Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.7 IgG concentration of saliva and OFCD columns show differences between 
male and female samples. Bar height represents the mean value ± SE. n = 20
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Similar levels of IgG concentration where seen when comparing 
the smoking and non-smoking group, with regard to sample 
collection (figure 3.8). The levels of IgG would be expected to be 
higher among smokers of poorer gingival health, as our smoking 
volunteers showed minimal to no signs of inflammation of 
gingivae, the collections levels between the smokers and non- 
smokers were comparable
Smokers 
Non Smokers
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.8 IgG concentration of saliva and OFCDs columns show differences between 
smokers and non-smokers samples. Bar height represents the mean value ± SE. n = 20
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3.6 Comparison of immunoglobulins and cotinine present in 
oral fluid collection
As previous experiments highlighted the differences in IgG 
released by the OFCDs, we addressed the collection of other 
immunoglobulins that are present within the oral cavity. The 
immunoglobulins present in oral fluid are IgG, IgA and IgM.
The examination of Immunoglobulin concentration was used to 
measure the potential function of each collector in its ability to 
collect OMT derivatives.
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Measuring IgG concentration in oral fluid
The IgG concentration collected by each OFCD was measured 
against the control (figure 3.9). The levels of IgG collected gave a 
similar range of values as stated in section 3.4.Comparable levels 
of IgG concentration were seen between the Orasure, Seradate 
and control (between 4 pg/ml - 5 pg/ml) this was significantly 
higher to the Salivette and Certus, and lower in comparison to 
Oracol. The Salivette IgG concentration (= 2pg/ml) was 
significantly lower in comparison to the Orasure, Seradate, Oracol 
and control but was significantly higher in comparison to the 
Certus. The Certus IgG concentration was significantly lower in 
comparison to all OFCDs (« 0.5 pg/ml). The Oracol IgG 
concentration was significantly higher in comparison to all tested 
OFCDs (ranging between 5 pg/ml - 7 pg/ml).Within the data it can 
be seen that the male cohort showed marginally higher levels of 
IgG concentration in comparison to females.
i i Male 
V////A Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.9: IgG concentration of saliva and OFCDs columns show differences 
between male and female samples. Bar height represents the mean value ± SE. 
n = 15
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Measuring IgA concentration in oral fluid
IgA concentration collected by each OFCD was measured against 
the control. Comparable levels of IgA were seen between Orasure 
and Seradate (20 pg/ml - 30 pg/ml), this was marginally lower in 
comparison to the control (=35 pg/ml), but significantly higher in 
comparison to Salivette, Oracol and Certus. Salivette IgA 
concentration (=15 pg/ml - 20 pg/ml) was significantly lower in 
comparison to Orasure, Seradate and control, but higher in 
comparison to Oracol and Certus (figure 3.10).
i i Male 
[xx\] Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.10: IgA concentration of saliva and OFCDs columns show differences 
between male and female samples. Bar height represents the mean value ± SE 
n = 15
Oracol IgA concentration (=10 pg/ml -15 pg/ml) was significantly 
lower in comparison to Orasure, Salivette, Seradate and control. 
Bur was significantly higher in comparison to the Certus. Certus 
IgA concentration (=0.5 pg/ml) was significantly lower in
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comparison to all tested OFCDs. The lower values shown in the 
Oracol can be associated with collection procedure as it is 
primarily directed to gingival surfaces, and possible retention of 
IgA within the foam material, this factor can also be witnessed in 
the Salivette. As the Concateno Certus doesn’t utilize 
centrifugation, this again is a likely limiting factor in its presentation 
of immunoglobulins.
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Measuring IgM concentration in oral fluid
IgM concentration collected by each OFCD was measured against 
the control (figure 3.11). The male cohort showed marginally 
higher levels of IgM in comparison to the females. Comparable 
levels of IgM concentration were seen between the Orasure and 
Salivette (1 pg/ml - 2 pg/ml) this was significantly lower in 
comparison to the Oracol, Seradate and control (2 pg/ml - 
3 pg/ml), but were significantly higher in comparison to Certus.
I------ 1 Male
Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.11: IgM concentration of saliva and OFCDs columns show differences 
between male and female samples. Bar height represents the mean value ± SE. 
n= 15
Comparable levels of IgM concentration were seen in Oracol and 
Seradate (3 pg/ml - 4 pg/ml) they were significantly higher in 
comparison to all tested OFCDs. The Certus IgM concentration 
(0.2 pg/ml) was the lowest in comparison to all tested OFCDs and 
control.
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As the Certus doesn’t utilize centrifugation, this again is a likely 
limiting factor in its presentation of immunoglobulins.
IgG: IgA ratio
The IgG: IgA ratio can be used as an indicator for affinity for each 
OFCD in its ability to gain a more OMT-rich sample of Oral fluid. 
The Oracol showed a higher ratio (0.5) in comparison to all 
OFCDs (0.1-0.2) and control (figure 3.12). All other tested OFCDs 
showed similar IgG: IgA ratio that were comparable to the control.
Male
Female
0.2 -
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.12: IgG: IgA ratio from OFCD and control samples between male and 
female. Bar height represents the mean value ± SE. n = 15
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OFCDS and monitoring of cotinine
The Seradate and OFCDs were tested for their ability to collect 
cotinine. Cotinine is a derivative on nicotine and is used a primary 
method of establishing smoking status. Our cohort within the study 
was a mixed group of males and females with low smoking habit 
ranging from 2-10 cigarettes per day. Cotinine levels were 
measured using Salimetrics cotinine assay and it was noted that 
while the collection procedure would take around 90 minutes to 
complete, this would have little effect on individual cotinine levels 
present in vivo. Cotinine half-life within the human body ranges 16- 
24 hours and is a better indicator than its parent counterpart 
nicotine which has a shorter half-life of 2-4 hours. Our data in the 
study showed no significant differences between the collection 
methods, in comparisons to gender (figure 3.13).
200 -y
I-------1 Male
W/ssa Female
100 -
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.13: Cotinine concentration measured in Saliva and OFCD samples. 
Columns show differences between male and female samples. Bar height 
represents the mean value ± SE. n = 20
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The range of values of cotinine measured 25 ng/ml -150 ng/ml. 
The number of male smokers expressed a greater amount of 
cotinine concentration in comparison to females. The factors are 
suggestive of males smoking outside of sociable hours or smoking 
more than their female counterparts. Cotinine charts are 
suggestive of low to moderate smoking given the values are 
ranged far below the 300 ng/ml cut-off. There is an elevation of 
cotinine levels in particular in the Seradate and Oracol OFCD 
these factors can be attributed to concentration effects of the 
sample during processing. As both the Seradate and Oracol 
collection methods samples are collected close to gum line, there 
is a possibility that they are able to collect a sample of greater 
concentration.
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An assessment of bias in the order of sample collection 
OFCDs and monitoring of IgG
In this data we saw differences in IgG levels of the Salivette and 
Certus (figure 3.14). The Salivette result in reverse collection 1 
shows a spurious value (= 7 pg/ml), as reverse collection 2 shows 
a normal IgG concentration. It appears that irrespective of the 
order of collection the OFCDs all maintain a consistent level of IgG 
collection. The levels of IgG are comparable with previous 
collections. The time period of rest between each collection of 15 
minutes was sufficient to allow resting periods to return within the 
oral cavity alongside rinsing of the mouth with water.
i i Normal collection 
■■ Reverse Collection 1 
i'w'h Reverse Collection (2)
Saliva Orasure Salivette Oracol Seradate Certus
Figure 3.14: IgG concentration of saliva and OFCDs to assess bias in order of 
collection .Bar show differences between smokers and non-smokers samples. 
Bar height represents the mean value ± SB. n = 12
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OFCDs and the monitoring of cotinine
The collection of cotinine is not as subjective as the collection 
order bias of IgG (figure 3.15). Cotinine levels will fluctuate with 
regard to levels of cigarettes smoked, during the separate 
occasions of collection. The data shows that in each subsequent 
collection the levels of cotinine are within ranges of the other 
tested collectors. The bias study shows that cotinine levels are 
less likely to change either by stimulated or unstimulated oral fluid 
collection.
200 n
i i Normal Collection 
IHI Reverse Collection 
IVol Reverse collection (2)E 150 -
V 100 •
Saliva erasure Salivette Oracol Seradate Certus
Figure 3.15 Cotinine concentrations of saliva and OFCDs to assess bias in 
order of collection .Bar show differences between smokers and non-smokers 
samples. Bar height represents the mean value ± SE. n = 12
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3.7 Discussion
The Seradate OFCD prototype and its novel method of use has 
been placed through a set of stringent tests to provide further 
information on where the next stage of development in making an 
OFCD that can collect a higher titre of OMT derived proteins. By 
creating a set of standards, measurements were taken from a pure 
source of OMT, OFCDs and normal drooled oral fluid, it's now 
possible to make comparisons between each method and whether 
any OFCD truly gains a sample that is close to the values seen in 
OMT.
With regards to that question the most simple answer is no, a pure 
sample of OMT as stated in the literature can exhibit values into 
the region of 200-fold of that seen in our collected oral fluid 
samples, our collection of OMT has shown levels with that given in 
the literature. The standardisation of OMT collection is dependent 
on the method of collection. The collection procedure is non- 
invasive and final volumes of OMT collected are between 0.2 pl- 
1.5 pi. The collection of OMT itself is non-standardised and there 
are many methods of extraction of OMT within literature. Further 
validation work on the collection of OMT using different filter 
papers and methods of quantifying the final volume would be 
useful increasing the accuracy of the data. The sample buffer used 
in the extraction of OMT further diluted the samples, so it could be 
used for subsequent testing in assaying for IgG.
As extraction of OMT from filter paper is also subjected to different 
methods, further sample collections would have helped to 
elucidate problems faced in quantifying our final volumes. It was 
also interesting to note that the two methods of extraction of intra- 
crevicular and extra-crevicular collection didn’t differ so greatly. As
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the volume of OMT present in such low volume, lower dilution of 
the strip would’ve possibly given a higher IgG titre equivalent to 
that stated in the literature. The levels of OMT are also subject 
dependant, our group of volunteers all exhibited very good oral 
health ( as assessed by the dentist), and as such the monitoring of 
immunoglobulins showed comparable data in both male and 
female volunteers and within smokers and non smokers.
The standards taken from OFCDs showed relatively low significant 
difference against the control of drooled oral fluid, the values taken 
by the OFCDs are relative to those listed in previous studies. The 
exception to the collection was seen by the Oracol OFCD which 
tested for a greater release of IgG; this factor can be attributed to 
its foam based material that collected a lower volume of oral fluid 
in comparison to the other OFCDs. The volume of oral fluid 
collected has an effect on the final dilution of OMT based proteins; 
similarities in volume collected were expressed in the Orasure 
OFCD however its measurement of sample collection is 
complicated by the addition of its preservative buffer. From our 
initial findings it can suggested that the material used within the 
Oracol collector has a greater affinity for OMT capture and release 
and centrifugation of the sample gives a higher concentration of 
IgG antibodies. Conversely the Concateno Certus shows a lower 
level of IgG this value is taken into account of its dilution into its 
own buffer and the release of oral proteins may not be sufficiently 
eluted by rinsing of the collector alone. Comparable tests could be 
conducted on other collectors to see how effectively samples can 
be eluted in a buffer without the requirement for centrifugation.
The idea of not using centrifugation for final processing of the 
sample would be ideal for less equipped laboratories and provide
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greater diversity to the use of oral fluid as a point of care 
diagnostic tool.
The levels of IgA monitored were significantly higher in the control 
and Seradate collection device, as our main purpose in the 
development was to shield from salivary secretions, adequate 
measures were not in place to account for the collection of saliva 
from the floor of the mouth where most of the saliva collected, this 
would account for the higher IgA content witnessed in the 
Seradate collector. All other OFCDs aside from the Orasure 
showed lower affinity for IgA collection. As IgA is predominantly 
released from the salivary glands, it can be suggested that the 
OFCDS are mainly rubbed on the gum surfaces and there is a 
possibility of IgA capture within the collectors, this is an additional 
component that can be validated for future OFCDs in their ability 
to monitor salivary antibodies.
IgM is generally found in lower volumes in oral fluid due to size of 
the compound; the levels of IgM were comparable with those 
collected in IgG but were expressed in a lower level. This suggests 
that IgM levels are often masked by IgG as an alternate method 
for validation of an oral fluid sample. With respect to the size of 
IgM, there is a greater potential to bind to the test material further 
validation on the release of IgM from respective OFCDs may 
provide insight into the use of IgM in future studies.
The IgG: IgA ratio was used as an indicator for affinity for each 
OFCD in its ability to gain a more OMT-rich sample of Oral fluid 
The Oracol showed highest IgG to IgA ratio, the remaining OFCDs 
all showed comparable levels. This suggests that Oracol has a 
greater affinity for IgG in comparison to the other OFCDs and its
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selective nature is dearly an attribute that can be further studied in 
regard to collecting a more OMT-rich sample.
The OFCDs were tested on their ability monitor cotinine the assay 
used was standardised to account for dilutions in both the Orasure 
and Certus collectors, the cotinine assay didn’t provide much 
information on our non-smoking cohort as levels for the assay 
were below the cut-off, the male and females tested for smoking 
showed varying levels of cotinine in each of the tested collectors in 
particular the Seradate and Oracol, which showed a slight 
significant difference in collection in comparison to the OFCDs and 
control. Possible reasons for the differences are that potentially 
related to lower sample volume collection or concentration of 
cotinine within the material.
A collection order of oral fluid samples was studied to see any 
differences that may have occurred as a result of collecting 
samples. The samples were collected on 3 separate occasions to 
account for differences in levels monitored. Initial collection was 
done in the standard order, and was compared to reverse order of 
collection on 2 separate occasions. The times of sample collection 
were kept the same to account for diurnal variability. The final data 
showed no significant difference in the samples collected. As each 
method was conducted and allowed for adequate re-establishment 
of oral cavity at resting state, there was no variation shown.
This was not the case when testing for cotinine in the reverse 
order, as cotinine levels are dictated by the number of cigarettes 
smoked, the results showed no significant differences in the 
collection order, as the levels of cotinine measured almost 
mirrored the previous data sets.
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Closing comments
The testing of the Seradate prototype in comparison to available 
testing methods has shown that the levels of collection are within 
the ranges collected by current marketed OFCDs, the collection is 
a lot lower in comparison to pure OMT collection.
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Chapter 4
The effects of temperature on the stability of oral fluid 
4.1 Introduction
Oral fluid with its distinct advantages as a non- invasive collection 
medium can be collected stored and transported at a lower cost in 
comparison urine and blood, but it suffers from one major factor 
and that is its’ stability after coiiection. Numerous studies have 
been conducted on oral fluid sample processing and in particular 
in the field of oral fluid proteomics (Messana, Cabras et al. 2004; 
Hu, Xie et al. 2005; Chevalier, Hirtz et al. 2007; Schipper, Loof et 
al. 2007). Oral fluid is a host to not only endogenous proteases 
within saliva but also exogenous proteases presented by bacteria 
within oral flora. Proteases in oral fluid play an important role in the 
post-translational modification of proline-rich proteins, statherins 
and cystatins. These proteases regulate breakdown of oral fluid 
components once saliva is made present within the oral cavity, 
and the process continues outside of this environment also 
(Schipper, Loof et al. 2007).
Sample preparation for use in oral fluid diagnostics aims to ensure 
that constituents of oral fluid remain largely unaltered from time of 
collection to time of storage. As samples collected for oral 
diagnosis are often collected on off-site locations from areas of 
testing, measures are required to be placed that will hinder 
degradation and to achieve a degree of stability.
Current marketed OFCDs such as the Orasure and Certus take 
this into account by providing a buffer solution with the collector 
(Cordeiro, Turpin et al. 1993; Cameron and Carman 2005). The 
buffer solution is anti-bacterial to lower the effects of degradation
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of saliva proteins by endogenous and exogenous factors. The 
stability tests conducted using the Orasure buffer solution have 
shown stability of oral fluid test constituents ranging from drugs to 
immunoglobulins at various temperatures (Malamud 1997; 
Cameron and Carman 2005).
As most literature based on sample stability covers oral fluid 
samples collected within a controlled environment, samples are 
immediately placed on ice for same day testing with the addition of 
protease inhibitors or subjected to freezing either at -20°C, -86°C 
or snap-frozen in liquid nitrogen (Cameron and Carman 2005; Hu, 
Xie et al. 2005; Chevalier, Hirtz et al. 2007). The temperature at 
which the collected samples can be subjected to prior to analysis 
is variable on external factors such as location of collection and 
surrounding temperature.
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4.2 Aims
To test the stability of the oral fluid samples and its contents, the 
concentration of IgG and cotinine were measured. Oral fluid 
samples were collected using the Seradate and OFCDs (The oral 
fluid collection and testing of IgG and Cotinine were conducted in 
the same manner as described in chapter 4).
A cohort of female and male volunteers, were separated into 
groups of smokers and non-smokers.
Each collected sample was aliquoted into separate microfuge 
tubes to prevent contamination and to prevent free-thaw errors 
that can arise in frozen samples. The samples were collected 
using the Seradate, Orasure, Salivette, Oracol, Certus and normal 
drooled oral fluid was used as a control.
4.3 Materials and Methods
Stability of oral fluid at different temperatures
To test the stability of the collected samples, each was subjected 
to a range of temperatures that were documented in the literature. 
A time course study was conducted with initial values taken on the 
day of collection and then at intervals of 3, 7, 14, 21,28 days 
respectively. The samples were tested for IgG and cotinine 
concentration using Human IgG Elisa Quantitation Kit Bethyl 
Laboratories Inc (Montgomery, USA) and Human Salivary cotinine 
detection kit (Salimetrics Europe, Suffolk, UK).
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Oral fluid storage at room temperature
All test samples were aliquoted, labelled and sealed into 1.5ml 
microfuge tubes (Eppendorf, UK) and placed on microfuge rack 
away from direct sunlight and left at normal room temperature. 
Prior to testing all samples were centrifuged (9000g for 10 
minutes) to remove any cellular debris.
Oral fluid storage using refrigeration (4°C)
All test samples were aliquoted, labelled and sealed into 1.5ml 
microfuge tubes (Eppendorf, UK) prior to placement within a 
refrigerator. Prior to testing all samples were centrifuged (9000g 
for 10 minutes) to remove any cellular debris.
Oral fluid storage using freezer (-20°C)
All test samples were labelled and sealed into 1.5ml microfuge 
tubes (Eppendorf, UK) prior to placement within a freezer. Prior to 
testing all samples were centrifuged (9000g for 10 minutes) to 
remove any cellular debris.
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4.4 Monitoring the stability of IgG at different storage 
temperatures
Stability of IgG at room temperature
Measurements for the stability of IgG from collected samples 
taken using OFCDs and control at room temperature (See figure 
4,1).There was no significant differences in levels of IgG 
concentration between the male and female cohort.
An elevation in IgG concentration was seen on day 3 post 
collection in all tested OFCDs. Post day 7 samples that exhibited 
signs of degradation include Seradate, Oracol, Salivette and 
Control. These exhibited a similar trend in IgG concentration 
throughout the time scale. Seradate, Oracol, Salivette and Control 
were treated with protease inhibitors and showed a significant 
decline in IgG concentration in comparison to the Orasure and 
Certus (that used an anti-bacterial buffer).
Post 21 Days the Salivette sample could not be accurately 
measured as the IgG levels were below the detection range of the 
assay.
On Day 28 samples collected using the Salivette, Oracol, 
Seradate and control could not be accurately measured as the 
Levels of IgG were below the detection range of the assay.
There were no significant changes in the levels of IgG in both the 
Orasure and Certus over the period of 28 days
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Stability of IgG at 4°C
Measurements for the stability of IgG from collected samples taken using 
OFCDs and control at 4°C (See figure 4.2)There was no significant 
differences in levels of IgG concentration between the male and female 
cohort.
All tested samples were stable post day 7 of the study; this was expected 
as the samples were maintained at a constant lower temperature.
Post Day 14 the samples treated with protease inhibitor showed signs of 
degradation this includes the Oracol, Seradate, Salivette and control 
samples in comparison to the Orasure and Certus.
Post Day 21 sample degradation was more pronounced in the in Oracol, 
Seradate, Salivette and control samples.
On Day 28 Salivette, Oracol, Seradate and control samples could not be 
accurately measured as the Levels of IgG were below the detection 
range of the assay.
There were no significant changes in the levels of IgG in both the 
Orasure and Certus over the 28 day period.
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Stability of IgG at -20°C
According to the literature the stability of IgG at -20°C should show a 
greater resistance to breakdown and exhibit lower degradation. In figure 
4.3 the Seradate and control samples showed an initial decline in levels 
of IgG, but stabilised after day 7 of the study. Both the Certus and 
Salivette samples maintained levels of stability. There was a steady 
decline in IgG levels with regards to the Orasure sample in comparison to 
other temperature, but the discrepancies showed no significant changes 
overall.
There was a steady decline associated with the Oracol samples, as 
these samples were not treated any differently to the other test samples, 
this discrepancy can be associated with possible contamination of the 
sample.
On day 28 all samples were within the detection range of the IgG assay 
and showed a greater stability in comparison to 4°C and room 
temperature.
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4.5 Monitoring the stability of cotinine at different storage 
temperatures
Stability of cotinine at room temperature
The stability of cotinine from collected samples, using OFCDs and control 
at room temperature over a period of 28 days (Figure 4.4).
There were no significant differences in cotinine levels between both the 
male and female cohort.
There was a slight significant difference in cotinine concentration in both 
the Oracol and Seradate samples, between time points day 7 and day 28 
this could be associated with sample handling and assay inaccuracies. 
Overall there were no significant changes in the stability of cotinine over 
the period of the study.
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Stability of cotinine at 4°C
The stability of cotinine from collected samples, using OFCDs and control 
at room temperature over a period of 28 days (Figure 4.5). There were 
no significant differences in cotinine levels between both the male and 
female cohort.
The levels of cotinine concentration were consistent throughout the study 
period. There were slight significant differences presented by Oracol, 
Orasure and Seradate. The maintenance of a uniform temperature (4°C) 
showed greater stability in the levels of cotinine measured throughout the 
period of study.
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Stability ofcotinine at -20°C
The stability of cotinine from coliected samples, using OFCDs and control 
at room temperature over a period of 28 days (Figure 4.6). There were 
no significant differences in cotinine levels between both the male and 
female cohort.
The levels of cotinine concentration were consistent throughout the study 
period. The maintenance of a uniform temperature (-20°C) showed 
greater stability in the levels of cotinine measured throughout the period 
of study in comparison to the tested parameters of 4°C and 21 °C.
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4.6 Discussion
We looked at the stability of oral fluid collected using different 
OFCDs and drooled oral fluid (Control) over a range of controlled 
temperatures. To do this the levels of IgG and cotinine were 
measured. The degradation studies cited in literature only cover 
shorter time periods between 1-14 days (this is an approximation 
of the maximum time for a sample to be transported for testing 
purposes).
The tested samples were subjected to the following temperatures 
and the stability of IgG and cotinine were monitored
• Room Temperature (21 °C)
• Fridge (4°C)
• Freezer (-20°C)
The effects of temperature on the stability of IgG 
Room temperature (21°C)
A potential reason for witnessing a degradation of IgG post day 7 
in the Oracol, Seradate, Salivette and control can be related to the 
protease inhibitor used as the effects of protease inhibitors are 
directed to endogenous proteases present in oral fluid, that are 
derived from salivary glands and are often directed to serine, 
cysteine, metallo and aspartic proteases (Kennedy, Davis et al. 
1998; Schipper, Loof et al. 2007) and this doesn’t account for 
exogenous proteases released by bacteria within the oral fluid 
samples. These stipulations coincide with literature in a study 
conducted by Wong et al that had shown total salivary protein 
degradation within two weeks with the addition of protease 
inhibitors. Overall sample integrity can also be affected by sample 
contamination during and after processing.
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Fridge (4 °C)
The samples that were treated with protease inhibitor (Seradate, 
Oracol, Salivette and control) showed a decrease in stability over 
a period post 14 days at 4°C. This provides evidence that a lower 
temperature can improve sample stability until they are affected by 
bacterial components. Our findings show Post 14 day’s oral fluid 
samples show a decline in IgG concentration with exception of 
samples collected using the Orasure and Certus, as these OFCDs 
use anti-bacterial buffers. Oral fluid does contain a mixture of anti­
bacterial and anti-proteolytic components that can account for the 
initial resistance in IgG decline.(Malamud 1997; Esser, Alvarez- 
Llamas et al. 2008)
Freezer (-20°C)
Chevalier et al stated that oral fluid samples are stable at -20°C in 
the presence of protease inhibitors (Chevalier, Hirtz et al. 2007). 
This coincides with our findings as final concentrations of IgG 
measured in all tested samples showed greater stability at this 
temperature in comparison to room temperature (21 °C) and fridge 
temperature (4°C).
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The effects of temperature on the stability of Cotinine
Cotinine is not metabolised after expectoration, and is not affected 
by normal oral fluid proteases. A study by Foulds et ai on cotinine 
stability was conducted on samples of untreated saliva collected 
by cotton roll, their results showed differences in minimal change 
in cotinine levels over a 12 day period (Foulds, Bryant et al. 1994), 
all our OFCD samples were monitored for cotinine these showed a 
steady decline over the period of 28 days, but values were still 
within limits of the original concentration and would provide correct 
information for smoking studies. For long term maintenance of oral 
fluid samples, the ideal temperature of storage would be -20°C 
and post processing and testing should be conducted within a 
period of 14 days.
There was a difference in levels of cotinine between our female 
and male volunteers, as females showed a lower level in 
comparison to males. However this factor is unrelated to our 
stability study.
Closing comments
From our data it can be seen that the effects of sample storage 
are of utmost importance and further testing will be required in the 
testing of alternate anti-bacterial buffers to find an ideal storage 
solution for OFCD sample storage. Literature on the stability of 
oral fluid has suggested potential avenues that can be tested 
alongside our methods in the study. As protease inhibition within 
oral fluid is still a problem in oral fluid based studies, potential 
solutions would be to test the effects of pH on the oral fluid sample 
by changing acidity and alkalinity (these changes would also need 
to account for measurements of oral fluid components aside from 
those tested in this study) or using a higher temperature (boiling
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samples). These measures have the potential of denaturing or 
retarding the proteolytic effects of enzymes present with the test 
samples. Our study focussed on the stability of IgG and cotinine, 
further work can be suggestive of measuring other 
immunoglobulins (salivary IgA and IgM) to compare levels of 
stability within our chosen temperature range.
The samples stored at room temperature (21 °C) and at 4°C all 
showed signs of an initial increase in IgG concentration that was 
attributed to evaporation, further work to prevent this would be to 
wrap sample tubes in parafilm. It can therefore be concluded that 
oral fluid samples should be kept at temperatures of •*20oC or 
lower to increase sample integrity and standard protocols should 
be made in accordance to other laboratory methods especially 
when samples are to be analysed at later date.
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Chapter 5
The effects of smoking on stress markers present in oral fluid 
5.1 Introduction
Stress can be termed as a state in which the body’s homeostasis 
is disturbed. The stressor can be of biological, environmental, 
social, emotional, or of psychological nature. The body’s reaction 
to achieve homeostasis is called stress response. The monitoring 
of stress markers in oral fluid is documented within the literature, 
particular attention has focussed on the measuring the levels of 
salivary alpha amylase and cortisol (Gatti, Antonelli et al. 2009; 
Nater and Rohleder 2009; Almela, Hidalgo et al. 2011).Stress 
response is regulated by two primary neuro-endocrine systems, 
the hypothalamus pituitary- adrenocortical (HPA) system and the 
sympathetic adreno medullary system. Neuro endocrine markers 
such as salivary alpha-amylase and cortisol in serum or in oral 
fluid have an important role in establishing human responses to 
stressful events. Increases in salivary alpha-amylase upon onset 
of immediate stress have been tested on stressors such as 
physical exertion, cold and heat. The use of salivary cortisol 
measurements within oral fluid testing are well established in 
comparison to their serum counterpart. Salivary cortisol levels 
have been used to monitor the activity of the HPA axis. (Gatti, 
Antonelli et al. 2009; Nater and Rohleder 2009). In Chapter 4 
OFCDs were tested to measure cotinine levels, this was used as 
an indicator of smoking status in individuals, as cotinine levels and 
inter individual monitoring can provide a more accurate method of 
establishing number of cigarettes smoked in comparison to self 
admission(Montalto and Wells 2007; Fu, Fernandez et al. 2009; 
Almela, Hidalgo et al. 2011). Smoking is a dehabilitating habit,
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which affects millions worldwide. Nicotine is the main component 
of tobacco smoking that leads to addiction. Once nicotine is 
ingested by smoking or oral administration (tobacco chewing) it is 
metabolised by the cytochrome p-450 within the liver and is 
converted into cotinine and nicotine-N-oxide. Cotinine accounts for 
80% of the metabolised content of nicotine and has a half-life of up 
to 24 hours in vivo; this is in contrast to nicotine that exhibits a 
much shorter half-life of 2 hours.
The monitoring of cotinine is therefore a better indicator for 
measuring smoking status even when smoking has ceased, as 
cotinine can be found within oral fluid for periods of up to 10 days 
and for longer periods within hair and nail samples(Fu, Fernandez 
et al. 2009; Tzatzarakis, Vardavas et al. 2012).
Smokers report they smoke more under stress and many smokers 
believe that smoking reduces stress (Hauge, Torgersen et al. 
2012), the links between Smoking and the induction of stress are 
not lucid in the literature. The influence of smoking and its effects 
on oral fluid markers of stress will be examined. To measure 
markers of stress alongside smoking the levels of alpha-amylase, 
cortisol and albumin will also be measured.
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5.2 Aims
The aims are to test the Seradate against the OFCDs by 
measuring stress markers in smoking and non-smoking 
volunteers. The smoking status of the individuals will be verified by 
cotinine levels present in the collected samples. The samples will 
be tested for alpha-amylase, albumin, cortisol and 
immunoglobulins IgA, IgG and IgM. Based upon smoking status of 
the individuals, comparisons will be made to the corresponding 
stress markers. The levels of stress markers in relation to gender 
will also be tested.
The measurement of the concentrations of albumin and 
immunoglobulins IgA, IgG and IgM are to provide further 
information on the effects of smoking on vascular permeability and 
gum integrity of the smoking and non-smoking cohort. The levels 
of immunoglobulins in smoking samples will provide an insight into 
possible compensatory mechanisms that are related to poor oral 
immunity that results from oral hygiene in smokers.
The samples were collected from a group of male and female 
volunteers aged between18-30. This group was further sub­
divided into smokers and non-smokers.
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5.3 Materials & Methods
Measuring levels of cotinine and immunoglobulins in oral 
fluid
The levels of cotinine and immunoglobulins were measured using 
the same methodology as stated in chapter 4 using Human 
IgA/IgM/IgG Elisa quantitation Kit Bethyl Laboratories Inc 
(Montgomery, USA) and Human Salivary Cotinine detection kit 
(Salimetrics Europe, Suffolk,UK).
Measuring levels of albumin in oral fluid
The albumin presence in the samples was tested using Human 
albumin Elisa quantitation kit Bethyl Laboratories Inc 
(Montgomery, USA) in accordance to manufacturer’s instructions. 
96 well High Bind flat bottomed plate (Costar Corning 
Lifesciences, UK) were coated with goat anti-human affinity 
antibody (Primary Antibody, Bethyl laboratories Inc, USA) The 
number of wells used was determined by assay standards, 
controls and the total number of samples tested (either duplicate 
or triplicate). 1 pi of capture antibody diluted with 100ul of coating 
buffer (0.05 M Carbonate-Bicarbonate Sigma Aldrich, UK) 
administered to each test well. The plate incubated at 21 °C for 60 
minutes or overnight at 4°C.
The coating buffer was removed by a 3 - step wash (Tecan 
Columbus plate washer. Austria. Phosphate buffered saline, 
0.05% Tween 20).Each step of the wash is involves washing of 
the wells and aspirating the wells, this process is repeated a total 
of three times within the 2-step wash process, the plates are then 
dried by tapping onto blue roll. 200 pi of blocking solution 
(Phosphate buffered saline, 1% BSA, pH 8.0) was added to each
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well. The plate was incubated for 60 minutes at 37°C. After 
incubation the blocking solution was removed by 3 - step wash (as 
previously described).
The assay standards used human serum as reference (final serum 
concentration 1000 ng/ml according to manufacturer’s guidelines). 
100 pi of sample diluent (Phosphate buffered saline 1% BSA, 
0.05% Tween 20, pH 8.0) was added to each well. 100 pi of dilute 
standard was added to the first well, mixed and 100 pi removed 
and added to the second well, the process was repeated for the 
next 7 wells. This produced a standard curve ranging from 
1000 ng/ml - 7.8 ng/ml. Oral fluid samples were added these were 
diluted to optimal concentration to specific wells. The plates were 
then incubated at 21°C for 60 minutes.
The samples were removed by 5 - step wash (This is a similar 
process to the 3 - step wash). Secondary HRP detection antibody 
was added to each test well, this was diluted from stock 
(1:50,000).100 pi of secondary HRP-detection antibody was 
added to each well and the plate incubated for 60 minutes. After 
Incubation the secondary HRP-detection antibodies were removed 
using a 5-step wash and 100 pi 3, 3’, 5, 5’-Tetramethylbenzidine 
(TMB. Sigma Aldrich) was added to each well. The plate was 
sealed, covered and placed on a rotating platform for colour 
development. The development time was between 5-10 minutes, 
the reaction was stopped by adding 100 pi 4N H2SO4 to each test 
well. The plate was analysed at 450 nm on a spectrophotometer 
(J Bio LP 400). The sample Immunoglobulin concentrations were 
calculated from a standard curve using Microsoft Excel (For a 
detailed list of materials used please refer to appendix B).
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Measuring levels of cortisol in oral fluid
To measure sample cortisol levels Human salivary cortisol 
detection kit (Salimetrics Europe, Suffolk,UK) was used according 
to manufacturer’s instructions. All reagents and plates were 
brought to room temperature. 1 X Wash Buffer was prepared.
25 pi of standards, controls, and unknowns were placed into 
appropriate wells. 25 pi of assay diluents was pipetted into an 
empty well to account for control and non specific binding. The 
conjugate antibody was diluted 1:1600. 200 pi of conjugate 
antibody was added to each test well. The plate was mixed at 
500rpm for 5 minutes on a plate shaker. The plate was then 
incubated for 55 minutes at room temperature (21 °C). The test 
samples underwent a four step wash with 1X wash buffer using 
Tecan Columbus Plate Washer (Austria). The plate was dried and 
200 pi of 3, 3’, 5, 5’- Tetramethylbenzidine solution was added to 
each well (Sigma Aldrich, UK). The plate was mixed for 5 minutes 
at 500 rpm or tapped to mix. The plate was incubated in dark at 
21 °C for 25 minutes. 50 pi of stop solution was added to each 
well. The plate was mixed for 3 minutes at 500 rpm on a plate 
shaker.The plate was analysed at 450 nm on a spectrophotometer 
(JBio LP 400).The cortisol concentrations in each sample were 
calculated from a standard curve using Microsoft Excel (for a 
detailed list of materials used please refer to appendix B).
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Measuring levels of alpha-amylase in oral fluid
To measure alpha- amylase in samples the salivary alpha amylase 
detection kit (Salimetrics Europe, Suffolk, UK) was used according 
to manufacturer’s instructions.
The plate reader was set to incubate at 37°C and to read in center 
measurements using kinetic mode at one minute and then at three 
minutes. Samples were diluted 1:10 with assay diluent. The alpha- 
amylase substrate was heated to 37°C in an incubator. 8 pi of 
controls or diluted test samples was added to each well. 320 pi of 
pre-heated alpha-amylase conjugate substrate solution was added 
each well by multichannel pipette. Measurements were taken at 1 
minute and 3 minutes. The 1 Minute reading was subtracted from 
the 3 Minute reading to give final value for amylase activity (for a 
detailed list of materials used please refer to appendix B).
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5.4 The monitoring of stress markers collected using OFCDs
Comparing cotinine concentration in male and female 
smokers
The levels of cotinine were measured in the cohort, the group was 
sub-divided into 2 groups of male and female participants, the 
values representing the non-smoking individuals were not included 
as they fell out of the range of the assay and graphical 
representation would have resulted in a negative plot (see figure 
5.1).
100 n
Male
Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.1 The levels of cotinine collected by various collection methods. Bar 
height the mean value ±SE. n =15.
The data shows that the cotinine values were significantly higher 
in females than males, possible reasons for this are samples were 
collected prior to the summer examination period at the university 
this could account for higher levels of cotinine with response to 
smoking caused by the onset of stress. The range of cotinine
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values is fairly low and although this is indicative of smoking 
status, individual smoking status was not taken into consideration. 
The cotinine levels shown are indicative of a light to moderate 
smoking habit (1-10 cigarettes per day). The consistency of each 
OFCD in monitoring cotinine is comparable to one another and 
there are no significant differences in the collection methods the 
only difference visible are that the female cohort showed higher 
concentration of cotinine in comparisons to male.
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Comparing levels of salivary albumin in males and females
The levels of albumin were measured in the group of smokers and 
non-smokers (figure 5.2). The levels of cortisol (=1500 ng/ml) in 
Orasure, Salivette, Seradate and Certus, these were significantly 
higher in comparison to the control (=1200 ng/ml). The Oracol 
collected the least amount of albumin (=1000 ng/ml) in comparison 
to all tested OFCDs and control.
i i Smokers 
■■ Non-Smokers
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.2 Comparing levels of albumin collected between smokers and non- 
smokers. Bar height the mean value ± SE. n =15.
The levels of albumin were measured in male and females (figure 
5.3). The levels of cortisol (=1500 ng/ml) in Orasure, Salivette, 
Seradate and Certus, these were significantly higher in 
comparison to the control (=1200 ng/ml). The Oracol collected the
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least amount of albumin (»1000 ng/ml) in comparison to all tested 
OFCDs and control.
2000 n
I------ 1 Male
Y////A Female1800 -
1600 -
1400 -
1200 -
1000 -
600 -
400 -
200 -
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.3 Comparing levels of albumin collected between male and female. Bar height 
the mean value ± SB. n =15.
There were no significant differences between the levels of 
albumin in neither smoking / non-smoking group nor the male and 
female group.
The measured levels of albumin showed no significant differences 
in either of the test groups this suggests that albumin can be used 
as constant by which to monitor OFCD samples for the 
involvement of OMT based proteins and its’ uses as a 
complimentary marker for commercial OFCD methods that use 
IgG as the sole entity for sample validity.
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Comparing levels of salivary cortisol in males and females
The levels of Cortisol were measured in the group of smokers and 
non-smokers (figure 5.4). The levels of cortisol (ranging from 30 
ng/ml - 50 ng/ml) in Salivette and Oracol, this was significantly 
lower in comparison to the control (50 ng/ml - 80 ng/ml) but 
significantly higher in comparison to Orasure, Seradate and Certus 
(10 ng/ml -15 ng/ml)
The cortisol levels fluctuated between collection methods but 
these values were only marginally different when comparing the 
smokers and non smokers.
120 n
100 -
I i Smokers 
■■ Non-Smokers
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.4 Comparing levels of cortisol collected between smokers and non-smokers 
.Bar height the mean value ±SE. n =15.
The levels of Cortisol were measured in the group of males and 
females (figure 5.5). The levels of cortisol (ranging from 40 ng/ml- 
50 ng/ml) in Salivette and Oracol, this was significantly lower in
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comparison to the control (60 ng/ml - 80 ng/ml) but significantly 
higher in comparison to Seradate (20 ng/ml - 40 ng/ml) and 
Orasure and Certus («10 ng/ml). The difference between Males 
and females showed no significant difference in the levels of 
cortisol monitored.
160 -i
140 -
I------ 1 Male
v/ss/A Female
120 -
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.5 Comparing levels of cortisol collected between male and female .Bar 
height the mean value ±SE. n =15.
The control sample of drooled saliva expressed an excess in 
cortisol levels measured, this value only varied in slight 
significance to other samples and was elevated in the non­
smoking cohort. The differences in cortisol values by both the 
Salivette and Oracol could be associated with sample 
concentration within the material as they differ from the trend seen 
by all other collection methods.
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Comparing levels of salivary alpha-amylase activity in males 
and females
The activity of alpha-amylase was measured in the group of 
smokers and non-smokers (figure 5.6). The levels of alpha- 
amylase activity range from 50 U/ml -90 U/ml in the Salivette 
which significantly higher in comparison to the control (30 U/ml - 
40 U/ml), Orasure, Oracol, Seradate (15 U/ml - 20 U/ml) and 
Certus (5 U/ml)
There is marginal elevation of alpha amylase in smokers in 
comparison to the non-smokers group, the only exception to the 
trend can be seen in drooled saliva sample.
140 -
120 -
Smokers
Non-Smokers
100 -
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.6 Comparing levels of alpha-amylase activity measured between smokers and 
non-smokers. Bar height the mean value ± SE. n =15
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The activity of alpha-amylase was measured in the group of males 
and females (figure 5.7). The Salivette (50 U/ml) was significantly 
higher in comparison to the control (30 U/ml - 50 U/ml), Orasure, 
Oracol, Seradate (15 U/ml - 20 U/ml) and Certus (5 U/ml).
120 -i
100 ■
Male
Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.7 Comparing levels of alpha-amylase activity measured between male and 
female. Bar height the mean value ± SE. n =15
Within the male and female sub-groups there were no significant 
differences in the levels of alpha-amylase activity amongst the 
individual .But differences in alpha-amylase activity can be noted 
in Salivette which showed higher affinity for alpha-amylase release 
and in contrast the Certus showed the least.
As the values for the remaining OFCDs fall within range of values 
dictated by drooled saliva (control group), there is a scope for use 
of OFCDs monitoring alpha-amylase activity.
147
Chapter 5
Comparing levels of salivary immunoglobulins in males and 
females
Comparing salivary IgA in males and females
The levels of IgA were measured In the group of smokers and 
non-smokers (figure 5.8).The control (30 pg/ml - 50 pg/ml) was 
significantly higher in comparison to Orasure, Oracol, Seradate 
(=30 pg/ml), Salivette (=20 pg/ml) and Certus (=10 pg/ml).
Smokers
Non-Smokers
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.8 Comparing concentration of IgA measured between smokers and non- 
smokers using various collection methods. Bar height the mean value ± SE. n =15
There was no significant difference between smokers and non- 
smokers. IgA levels were consistent amongst the OFCD 
collections; the variation seen in the control group is suggestive of 
no absorptive material interference in a pure oral fluid sample. The 
comparatively low levels of IgA presence by the Certus are linked
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to previously stated reasons of processing the sample (Certus 
does not use centrifugation to release collected oral fluid).
The levels of IgA were measured in the group of males and 
females (figure 5.9). The control (*35 pg/ml) was significantly 
higher in comparison to Orasure, Seradate (20 pg/ml - 30 pg/ml), 
Salivette (10 pg/ml - 20 pg/ml), Oracol (10 pg/ml -15 pg/ml) and 
Certus (*10 pg/ml).
The levels of IgA were significantly higher in males in comparison 
to females by individual OFCDs however no difference was 
evident within the control group. This could be related to material 
absorption.
I-------1 Male
iW\i Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.9 Comparing concentration of IgA measured between Males and Females using 
various collection methods. Bar height the mean value ± SE. n =15
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Comparing salivary IgG in males and females
The levels of IgG were measured in the group of smokers and 
non-smokers (figure 5.10)The Oracol (8 pg/ml) was significantly 
higher in comparison to control, Orasure, Seradate (»5 pg/ml), 
Salivette (=2 pg/ml) and Certus (=0.5 pg/ml). There was no 
significant difference between the smokers and non-smokers 
among individual OFCDs. The possibility of this occurring is quite 
unique and will be examined in the discussion.
Smokers
Non-Smokers
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.10 Comparing concentration of IgG measured between smokers and non- 
smokers using various collection methods. Bar height the mean value ± SB. n =15
The levels of IgG were measured in the group of males and 
females (figure 5.11). The Oracol (4 pg/ml - 7 pg/ml) was 
significantly higher in comparison to control, Orasure (*4 pg/ml), 
Seradate (3 pgml), Salivette (»2 pg/ml) and Certus («0.5 pg/ml).
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In both test groups the IgG levels were highest by collection of the 
Oracol, and lowest levels of IgG were collected by the Certus and 
Salivette.
I-------1 Male
v////a Female
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.11 Comparing concentration of IgG measured between Male and Female using 
various collection methods. Bar height the mean value ± SE. n =15
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Comparing salivary IgM in males and females
The levels of IgM were measured in the group of smokers and 
non-smokers (figure 5.12). The Control (2 pg/ml - 6 pg/ml) was 
comparable Oracol and Seradate. These were significantly higher 
to Orasure (=1 pg/ml) and Certus (=0.5 pg/ml). There was no 
significant difference between the smokers and non-smokers 
among individual OFCDs.
Smokers
Non-Smokers
Saliva Orasure Salivette Oracol Seradate Certus
Figure 5.12 Comparing concentration of IgM measured between smokers and non- 
smokers using various collection methods. Bar height the mean value ± SB. n =15
The levels of IgM were measured in the group of males and 
females (figure 5.13). The Seradate (2-6 pg/ml) was comparable 
to the Oracol. These were significantly higher to control (=3 pg/ml), 
Orasure, Salivette (1.0 pg/ml -1.5 pg/ml) and Certus (=0.5 pg/ml). 
There was no significant difference between the males and 
females among individual OFCDs.
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Lower levels of IgM were presented by the Orasure and Salivette 
that are potentially related to cotton based interference with the 
assay.
E
U)
2c
$c
CD
I-------1 Male
W///A Female
Saliva Orasure Salivette Oracd Seradate Certus
Figure 5.13 Comparing concentration of IgM measured between smokers and non- 
smokers using various collection methods. Bar height the mean value ± SE. n =15
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5.5 Discussion
We aimed to measure variation of oral stress markers on the 
effects of smoking. Our data was collected amongst a group of 
males and females and a sub group of smokers and non smokers, 
both test cohorts showed no significant differences in the 
monitoring of stress markers and in particular the measurement of 
stress markers on smoking. The levels of cotinine within the 
femaie cohort were higher than those in the male group, alongside 
the reasons given previously, its noted within the literature that 
females have a higher metabolism of nicotine and will therefore 
report higher levels of cotinine in comparison to males (the 
opposite was observed in our test group in chapter 4)(Benowitz, 
Lessov-Schlaggar et al. 2006; Berlin, Gasior et al. 2007).
The levels of albumin within the samples served as control in 
terms of sample validity. The level of albumin in oral fluid is 
representative of OMT presence. Each of the tested OFCDs 
including control drooled oral fluid showed respective albumin 
levels. The levels of albumin between smokers and non-smokers 
were indifferent, which is supported by the literature, as increases 
in albumin levels are linked to immunodeficiency.
The measurement of alpha-amylase activity within the groups 
showed low levels and were within normal ranges of values 
measured in oral fluid (Nater, Rohleder et al. 2005; Nater and 
Rohleder 2009). The effects of smoking on levels of alpha- 
amylase could show levels of increase and decrease, the samples 
showed lowered salivary alpha amylase have also been 
associated with smoking caused by inhibition to structure and 
function of salivary alpha-amylase by acidic aldehydes that are 
present in tobacco smoke(Granger, Blair et al. 2007). It has also
154
Chapter 5
been reported that smoking has no effect on salivary alpha- 
amylase release and is attributed to other exogenous factors such 
as sleep deprivation, body weight and height.
The measurement of cortisol was conducted in the afternoon to 
allow for controlled values to be taken. The levels of cortisol were 
predominantly higher in smokers than non-smokers. Literature 
suggests the possible reason for this is via the activation of HPA 
via nicotinic receptor activation, thus showing an elevation in 
cortisol levels (Badrick, Kirschbaum et al. 2007). This however is 
inconclusive and relation between cortisol levels and smoking are 
still ambiguous. The possible reasons for these findings are due to 
limitations within the study. The age group of the tested cohort 
ranged from student volunteers between the ages of 18-30 and as 
the smoking activity was not successfully monitored either by the 
fagerstrom test or self-admission by individuals. An estimation of 
cigarettes smoked was done measuring cotinine levels against 
salivary nicotine index. The cohort gave values of low to moderate 
smoking status. The tested individuals all answered yes to regular 
dental visits and this provided an insight into oral health of the 
volunteers. The monitoring of immunoglobulins and possible 
compensatory mechanisms for oral health could not be suitably 
established. The limitations to our study was on the induction of a 
stressor and the effects of smoking, the samples were collected 
prior to impending summer examinations of the tested individuals, 
this could have caused the differences measured in values for 
stress hormones and the link to the effects of smoking could not 
therefore be well established. As the test was conducted in the 
course of one day at one set time point, further tests on alternate 
days prior to the examination may have provided more conclusive 
data.
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By diversifying our age groups to encompass a greater age cohort 
would have provided a greater level of depth to the study. As the 
examination of oral health status is monitored in dental 
publications this could provide screening of test groups to 
compare smokers with poor oral health to those with good oral 
health. As most published data focuses on disease groups 
information is often related to normal and healthy. In the case of 
our study the groups seem to have merged so no real differences 
are evident (Bunyaratavej 2006; Vellappally, Fiala et al. 2007).
The collection ability of OFCDs was tested on stress markers 
present in oral fluid. Studies have shown the use of cotton based 
OFCDs show alteration to actual levels cortisol and IgA present 
within normal drooled oral fluid (Strazdins, Meyerkort et al. 2005; 
Kidd, Midgley et al. 2009; Kozaki, Hashiguchi et al. 2009). This will 
account for both the Salivette and Orasure OFCDs which showed 
a lower representation of IgA and cortisol respectively. These 
findings were inconclusive within our data as levels were 
comparable with other non-cotton based collection methods.
Closing comments
The effects of absorptive materials has a different effect on final 
concentrations monitored in assays, these effects will require 
further standardisation especially in the monitoring of hormones 
and immunoglobulins alike as they may provide false information 
to true values present in the human body.
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Chapter 6
The screening of oral fluid proteins 
6.1 Introduction
The field of proteomics and its advancement in identifying oral fluid 
proteins have used many analytical methods that include 1D SDS 
PAGE and 2-D gel electrophoresis protein gels coupled with 
liquid/gas chromatography mass spectrometry.
The oral fluid matrix is a mixture of protein taken from various 
salivary glands (the parotid gland, submandibular gland, 
sublingual gland and minor salivary glands that lie beneath the 
oral mucosa), OMT and oral micro-biota present within the oral 
cavity. The quantitation and qualitation of oral fluid proteins will 
help establish its composition, physiological functions and its 
potential use as a prognostic and diagnostic fluid. Oral fluid has 
been quantitated to measure metabolic alterations and 
pathological conditions that are associated with abnormal 
concentrations of proteins. (Helmerhorst and Oppenheim 2007;
Hu, Loo et al. 2007; Messana, Inzitari et al. 2008).
The composition of oral fluid has been found to differ in its 
constituents in profiling studies post collection, and shows inter- 
variability and intra-variability between individuals. This has been 
associated to the period of sample collection and additional 
exogenous factors (diurnal changes, eating habits, exercise and 
oral and systemic health). The protein profiles taken from 
individual salivary glands also show different levels of proteins, 
which is evident as either an increase/decrease or lack of protein 
presentation in comparison to whole oral fluid samples.(Hu, Loo et 
al. 2007; Messana, Inzitari et al. 2008).
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Oral fluid proteins that have been studied include proline rich 
proteins (PRPs) these account for 60 % of the total oral fluid 
proteome and are subdivided into acidic, basic and glycosylated 
groups. Their main functions are the modulation of calcium ions 
within the oral cavity. They also perform other essential functions 
within the oral cavity that are yet to be discovered. Histatins are 
small peptides that possess powerful anti-fungal properties. 
Statherins are involved in calcium ion homeostasis and teeth 
mineralisation. Cystatins are inhibitors of cysteine proteases and 
protect against oral cavity pathogens. Salivary a-amylase 
accounts for 20% of salivary weight in oral fluid proteins and is the 
most abundant of the singular proteins in oral fluid. It exhibits a 
few differences from its pancreatic counterpart, and it is found in 
oral fluid in various glycol-isoforms .Proteins originating from OMT 
include serum proteins like salivary IgA, IgG and albumin, proteins 
of the S100 class and other calcium binding proteins, defensins, 
thymosin b4 and different peptide hormones.
It is best to view oral fluid proteins within the oral cavity as fish 
within a tank. The oral cavity collectively recycles proteins from 
exfoliated cells and oral flora and includes proteins originating 
from salivary glands and OMT. The distributions of proteins within 
the oral cavity are dictated by diffusion and concentration 
gradients. The protein composition in oral fluid is multivariate and 
the presence of minute quantities of proteins that show non­
functional properties may provide answers on oral mucosal 
degenerative disease and the classification of opportunistic 
infections within the oral cavity.
To account for changes in protein profiles, research groups have 
looked at ways to standardize the collected samples; so as to 
reduce sample variability. To compensate for individual variations
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in oral fluid samples, collected samples are often pooled before 
they are processed.(Hu, Loo et al. 2007). The preparation of Oral 
fluid samples prior to analysis is dependent on the compounds of 
interest in a particular study. The profiling of the oral fluid proteins 
by 2D gel electrophoresis has been subjected to many problems 
including distortion, smearing and unclear gels. The contributing 
factors to this are the presence of high molecular weight proteins 
such as alpha-amylase and albumin. In order to gain clearer 
protein profiles various methods of sample preparation have been 
used to limit or remove these components so as to provide a 
clearer profile and allow the analysis of low abundant proteins, and 
proteins that are masked by these high molecular weight 
proteins.(Deutsch, Fleissig et al. 2008; Messana, Inzitari et al. 
2008).
Alongside the removal of high molecular weight proteins, the use 
of gradient 2D gels has also been used to allow for the 
identification of low molecular weight proteins, 2D gel profiling has 
range of 120Kda-10 Kda, Proteins that fall above or below this 
range cannot effectively be monitored. Oral fluid processing is 
easier to perform than its serum counterpart, and has 
subsequently led to the discovery of new proteins within oral fluid 
that are of serum based origin (OMT derivatives); in particular 
serum based disease markers.(Amado, Vitorino et al. 2005; 
Helmerhorst and Oppenheim 2007)
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6.2 Aims
Our aims are to look at oral fluid proteins collected using the 
Seradate and OFCDs (used in chapter 4 and 5) in comparison to 
drooled oral fluid (Control).
1D SDS PAGE protein profiles will be used to screen abundant 
proteins collected by the Seradate, Orasure, Oracol and Certus 
against the control. The proteins that show highest intensity 
(abundance) will be reviewed, to provide qualitative evidence of 
protein presented by OFCD collection.
2D gel electrophoresis will be used create a protein screening 
profile of the Seradate OFCD against the control. The samples will 
be prepared using 3 different methods, to compare any variations 
in proteins presented between the tested samples. The methods 
used will be a standard method (developed by Dr. Deborah Ward) 
and two separate methods cited within literature by Castagnola et 
al and a new method developed by Deutsch et al. The standard 
method will function as control in comparison to the other 
methods.(Deutsch, Fleissig et al. 2008; Messana, Inzitari et al. 
2008).
The protein profiles from each sample preparation method will be 
screened and compared to provide the most suitable method for 
use in subsequent follow-up experimentation that will be 
supplemented by the use of mass spectrometry. The proteins will 
be identified using oral fluid 2D gel profiles taken from literature 
(Huang 2004).The examination of proteins within the 2D profiles 
will be directed to the screening of proteins that are of OMT-origin 
within oral fluid.
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6.3 Materials & Methods
Sample preparation for 1D gel electrophoresis
The oral fluid samples tested were collected in the same manner 
as shown in chapter 4. The protein concentration of each sample 
was determined using the Biorad protein concentration assay. The 
samples were precipitated using 10% TCA Acetone overnight. A 
final concentration of 50 pg/ml for each sample was used. The 
collected samples were mixed 4:1 with 5 X sample buffer (10% 
w/v SDS 10nM Dithiothreitol 20% v/v Glycerol 0.2M Tris-HCL 
0.05%w/v bromophenol),boiled at 65° C for 10 minutes via heat 
block.
1D gel electrophoresis
Stacking gel (1.25M Tris-HCI, pH 6.8) and resolving gel 
(3M Tris-HCI, pH 8.85) preparation can be found in appendix B. 
Samples were added to wells. 10 pi of ladder marker was placed 
in the first well followed by 10 pi of each test sample in adjacent 
wells. Any remaining wells were filled with sample buffer to provide 
an even load, so as to prevent the gel from smearing.
The gels were run at 100V for 15 minutes 200V until the dye front 
migrated to the end of the gel. The gel was then removed and 
stored in container with fixing solution prior to staining. The gels 
were incubated in fixing solution for 5 minutes at 55°C (shaking). 
The Fixing solution was removed by aspiration and the gels were 
incubated in staining solution for 10 minutes at 55°C (shaking).
The gels were washed with distilled water and incubated on a 
shaker in de-staining solution for 10-15 minutes at 55°C. The gels
161
Chapter 6
were then stored in H2O with acetic acid to prevent drying. The gel 
image was recorded using a densitometer.
Standard method for sample preparation for 2D gel 
electrophoresis
The protein concentration of each sample was determined using 
the Biorad protein concentration assay. The samples were 
precipitated using 10% TCA Acetone overnight.
Castagnola method for sample preparation for 2D gel 
electrophoresis (only used on drooled saliva and Seradate)
The protein concentration of each sample was determined using 
the Biorad protein concentration assay. 10 pi 0.05M 2,2,2- 
trifluoroacetic acid (TFA) to the sample.The samples were 
precipitated using 10% TCA Acetone overnight.
Deutsch method sample preparation for 2D gel 
electrophoresis (only used on drooled saliva and Seradate)
The samples were placed into a 1 ml syringe (Beckmann) with a 
0.45mm filter (Millipore). The syringe contained 1g potato starch 
(Sigma Aidrich). 600pl of distilled water hand pressed into the 
syringe to saturate the starch. A volume of 1ml saliva (2*500pi 
aliquots) was hand pressed and filtered. The resultant filtrate 
concentration was determined using the Biorad protein 
concentration assay (Biorad Laboratories). The samples were 
precipitated using 10% TCA Acetone overnight.
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2D get electrophoresis
Preparation and focusing of first dimension gels
3.4 mg of DTT, 2 pil of biolytes added to 1ml IEF rehydration 
solution was added to a microfuge tube. The tube was placed on a 
vortex and either 320 pi (17cm strips) or 135 pi (7 cm strips) of the 
mixture was added to the pre-prepared sample (precipitated 
protein pellet). The sample/rehydration solution was placed on 
vortex and left on a rotating platform at 21 °C for period of 60-120 
minutes (The sample was vortexed at 15 minute intervals). Once 
dissolved, the sample was centrifuged at 8000g for 5 minutes then 
applied to Immobilised pH gradient strip (IPG 3-10 ML, Biorad 
laboratories). Sample solution was then added to the strip holder. 
(300 pi (17cm strips) or 125 pi (7cm strips) added to the strip 
holder. The IPG strips were placed gel side down and covered 
with 1 ml of mineral oil.
Preparation of the 2nd dimension
The glass plates were rinsed using ethanol. The plates were 
mounted as a sandwich between 2 spacers. The plates were 
placed within the support construct (placed on a flat surface) and 
the clamps adjusted to secure construct. Distilled water was used 
to check for any leaking prior to the addition of the resolving gel.
The resolving gel and stacking gel mixture (detailed materials can 
be found in Appendix B) was poured between the plates leaving a 
2 cm gap at the top. The layer of Saturated Butan-2-ol was then 
added. Prior to adding the resolving gel is washed using distilled 
water to remove any saturated butan-2-ol. The stacking gel
163
Chapter 6
mixture is poured on top of the resolving gel. Followed by the 
addition of saturated butan-2-ol
Preparation of the IPG strips and running 2nd dimension
2*12 ml equilibration buffer added to 240 mg of DTT, 300 mg of 
IAA, rotated to dissolve. The IPG strips equilibrated for 15 minutes 
in DTT equilibration buffer, the strip were removed and 
equilibrated 15 minutes in IAA equilibration buffer.
The saturated Butan-2-ol was removed from the PAGE gel (See 
Section 2.8.4). The equilibrated IPG strip was placed on top of the 
stacking gel with good contact on all points. The strip is then 
covered with melted agarose gel. The Gel units were then 
assembled and run. For large gels, 15 m/A per gel for 30 minutes 
until the dye front migrated to the end of the gel. For mini gels 100 
V for 15 minutes 200V until the dye front migrated to the end of the 
gel. Once completed gels removed and stored in a container 
containing fixing solution prior to staining.
Siiver staining of 2D gels
The fix solution was removed using aspiration, and sensitisation 
solution was added, the gel was left to incubate for 30 minutes on 
a rotating platform. The Sensitisation solution was removed 
followed by 3 - step wash using distilled water (allowing an 
incubation period of 5 minutes between each wash). The distilled 
water was removed and silver stain solution was added. The 
container was covered and incubated on rotating platform for 20 
minutes. After this period the siiver stain solution was removed 
and the gel washed twice (incubation period of 1 minute).
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Development solution was added to the gel, this incubation period 
can vary between 5-10 minutes until banding can be seen on the 
gel surface. Stop solution was immediately added to prevent 
further staining and the gel image was recorded using a 
densitometer.
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6.4 The differences in protein composition of OFCDs using 1D 
gel Electrophoresis
The protein content of the samples was measured using the 
Bradford Assay (see materials and methods). The OFCDs used 
were the Seradate, Orasure, Oracol and Certus. Each of the 
protein profiles were compared to the control (drooled oral fluid). 
The initial visualization of the 1D SDS PAGE profiles showed a 
greater intensity of bands produced by OFCDs in comparison to 
the control (figure 7.1), the possible reasons for this are 
associated with retention of water within OFCD swabbing material 
that caused the samples to show a higher protein concentration in 
comparison to the control. The Proteins that presented maximum 
intensity was identified by weight these included albumin, alpha- 
amylase, Ig-Heavy Chain, Ig-Kappa Light Chain or alpha-amylase 
fragment, and cystatins. The orai fluid samples were taken from 4 
individuals and the collection procedure was conducted in the 
same manner as described in chapter 3. From the data its can be 
seen that samples collected all show similar protein profiles of 
abundant proteins (indicated by arrows on figure 6.1).
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Chapter 6
Comparing intensity levels of albumin
The measurement of albumin was done qualitatively using the 
mean gray value of each of the bands using Image J software.
The values were compared to that of the control and the variation 
of protein intensity was worked out as a percentage. In figure 6.2 
the Orasure expressed a 25% increase in albumin collection 
Seradate (10%) and Oracol (10%) in comparison to the control. 
The Level of albumin collected by the Orasure was significantly 
higher in comparison to the other collection devices The Certus 
expressed albumin levels lower than that collected from the 
control, and is associated with processing of the sample after 
collection. The Seradate expressed no significant differences 
against the Oracol, both the Seradate and Oracol showed 
significantly lower values of Albumin in comparison to the Orasure.
-10 -
-20
Orasure Oracol Serudate Certus
Figure 6.2 The level of albumin detected in relation to oral fluid. The mean grey 
value for each band was compared with that of expectorated oral fluid. The 
percentage value is a quantify intensity expressed in each band and 
corresponds to level of protein visualized. Error bars show ± SEM. n =4.
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Comparing intensity levels of alpha-amylase
The intensity levels of alpha-amylase were compared from the 1D 
profile (Figure 6.3) the findings show that the Orasure and 
Seradate OFCDs show a 20% increase in alpha-amylase 
collection, Oracol (10%) compared to OF. There was no 
statistically significant difference in the intensity of the protein 
between the Orasure, Oracol and Seradate. The Certus showed 
lower levels of alpha-amylase levels in comparison to the control.
Orasure Oracol Serudate Certus
Figure 6.3 The level of alpha-amylase detected in relation to oral fluid. The 
mean grey value for each band was compared with that of expectorated oral 
fluid. The percentage value is to quantify intensity expressed in each band and 
corresponds to level of protein visualized..Error bars show ±SEM. n =4
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Comparing intensity levels of Ig-Heavy chain
The Intensity levels of Ig-Heavy chain were compared with the 1D 
profile (see figure 6.4) the percentage difference in comparison to 
the control showed an increase in Ig-Heavy Chain collection by 
Orasure (20%) Seradate (15%), Oracol (10%).There was 
statistically no significant difference in the Intensity levels of the 
protein between the Orasure, Oracol and Seradate. The Certus 
showed statistically significant lower Intensity levels of Ig-Heavy 
Chain in comparison to control.
Orasure Oracol Serudate Certus
Figure 6.4 The level of Ig-Heavy chain detected in relation to oral fluid. The 
mean grey value for each band was compared with that of expectorated oral 
fluid. The percentage value is to quantify intensity expressed in each band and 
corresponds to level of protein visualized. Error bars show ± SEM. n =4.
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The Intensity levels of Ig- Kappa Chain/Fragment of alpha- 
amylase detected in the 1D gel profile in comparison to the control 
(see figure 6.5) The percentage in difference of intensity measured 
against the control Orasure (20%) Seradate (10%), Oracol (8%). 
There was statistically no significant difference between the 
Orasure, Oracol and Seradate. The Certus showed statistically 
significant lower Intensity levels of Ig-Heavy Chain in comparison 
to control.
<D
E
Orasure Oracol Serudate
H --10 J
Figure 6.5 The level of Ig- Kappa Light chain/ alpha-amylase fragment detected 
in relation to oral fluid. The mean grey value for each band was compared with 
that of expectorated oral fluid. The percentage value is to quantify intensity 
expressed in each band and corresponds to level of protein visualized. Error 
bars show ± SEM. n =4.
171
Chapter 6
Comparing levels of cystatins
The Intensity levels of cystatins detected in the 1D gel profiles 
(see figure 6.6) show that the Orasure, Seradate and Oracol 
expressed a 10% increase in cystatins collection in comparison to 
the control. The Orasure, Seradate and Oracol showed no 
statistically significant difference in the expression of the protein 
.The Certus showed statistically significant lower Intensity levels of 
Ig-Heavy Chain in comparison to control.
Figure 6.6 The level of cystatins detected in relation to oral fluid. The mean 
grey value for each band was compared with that of expectorated oral fluid. The 
percentage value is to quantify intensity expressed in each band and 
corresponds to level of protein visualized. Error bars show ± SEM n =4.
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6.5 2D gel using different methods of sample preparation to 
show differences in protein profiles of Seradate against 
control
The Oral fluid samples collected using the Seradate was 
compared against the control to examine differences in protein 
profiles using 2D gel electrophoresis. The samples were collected 
from 5 individuals and pooled to reduce variability.
Three different sample preparation methods were used
1. The standard method was used as control (Developed by Dr. 
Deborah Ward. University of Liverpool)
2. The Castagnola Method. The addition of 2,2,2-trifluoroacetic 
acid (TFA) to the sample, this is expected to inhibit a number of 
degradation enzymes in the sample. The method is used to 
remove high molecular weight proteins such as albumin and a- 
amylase, to help produce a clearer 2D profile of oral fluid 
proteins(Castagnola, Inzitari et al. 2004; Messana, Inzitari et al. 
2008).
3. The Deutsch Method removes alpha amylase by affinity 
adsorption to potato starchto help produce a clearer 2D Profile of 
oral fluid proteins (Deutsch, Fieissig et al. 2008).
The different sample preparation methods were tested for any 
reductions in protein intensity between the Seradate and the 
control, and to examine any interference within the gels, that may 
cause distortions or smearing in the 2D profiling of oral fluid 
proteins.
The main proteins of interest were identified using current 
literature as a reference(Huang 2004) (see table 6.1) and marked
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on figures 6.8, 6.10 and 6.12. These were used to measure 
differences in protein profiles between Seradate and control. 
Qualitative measurements of Intensity were taken for proteins of 
interest using the mean grey area using Image J software. The 
difference in protein intensity was recorded as a percentage to 
show either an increase or decrease in protein intensity collected 
by comparing the Seradate against the control.
Area Protein
1 Albumin*
2 Alpha-Amylase
3 Prolactin Inducible Protein
4 Ig-Kappa Chain*
5 Cystatins
6 G3P dehydrogenase
7 Haemaglobin Beta Chain*
Table 6.1 Predominant proteins expressed in oral fluid and seen in figures 6.8, 
6.10 and 6.12. *OMT derivative markers
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2D Gel comparisons of Seradate against control using the 
standard method.
The 2D gel profiles were run using the standard sample 
preparation method. The differences in protein intensity were 
measured for the 7 proteins of interest. The data collected (see 
figure 6.7 and 6.8) show elevations in levels of albumin, prolactin 
Inducible protein and hemoglobin beta chain. The involvement of 
these proteins shows that the Seradate has an affinity for OMT 
derived proteins. The reductions in levels of a-amylase, Ig-heavy 
chain, and cystatins show possible retention of components within 
the absorbent material of the Seradate.
-80
Figure 6.7 The percentage of Seradate proteins in relation to control (the 
standard sample preparation method). 1. Albumin 2.Alpha-amylase 3.Prolactin 
Inducible Protein 4.lg-Kappa Chain S.Cystatins 6. G-3-P dehydrogenase 7. 
Haemoglobin Beta Chain. The samples were pooled from 5 individuals. The 
SEM is too small to show graphically <0.5%.
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2D Gel comparisons of Seradate against control using the 
Castagnola method.
The 2D gel profiles were run using the preparation method 
suggested by Castagnola et al (Castagnola, Inzitari et al. 2004; 
Messana, Inzitari et al. 2008). The variation of protein intensity 
was measured for the 7 proteins of interest. The data collected 
(see figure 6.9 and 6.10) shows elevation in levels of prolactin 
inducible protein and cystatins. The involvement of these proteins 
shows that Seradate shows elevated levels of OMT derived 
constituents. The low levels shown by other proteins may have 
been caused by the method and the possible retention of sample 
with the absorbent material of the Seradate.
-40 -
-60 -
Figure 6.9 The percentage of Seradate proteins in relation to control using 
Castagnola sample preparation method. 1. Albumin 2.Alpha-amylase 
3.Prolactin Inducible Protein 4.lg-Kappa Chain 5.Cystatins 6. G-3-P 
dehydrogenase 7. Haemoglobin Beta Chain.The samples were pooled from 5 
individuals. The SEM is too small to show graphically £0.5%.
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2D Gel comparisons of Seradate against control using the 
Deutsch method.
The 2D gel profiles were run using the preparation method 
suggested by Deutsch et al (Deutsch, Fleissig et al. 2008).The 
variation of protein intensity was measured for the 7 proteins of 
interest. The data collected (see figure 6.11 and 6.12) shows 
increased intensity of all proteins of interest, when comparing the 
Seradate against control. The method of sample preparation 
shows a reduction in proteins present within the control sample, 
there is a comparable reduction in protein intensity in the Seradate 
gel. Possible reasons for this are a more concentrated level of 
high molecular weight proteins present within the Seradate sample 
that could not be effectively cleared by the sample preparation 
method.
60 i
50 -
40 -
30 -
20 -
Figure 6.11 The percentage of Seradate proteins in relation to control using 
Deutsch sample preparation method. 1. Albumin 2.Alpha-amylase 3.Prolactin 
Inducible Protein 4.lg-Kappa Chain S.Cystatins 6. G-3-P dehydrogenase 7. 
Haemoglobin Beta Chain. The samples were pooled from 5 individuals. The 
SEM is too small to show graphically <0.5%.
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A comparison between the protein preparation methods
Each of the tested preparation methods for the Seradate samples 
was compared against the control. Table 6.2 shows the levels of 
abundant proteins present as a percentage. This can also be seen 
in figure 6.13.
Protein Standard Castagnola Deutsch
Albumin* 10 -50 30
Alpha-Amylase -5 -20 18
Prolactin 15 15 8
Inducible Protein
Ig-Kappa Chain* -10 -50 50
Cystatins -40 5 18
GBP -60 -45 40
dehydrogenase
Haemoglobin 5 -70 8
Beta Chain*
Table 6.2 The percentage of proteins presented by the Seradate in comparison 
to the control using 3 different sample preparation methods.
A greater percentage of proteins were presented by the Seradate 
in comparison to the control, this included albumin (Standard 10%, 
Deutsch 30%), prolactin (Standard 15%, Deutsch 8%) and 
hemoglobin beta chain (Standard 5%, Deutsch 8%) with both 
standard and Deutsch method. An increase in Prolactin was also 
shown in Castagnola method (15%) in comparison to the control. 
Both the Deutsch method and Castagnola method presented a 
greater amount of cystatins in comparison to the control
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(Castagnola 5%, Deutsch 18%) this was higher than the level 
presented by the standard method (- 40%).
The results show a greater level of protein presentation using the 
Deutsch method in comparison to the standard and Castagnola 
sample preparation.
Figure 6.13 The percentage of Seradate protein Intensity in relation to control 
using all 3 sample preparation method. 1. Albumin 2.Alpha-amylase 3.Prolactin 
Inducible Protein 4.lg-Kappa Chain S.Cystatins 6. G-3-P dehydrogenase 
7. Haemoglobin Beta Chain. The samples were pooled from 5 individuals.
The SEM is too small to show graphically ^0.5%.
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6.6 Discussion
To screen for the presence of abundant proteins collected using 
the Seradate and OFCDs could provide potential monitoring of 
oral based proteins that can be identified by mass spectrometry. 
Our interest lay in screening abundant proteins that were 
presented by the previously tested OFCDs and the control (see 
chapter 3). For oral fluid profiling the following parameters were 
used.
• Oral fluid Protein profiling using 1D SDS PAGE
• Using 2D gel electrophoresis to Compare oral fluid sample 
preparation and its effects on protein profiling
Oral fluid Protein profiling using 1D SDS PAGE
Initial profiles were examined using 1D SDS PAGE gels, these 
showed comparable presentation of abundant proteins by all our 
tested methods. The Abundance of proteins was measured by 
intensity to provide a qualitative value for each of the visualized 
proteins. The screening of OMT derived proteins (serum-based) 
within the OFCDs and control included albumin, Ig-heavy and 
kappa chain.(Almstahl, Wikstrom et al. 2001; Ng, Koh et al. 2003; 
Hershkovich and Nagler2004; Chiappin, Antonelli et al. 2007).
The intensity of the protein bands of these markers was higher 
amongst the OFCDS in comparison to the control. Both the Oracoi 
and Orasure (Figure 6.1) showed a greater level of protein 
distribution in comparison to the control, the reasons for this 
occurring can be related to the proteins being concentrated in a 
dilution dependant manner within the absorbent material; this 
factor is a recurring concept amongst the use of OFCD sampling
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techniques, there couid be also be a high protein affinity and 
release by the OFCDs absorbent material.(Strazdins, Meyerkort et 
al. 2005; Chang, Cohen et al. 2009; Kidd, Midgley et al. 2009; 
Kozaki, Hashiguchi et al. 2009; Almela, Hidalgo et al. 2011). The 
proteins banding seen within the gels could have also been 
caused by sample degradation during processing causing 
breakdown of the proteins and subsequent banding was a result of 
protein fragmentation (Chevalier, Hirtzet al. 2007; Schipper, Loof 
et al. 2007). As the data collected was qualitative, measurements 
of protein presence were associated to intensity rather than mass 
or concentration (using the mean grey area and the control sample 
as a reference).
Using 2D gel electrophoresis to compare oral fluid sample 
preparation methods and its effects on protein profiting
Both the Seradate and the control showed similar protein levels in 
the 1D SDS Page profile and 2D gel electrophoresis was used 
compare profiles of the two samples. The two samples were 
treated by 3 different methods of sample preparation ((Standard 
method (developed at the University of Liverpool, Castagnola 
method and Deutsch Method)) (Castagnola, Inzitari et al. 2004; 
Messana, Inzitari et al. 2008, Deutsch, Fleissig et al. 2008).
Our findings showed that oral fluid protein mapping using 2D gel 
Electrophoresis is not only dependant on the OFCD used but also 
on the method of sample preparation. The comparison was made 
between the Seradate against the control (drooled saliva). The 
data suggests that the use of the Deutsch method gave the most 
favorable results in the presentation of collected proteins using the 
Seradate, A greater percentage of proteins was presented by the 
Seradate in comparison to the control, this included albumin 
(Standard 10%, Deutsch 30%), prolactin (Standard 15%, Deutsch
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8%) and hemoglobin beta chain (Standard 5%, Deutsch 8%) with 
both standard and Deutsch method and an increase in Prolactin 
was also shown in Castagnola method (15%) in comparison to the 
control.
These findings are not definitive as the results may have been 
affected by the staining method of used (silver staining). Silver 
staining is used to provide greater resolution of proteins that are 
mapped on a gel, there is an associated risk of over staining that 
can cause a shift in the final intensity of the protein spots. Further 
staining protocols that could be used in the future include the 
colloidal coomasie blue stain; fluorescent dye stains (Cy3/ Cy5). 
These methods will help differentiate between sample 
preparations used and help rule out any discrepancies caused by 
the silver staining method.
Closing remarks
There is a further requirement for quantitative analysis of the 
proteins presented by our tested OFCDs; this requires the 
supplementation of LC/GC mass spectrometry. Due to time 
constraints this was not possible, but the findings within the gels 
show that both Seradate and the control samples gave very similar 
protein profiles. The increase of the detection of OMT derived 
proteins by OFCDs show that there is a distinct advantage in the 
collection of oral fluids using a collector as opposed to testing oral 
fluid alone.
This provides a potential background for the uses of OFCDs in 
standardising protein presence in oral fluid collections, the 
sampling methods will allow for large scale screening studies and 
factors such as sample variability and low testing volumes will no 
longer be an issue (Messana, Inzitari et al. 2008).
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Chapter 7 
Discussion
Seradate is an oral fluid collection device prototype that was 
designed with the intention of collecting oral fluid that is OMT 
protein-rich. The design and concepts were based on clinical 
experiments conducted by Pashley et al that suggested the 
collection of pure OMT (GCF) from the ginigival crevice is either a 
serum transudate or an inflammatory exudate (Alfano 1974; 
Pashley 1976).
Our view was to bridge the two forms of OMT and collect a sample 
that would exhibit transudate/ exudate properties. The method for 
collecting OMT as a pure sample has been done using a variety of 
methods, but the most common and non-invasive methods are via 
the insertion of filter paper within the gingival sulcus (intra- 
crevicular method) or outside the gingival sulcus (extra-crevicular 
method) (Loe and HoImpede.P 1965; Griffiths 2003). The collected 
samples and their comparison to serum based proteins levels are 
dependent on gingival health. The collection procedure does have 
limitations as it is time consuming and requires a dentist, this 
reduces its potential applications within a non-clinical environment 
or for use in mass screening studies(Strazdins, Meyerkort et al. 
2005).The collection procedure is non-invasive but removes the 
ease in sample collection that is offered by an OFCD.
Our initial aims were to create an OFCD that would potentially 
collect oral fluid that was richer in OMT content in comparison to 
current marketed collectors. This was proposed by collecting a 
sample by causing minor abrasion to the gum surface, the actions 
of rubbing (as used in the Oracol and Orasure) and mastication 
(our own additional function) to create an elevation in the release
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of OMT while maintaining that no blood is drawn. The collector 
should also shield from excess saliva to reduce the dilution factor 
of the final collected sample.
The Seradate prototype was tested alongside current marketed 
OFCDs and the tested parameters included were
• Seradate design and end user acceptance
• Immunoglobulins retention and release
• Stress markers retention and release
• Measuring smoking status of individuals (cotinine levels)
• Oral fluid sample stability
• Screening of protein profiles using 1D SDS PAGE and 2D 
gel electrophoresis
7.1 Seradate design and end user acceptance 
Seradate design
The Seradate prototype incorporated two forms of collection into 
its test design this included the abrasion motion and the biting 
motion. The dual functions of the Seradate were proposed to 
facilitate an increase in OMT outflow by causing mild trauma to the 
surfaces of the gingivae.
The absorbent material used for the collection head was D3727g; 
this showed the appropriate properties that were suited for our 
collector. The material could be easily molded and was 
comfortable enough to be placed within the oral cavity. It also 
showed a high uptake and release of tested fluids, with a low 
retention of testable proteins (IgG).
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Seradate was commended on its material use and comfort upon 
placement in the mouth in particular the gum surfaces. 
Contraindications were that the head of the applicator was too 
large and a reduction in the size of the absorbent material would 
have overall enhanced the experience.
End user acceptance
The validation of the Seradate prototype must work in tandem with 
the acceptance of the collector by the end user, the questionnaire 
used throughout the process of this study (See Appendix A and C) 
was to measure individual concerns and compliance with the 
collector and individual input into a list of limitations that may have 
been overlooked, that would provide future improvement. One of 
the main problems the volunteers stated was the swab material fell 
out during the collection, this is a design error and the use of pre­
moulded material would have been better suited for the collection 
procedure. The handle of the collector should’ve been more rigid 
and collection head should have been more flexible to allow easier 
placement with the oral cavity. The collection head was slightly too 
large and the material used (polyurethane) should’ve been softer 
especially in the collection head. The overall compliance of the 
Seradate for use in Oral fluid collection was acceptable by all 
users.
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7.2 Seradate and monitoring of oral fluid componants 
immunoglobulins (IgA, IgG and IgM)
Our findings show that the Seradate collection actions of abrasion 
and mastication to the gum surfaces did result in an increase in 
the capture of our surrogate marker for OMT (IgG), this increase 
was marginally higher in comparison our control (drooled oral 
fluid). Possible reasons for this occurring are linked to low levels of 
trauma caused to the gum surfaces. The levels of IgG measured 
were comparable to all tested OFCDs with the exception of the 
Oracol which collected a predominantly higher amount of IgG and 
the Concateno Certus which collected the least.
In comparison to our collection of OMT (intra-crevicular and extra- 
crevicular) all tested OFCDs showed a range of IgG that was 
between 15-25 fold lower in measured levels.
The levels of IgA measured were significantly higher in the control 
and Seradate collection device, as our main purpose in the 
development of the Seradate was to shield from salivary 
secretions, adequate measures were not in place to account for 
the collection of saliva from the floor of the mouth where most of 
the saliva collected, this would account for the higher IgA content 
witnessed in the Seradate collector, this is an additional 
component that can be validated for future OFCDs in their ability 
to monitor salivary antibodies.
IgM is generally found in lower volumes in oral fluid due to size of 
the compound; the levels of IgM were marginally lower in 
comparison to measured IgG levels. This suggests that IgM levels 
are often masked by IgG. IgM provides an alternate method for 
validation of an oral fluid sample. As IgM is large compound, it has 
a greater potential to bind to the collection material. Further
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validation on the release of IgM from respective OFCDs may 
provide insight into the use of IgM in future studies.
The IgG: IgA ratio was used as an indicator for affinity for each 
OFCD in its ability to gain a more OMT-rich Oral fluid sample The 
ratio was comparable between all OFCDs, with the exception of 
Oracol. The Oracol presented the highest IgG: IgA ratio therefore 
highlighting its proficiency in the collection of OMT based 
antibodies.
The levels of immunoglobulins collected by the Seradate were 
comparable to that of the control the material used in Seradate 
exhibited a low retention of constituents, its uses within the OFCD 
have been validated.(Strazdins, Meyerkort et al. 2005; Chang, 
Cohen et al. 2009; Kidd, Midgley et al. 2009; Kozaki, Hashiguchi 
et al. 2009).
The Seradate was designed to shield from the parotid gland 
secretions but the swab portions of the collector were exposed to 
sublingual and submandibular salivary secretions, caused by 
contact with the floor of the mouth. The increase in collected saliva 
directly diluted IgG content of the collected sample; this reduced 
the measurement of any elevation in IgG collected. As an 
alternative method to the collection, would have been to remove 
the absorbent material exposed to floor of the mouth and only 
process the material that is in contact with the anterior gum 
surface.
The order of collection of oral fluid samples was studied to 
measure the effects of stimulation on measured IgG levels within 
the tested samples. The samples were collected on 3 separate 
occasions to account for differences in levels monitored. Initial 
collection was done in the standard order, and was compared to
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reverse order of collection on 2 separate occasions. The times of 
sample collection were kept the same to account for diurnal 
variability. The final data showed no significant difference in the 
samples collected. As each method was conducted and allowed 
for adequate re-establishment of the oral cavity resting state, there 
was no variation shown.
Cotinine
The Seradate was tested on its ability to accurately measure 
cotinine. The cotinine assay used was standardised for all OFCDs 
(dilution factors were taken into account for the Orasure and 
Certus).
The cotinine assay assessment for non-smokers was given as a 
negative value, as the values fell below the range of the assay, the 
male and females tested for smoking showed varying levels of 
cotinine by each tested collection method, in particular the 
Seradate and Oracol, these showed a slight significant difference 
in collection in comparison to the other OFCDs and control.
The material based interference of the Seradate swab would 
require further validation in the measurement of cotinine. As 
cotinine testing by ELISA is primarily used as a screening method, 
this finding could be inconsequential. The levels of cotinine 
measured in the study were relatively low (mild smoking range), 
comparisons to medium/ heavy smoking groups would possibly 
provide a more detailed assessment of all tested OFCDs.
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Stress markers
The levels of albumin, alpha-amylase and cortisol were measured 
to establish the effects of smoking on stress markers, the results 
showed inconclusive data with the regard to the proposed 
hypothesis. The induction of stress was proposed as the samples 
were collected 2 weeks prior to the summer examinations of 
volunteers within the test group. However the levels of cotinine 
measured within the study didn’t account for long term smokers 
and cotinine levels dictated a iow to moderate level of cigarette 
consumption. A study involving a larger cohort of heavy to 
moderate/iight smokers would have provided a greater depth to 
the study. As the literature on smoking and stress mainly deals 
with the effects of stress upon smoking cessation this provides 
another unique parameter by which to assess the effects of 
smoking on stress hormones(Benowitz, Lessov-Schlaggar et al. 
2006; Badrick, Kirschbaum et al. 2007; Fu, Fernandez et al. 2009; 
Darlow and Lobe! 2012; Hauge, Torgersen et al. 2012). The 
measurement of alpha-amylase activity was subjected to one test 
parameter, as alpha-amylase levels are affected by the flow rate of 
saliva, an additional test would have been to measure secretion 
rate of amylase also. It is stated in the literature that salivary flow 
on tested markers can be influenced by the sampling collection 
methods used (DeCaro 2008; Almela, Hidalgo et al. 2011). As we 
compared the ability of each OFCD to measure oral-based 
hormones, this additional test would provide a further validation 
step for the use of the Seradate and subsequent validation for 
other OFCDs.
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7.3 Seradate and oral fluid sample stability
The effects of degradation of OFCD samples were compared to 
that of the control, our findings showed that samples remained 
stable for a shorter period of time outside of freezing temperature(- 
20°C)(Chevalier, Hirtz et al. 2007; Schipper, Loof et al. 2007; 
Almela, Hidalgo et al. 2011). It is suggested within the literature 
that oral fluid samples that are used in proteomic profiling are 
subjected to snap-freezing or immediately placed in -80°C 
refrigeration upon processing of the samples. This is to reduce 
oral fluid breakdown that is caused by salivary and bacterial 
proteolysis. The addition of protease inhibitors to the OFCD 
samples and control (with the exception of Certus and Orasure) 
showed reduction in IgG degradation over a period of 7 days at 
room temperature and 14 days at 4°C but IgG stability showed a 
steady decline after this point. The samples showed stability at - 
20°C throughout the duration of the study. The exceptions to the 
levels of IgG degradation were seen in the Certus and Orasure, 
both of which use an anti-bacterial buffer.
The stability of cotinine only showed mild signs of degradation 
after the two week period, this is accounted for in the literature as 
cotinine is no longer metabolised once the sample is collected and 
any form of degradation is caused by bacterial involvement. As the 
differences in cotinine levels were stable these samples could 
remain at room temperature for a period of up to 28 days. Oral 
fluid samples should be kept at -20°C immediately after collection 
if possible to prevent any breakdown, and to allow for accurate 
testing of oral fluid compounds.
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For long term storage samples should either be snap-frozen in 
liquid Nitrogen or placed at -80°C refrigeration(Messana, Cabras 
et al. 2004; Chevalier, Hirtz et al. 2007; Schipper, Loof et al. 2007; 
Aimela, Hidalgo et al. 2011).
7.4 Seradate and protein profiling
The protein profiling study that compared the levels of proteins 
presented by OFCDs against the control, showed the presence of 
OMT markers within each collected fluid. This alongside the 2D 
gel electrophoresis protein profile showed no significant difference 
in protein profiles between the Seradate and the control drooled 
oral fluid. Within the sample preparation methods the Deutsch 
method (Deutsch, Fleissig et al. 2008) gave a clearer profile in 
comparison to the Castagnola method (Messana, Inzitari et al. 
2008) and standard method of sample preparation. As the study 
only indicated the screening of abundant proteins that were of oral 
fluid and OMT origin, no significant differences in profiles were 
seen, this is suggestive for the use of OFCDs within salivary 
based proteomic studies and could potentially provide a method of 
enhancing protein presentation for easier identification.
7.5 Overview
The tests conducted on the Seradate prototype show it is able to 
function comparably and favourably in the monitoring of oral fluid 
compounds and in comparison to tested OFCDs.
With further refinement of design and material based testing, the 
Seradate has the potential for being a marketable property and 
these factors will be taken into consideration for the next phase of 
development.
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7.6 Conclusion
The Seradate OFCD showed promising results in its uses as an 
oral fluid collection device. The validation tests conducted show 
that its functionality is comparable to current marketed collectors.
The collection of testable proteins, drugs and hormones have 
shown comparable levels with normal drooled oral fluid. This 
shows the potential role for the Seradate in the standardisation of 
oral fluid for future sample testing.
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7.7 Future work
The design, manufacture and testing of a unique oral fluid 
collection device was validated throughout this thesis.
The Seradate was designed on established collection methods 
and was combined with unique alterations to increase the 
collection of OMT-rich oral fluid.
The 35 feedback questionnaires taken throughout the study (see 
Appendix C) provided a background for both user acceptance and 
user mediated improvement on the Seradate and tested OFCDs. 
The feedback showed that although the Seradate was deemed 
acceptable by all users, it was not without limitations. These points 
can be used as a guideline for streamlining the Seradate and other 
OFCDs as potential swabs, by taking into account improvements 
and limitations within each tested OFCD.
The further development and validation of the Seradate include
• Design
• Material testing
• Selective measurements of oral fluid components
• Oral fluid protein profiling
• Marker detection assay and lateral flow 
immunochromatographic assays
These factors can be used to improve on and establish further 
research into the development of an OFCD.
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Design
The limitations to the design of the Seradate were related to its 
unique method of collection (a combination of mastication and 
abrasion). Our findings showed that the mild abrasion caused by 
the Seradate caused a marginal increase in the levels of OMT 
released in comparison to the marketed OFCDs. As OMT release 
is dictated by gum health, this method alone will be insufficient in 
normal individuals. Our study on the use of filter paper to acquire 
OMT samples showed an elevation in OMT constituents (IgG), this 
method is well established and a method for standardising this 
collection needs to be addressed.
Material tests
The material tests for the seradate used the polyolefin material as 
it satisfied the criteria for our collection purposes. As the method of 
abrasion and mastication used only gave comparable levels of oral 
based constituents to OFCDs, a proposal for the use of sintered 
plastics can be suggested. The use of sintered plastics could be 
used in a similar manner as the pure OMT collection method 
stated in the thesis. This method would involve placement of the 
sintered plastic against the area of interest and removed once the 
material is saturated. With direct contact to the gum surface, OMT 
will be collected by capillary attraction. This method can 
incorporate shielding to reduce dilution of the final collected 
sample by saliva.
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Selective tests on oral compounds
The tested parameters for the validation of the Seradate looked at 
OMT specific components such as serum based immunoglobulins 
IgG, IgM, Albumin and salivary based IgA, alpha-amylase, cortisol. 
To test the accurate measurements for drugs found in oral fluid, 
the levels of cotinine were measured.
These tests provide a base from which further studies can be 
conducted, our findings with Seradate show that the collector in its 
current form is comparable to marketed OFCDs. By increasing the 
range of testable OMT/ Oral fluid components this will provide a 
stronger foundation for the acceptability of oral fluid for screening 
purposes and will aid in the standardisation of oral fluid.
Potential avenues that can be looked at include
- The measurement of cancer markers presented in oral fluid
- Diabetes and cardiovascular markers
- Screening of immunoglobulins associated with viral disease
Oral fluid protein profiling
The study on protein profiling of oral fluid provided an answer to 
the standardisation of a generic oral fluid sample (a whole saliva 
sample). Current research in oral fluid has shown that inter and 
intra-variability of sample collection causes problems to 
standardisation. As protein profiling of OMT and oral fluid have 
shown slight variance in composition this requires further 
validation and with 2d- gel electrophoresis coupled with mass 
spectrometry this can be developed further. To limit changes 
caused gel imaging and staining more appropriate methods of
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detection such as DIGE (differential gel electrophoresis) can be 
used, where two samples are run on the same gel and each 
sample is tagged with a unique spectrally resolvable florescent 
dye (Cy2,Cy3 and Cy5).
As the proteome of oral fluid is being analysed for its individual 
and collective secretions this can provide more robust information 
for potential markers associated with localised (oral) and systemic 
diseases.
Marker detection assay and lateral flow 
immunochromatographic assays
As the proposed use of Seradate is to provide fast and easy 
methods of oral fluid collection for screening purposes, this can be 
supplemented further with the development and standardisation of 
serum based immunoassay to account oral fluid based test 
components.
Lateral flow immunochromatographic assays provide a potential 
gap in the market especially where laboratory facilities are 
reduced and for on-site validation. This method can be developed 
to provide screening services for cancer markers presented in oral 
fluid (local and systemic), localised disease (periodontitis) 
systemic disease markers (diabetes, cardiovascular) and 
immunoglobulins associated with viral disease.
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UNIVERSITY OF
LIVERPOOL
Title of Research 
Project:
Researcher(s):
INFORMED CONSENT FORM
A comparison of different oral swabbing methods in 
the collection of whole saliva
Mr. Abadur Rohman, Dr.Stuart Marshall-Clarke Please
initial box
1. I confirm that I have read and have understood the information sheet for the 
above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my rights being affected.
3. I understand that, under the Data Protection Act, I can at any time ask for 
access to the information I provide and I can also request the destruction of 
that information if I wish.
4. I agree to take part in the above study.
Participant Name Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
The contact details of lead Researcher (Principal Investigator) are:
Dr. Stuart Marshall-Clarke 
Institute of Translational metScine 
Telephone: (0151) 794 5444 
Emai: stumc@liv.ac.uk
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UNIVERSITY OF
LIVERPOOL
An assessment of different oral swabbing methods in the collection 
of whole saliva
Feedback Questionnaire
Participant number 
Smoking Status
Please tick appropriate box:
Dental visits Regular Fairly Ocassionaly Hardly Never
regular
Feedback on swabbing methods (Scale 1-10 1= very poor; 10= excellent)
Aesthetics Ease of collection Comfort
Overall
experience
Method 1
Method 2
Method 3
Method 4
Method 5
Method 6
Method 7 NULL
Further Comments (please continue overleaf if required)
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LIVERPOOL
Information Sheet
A comparison of different oral swabbing methods in the collection 
of whole saliva
You are invited to participate in an exciting area of research. Prior to 
deciding whether to participate, it is important that you understand why 
the research is being conducted and also what it will involve. Please 
take time to read the following information carefully and if you’re unclear 
with any terms or anything you don’t understand feel free to ask us. You 
are also at complete liberty to discuss this with family, friends or G.P if 
you wish. We would like to highlight at this point that you are under no 
obligation to continue with the testing if you wish to withdraw at anytime 
and you should only agree to continue if you want to.
What is the Purpose of study?
There are currently various whole saliva swabs on the market. In this 
study we aim to assess different swabbing methods alongside a swab 
we developed to compare their overall ability in collecting whole saliva 
and to indicate smoking status.
Why have I been chosen to take part?
We are looking for healthy individuals in the university to test our oral 
swab alongside current marketed oral swabs. We are looking for 
smokers and non-smokers between the ages of 18-30. The swabs will 
be tested for smoking status.
Do I have to take part?
Your participation within the study is completely voluntary and you are 
free to withdraw from the study at anytime without explanation or 
incurring any disadvantage.
What will happen if I take part?
You will be asked to give 7 whole saliva samples using different 
swabbing methods. The procedures will be monitored by a dentist and a 
suitably trained individual.
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Collection Procedure
The estimated total time for collection of all samples will be between 1 
and 2 hours. The collection will take place in groups of 5 (Individual 
screening will also be available).
You will be asked to return on one further occassion to provide a second 
series of samples at a later date in the week. The estimated collection 
time will be 1 hour.
The times for collection will be given to you. All procedures will be 
monitored by a suitably trained individual.
Questionaire
Upon completion you will be asked to complete an informal questionaire. 
The informal questionaire will ask you to evaluate your experience of the 
ease of use and user friendliness for each of the swabs.
The results from the study will be made available to you upon request 
after completion of the study. You will be in the presence of research 
staff throughout all procedures. Please feel free to ask any questions if 
you are unsure at any stage.
Expenses and Payments
Upon completion of your participation you will receive re-imbursement 
for your time.
Are there any risks in taking part?
There are no risks involved. However if you feel discomfort at anytime. 
Please report this to research staff immediately.
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What If I’m unhappy or if there is a problem?
If you are unhappy at any stage during the study please contact the 
Principal investigator Dr. Stuart Marshall-Clarke (0151) 794 5444 
(stumc@liv.ac.uk1 and we will try to help. If however your complaint 
remains unresolved and you feel you cannot talk to us you should 
contact the Research Governance Officer on 0151 794 8290 
(ethics@liv,ac.uky When contacting the Research Governance Officer 
please provide your name and description of the study conducted (so it 
can be identified), the researcher(s) involved, and the details of 
complaint which you wish to make.
Will my participation be kept confidential?
All data collected will be anonymised and stored securely by the 
Custodian Dr. Stuart Marshall-Clarke (principal lnvestigator).The tests 
conducted are not appropriate for assesment of health status and 
therefore no information will be provided on participants’ health as part 
of the study.
Will my taking part be covered by an insurance scheme?
Participants taking part in a University of Liverpool ethically approved 
study will have cover.
What will happen if I want to stop taking part?
You are free to withdraw from the study at anytime without explanation. 
Any results we gain prior to this point may be used, if you are happy with 
this. Otherwise they will be destroyed and no further use will be made of 
them.
Who can I contact if I have further questions?
If you have any further enquiries please contact Dr. Stuart Marshall- 
Clarke (0151) 794 5444 (stumc@liv.ac.uk)
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Recruitment advertisement
UNIVERSITY OF
LIVERPOOL
Instituteof Translational Medicine
A comparison of different oral swabbing methods in the 
collection of whole saliva
We are lookingfor 20 healthy volunteers(smokers and non- 
smokers) to provideoral swab saliva samples, to compare 
differences in oral swabbing methods. Participants will be 
reimbursed for their time.
If you are interested please contact Abadur Rohman 
(abadur.rohman@gmail.com) or 07828676918
Version 3 18/03/2012
218
UNIVERSITY OF^ LIVERPOOL
COMMITTEE ON RESEARCH ETHICS
APPLICATION FOR APPROVAL OF A PROJECT INVOLVING 
HUMAN PARTICIPANTS, HUMAN DATA, OR HUMAN MATERIAL
This application form is to bt used by researchers seeking approval from the University Committee on Research 
Ethics or from an approved School Research Ethics Committee.
Applications to the University Research Ethics Sub-Committees, with the specified attachments, should be submitted 
electronically to ethics@liv.ac.uk. Applications to an approved School / Departmental Committee should be submitted 
to their local address, available at http://www.liv.ac.uk/researchethics/deptcommittees.htm.
RESEARCH MUST NOT BEGIN UNTIL ETHICAL APPROVAL HAS BEEN OBTAINED
This form must be completed by following the guidance notes, accessible at 
www.liv.ac.uk/researchethlcs.
Please complete every section, using N/A If appropriate. 
Incomplete forms will be returned to the applicant.
BEFORE COMPLETING YOUR APPLICATION PLEASE CONFIRM WHAT APPROVAL YOU ARE 
SEEKING (please check):
a) Expedited review of an individual research project □
b) Full committee review of an individual research project [X]
c) Expedited generic* approval □
d) Committee review generic* approval □
•to cover a cohort of projects using similar methodologies. Boundanes of the research must be defined clearly. Approval may be granted 
for up to 5 years and will be subject to annual review
Office Use Only (for final hard copies)
Reference Number RETH
Date final copy received:
Approval decision:
Approved - no conditions □
Committee □
Chairs Action □
Expedited □
Approved with conditions □
Committee □
Chairs Action □
Expedited □
Research Ethics Application Form 
Version 4.1 1
11/1/11
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Declaration of the:
Principal Investigator □ OR Supervisor and Student Investigator IEI 
(please check as appropriate)
The information in this form Is accurate to the best of my knowledge and belief, and I take full responsibility for 
It.
• I have read and understand the University’s Policy on Research Ethics
• I undertake to abide by the ethical principles underlying the Declaration of Helsinki and the University’s good 
practice guidelines on the proper conduct of research, together with the codes of practice laid down by any 
relevant professional or learned society.
• If the research is approved, I undertake to adhere to the study plan, the terms of the full application of which the 
REC has given a favourable opinion, and any conditions set out by the REC In giving Its favourable opinion.
• I undertake to seek an ethical opinion from the REC before implementing substantial amendments to the study 
plan or to the terms of the full application of which the REC has given a favourable opinion.
• I understand that 1 am responsible for monitoring the research at all times.
« If there are any serious adverse events, I understand that I am responsible for immediately stopping the 
research and alerting the Research Ethics Committee within 24 hours of the occurrence, via ethlcs@llv.ac.uk.
• l am aware of my responsibility to be up to date and comply with the requirements of the law and relevant 
guidelines relating to security and confidentiality of personal data.
• I understand that research records/data may be subject to Inspection for audit purposes If required In future.
• I understand that personal data about me as a researcher In this application will be held by the University and 
that this will be managed according to the principles established in the Data Protection Act.
• l understand that the information contained In this application, any supporting documentation and all 
correspondence with the Research Ethics Committee relating to the application, will be subject to the provisions 
of the Freedom of Information Acts. The Information may be disclosed In response to requests made under the 
Acts except where statutory exemptions apply.
« I understand that all conditions apply to any co-applicants and researchers Involved In the study, and that It Is 
my responsibility to ensure that they abide by them.
• For Supervisors: I understand my responsibilities as supervisor, and will ensure, to the best of my abilities, that 
the student Investigator abides by the University's Policy on Research Ethics at all times.
• For the Student Investigator: I understand my responsibilities to work within a set of safety, ethical and other 
guidelines as agreed In advance with my supervisor and understand that I must comply with the University’s 
regulations and any other applicable code of ethics at all times.
Signature of Principal Investigator □ or Supervisor S: ......................................
Date: (18/03/2012)
Print Name:Dr. Stuart Marshall-Clarke
Signature of Student Investigator:......................................
Date: (18/03/2012)
Research Ethics Application Form 
Version 4.1 
11/1/11
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Print Name:
SECTION A . IDENTIFYING INFORMATION
A1) Title of the research (please include a short lay title in brackets).
A comparison of different oral swabbing methods in the collection of whole saliva
A2) Principal Investigator □ OR Supervisor 0 (please check as appropriate)
Title: Dr Staff number:
Forename/Initials: Stuart Surname: Marshall-Clarke
Post: Senior Lecturer Department: Institute of translational 
medicine
Telephone: 0151 794 5444 E-mail: stumc@liv.ac.uk
A3) Co-applicants (including student investigators)
Title and 
Name
Post / Current 
programme (if 
student 
investigator)
Department/ 
School/Institution If 
not UoL
Phone Email
Mr. Abadur 
Rohman
PhD Student Institute of
translational
medicine
07828676918 abadur.rohman@gmail.com
Research Ethics Application Form
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SECTION B • PROJECT DETAILS
B1) Proposed study dates and duration (research must not begin until ethical approval has been
OBTAINED)
Please complete as appropriate:
EITHER
a) Starting as soon as ethical approval has been obtained [SI (please check if 
applicable)
Approximate end date: 01/08/2012
b) Approximate dates:
OR
Start date: End date:
B2) Give a full lay summary of the purpose, design and methodology of the planned research.
Background
Recent attention in medical screening has turned to whole saliva as means of diagnosis for 
disease, drugs of abuse and smoking status.
The constituents of whole saliva include saliva secretions from minor and major salivary glands 
and serum-like oral mucosal transudate. Oral mucosal transudate (OMT) is released as a 
flushing mechanism within the gum lining to prevent infection. This fluid exhibits serum like 
properties and this makes it of great interest because it offers the potential to screen for serum 
based markers non-invasively using whole saliva samples. IgG is a consituent of serum so its 
quantification in whole salive samples affords a means of assessing the contribution of OMT to 
the sample.
Collection of whole saliva provides rich in OMT could provide a rapid patient-friendly means of 
monitoring disease process, drugs of abuse or smoking status (by measuring a constituent of 
nicotine known as cotinine).
Currently a number of devices are available for collecting whole saliva this is done either by a 
swab or a drooled saliva sample. The method of swabbing Involves either rubbing or placing the 
swab near the gums until fully saturated. Very little work has been done to assess or optimise 
these devices for their performance in collecting OMT rich saliva.
Aims
We have recently developed a novel device for collection of whole saliva. It has been specifically 
designed to maximise collection of OMT-rlch samples. The aim of this study is to compare our 
device with those currently available commercially. To assess device effectiveness we will 
compare the volume of whole saliva collected and assess the OMT content of the samples by 
measuring IgG levels. To assess the usefulness of the device in a likely application we will also 
compare its ability to detect cotinine in samples from smokers and non-smokers. For a full 
assessment of the extent of OMT contribution to the samples obtained we will also collect "pure" 
OMT from the gingival crevice.
Research Ethics Application Form
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We will also assess the ease and comfort of use by asking each study subject to complete a 
short questionaire.The purpose of the questionaire is to gauge user friendliness of the collection 
methods tested. The questionnaire will ask for the volunteers smoking status and maintenance of 
oral hygiene. It will also ask for preferences in the swabbing methods tested. The factors that will 
be included in the questionaire are the aesthetics of the swab, ease of collection, comfort in use 
and overall experience. This will be graded on a 1 to 10 scale (1* Very Poor; 10= Excellent).
The volunteers will be free to add any further comments they want to share with regard to the 
study.
Cohort
For this study we require 20 individuals male/female (10 smokers and 10 non-smokers) recruited 
from the University of Liverpool (age group of 18*30). Volunteers will be recruit by advertising the 
study on the University Announcements page and written consent will be sort prior to engaging 
with the collection of samples.The results from the tests will be available to individuals upon 
request. All data collected will be stored In accordance Data protection act 1998 and Freedom of 
information act (2000)
Methods of oral swabbing 
Method 1
This method involves the placement of a filter paper strip into the gingival crevice (the gap 
between gum and tooth) for a period of 30 seconds. This procedure is well established and will 
be carried out by a qualified, experienced dentist.
Method 2
Our developed swab (Seradate) simply requires the participant to ‘bite’ down on a swab for two 
30 second periods with a brief rest in between.
Method 3
The Orasure® swab requires the volunteer to swab the lower cheek and gum, until the pad is 
moist. The pad is held in place for a period of 2 minutes after which it will be taken out.
Method 4
The Salivette® swab is placed either above or below the tongue. Once the material is saturated it 
is removed.
Method 5
The Certus® swab is used in the same manner as the Orasure®.
Method 6
The Oracoi® swab is used in the same manner as the Orasure
Research Ethics Application Form
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Method 7
Passive Drooled whole saliva, the collection is done by askin volunteers to passively drool into a 
tube.
Sample Storage
Each of the collected samples will be placed in preservative and placed In *8Q'C freezer until 
required for testing. The Storage of the samples and work will be conducted in the university 
premesis (Licensed) and will be done in accordance with the Human Tissue Act.
Collection Procedure
Primary Collection
Each procedure will take 5 minutes and will be followed by a rest period before the next 
procedure is undertaken. Volunteers will be asked rinse their mouths with cold water between 
each swabs.
The estimated total time for collection of all samples will be between 1 and 2 hours. The 
collection will take place in groups of 5.
Repeat Collection
A second series of samples will be collected within the following 7 days using only methods 2- 
7.The estimated time for collection will be 1 hour.This is will be done so as multiple samples are 
available for testing and will help address any inconsistencies in the measured markers (IgG and 
Cotinine) within the study,as well as assess the bias in order of collection by the swabs..
B3) List any research assistants, sub-contractors or other staff not named above who will be 
involved in the research and detail their involvement.
Dr. Bhavish Patel (Collection of sample 1)
B4) List below all research sites, and their Lead Investigators, to be included In this study.
Research Site Individual Responsible Position and contact details
Institute of translational 
medicine
Abadur Rohman PhD Student
07828676918
B5) Are the results of the study to be disseminated in the public domain? 
YES [Xj NO □
> If not, why not?
Research Ethics Application Form
Version 4.1 3
11/1/11
224
B6) Give details of the funding of the research, including funding organisation(s), amount applied 
for or secured, duration, and UOL reference
Funding Body Amount Duration UoL Reference
Self funded £2500 1 year
B7) Give details of any interests, commercial or otherwise, you or your co-applicants have in the 
funding body.
none
CD
SSSIISN C.-.EXPEBlIEB.fieflEfl
a) Will the study Involve recruitment of participants outside the UK? No
b) Does the study involve participants who are particularly vulnerable or unable 
to give informed consent? fe.g. children, people with learning or communication 
disabilities, people in custody, people engaged in illegal activities such as drug-taking, 
your own students in an educational capacity) (Note: this does not include secondary 
data authorised for release by the data collector for research purposes.)
No
c) Will the study require obtaining consent from a "research participant 
advocate” (for definition see guidance notes) in lieu of participants who are 
unable to give informed consent? (e g. for research involving children or, people 
with learning or communication disabilities)
No
d) Will it be necessary for participants, whose consent to participate in the study 
will be required, to take part without their knowledge at the time? (e.g. covert 
observation using photography or video recording)
No
e) Does the study involve deliberately misleading the participants? No
f) Will the study require discussion of sensitive topics that may cause distress or 
embarrassment to the participant or potential risk of disclosure to the researcher 
of criminal activity or child protection issues? (e.g. sexual activity, criminal activity)
No
g) Are drugs, placebos or other substances (e.g. food substances, vitamins) to 
be administered to the study participants or will the study involve invasive, 
intrusive or potentially harmful procedures of any kind?
No
h) Will samples (e.g. blood, DNA, tissue) be obtained from participants? Yes
i) Is pain or more than mild discomfort likely to result from the study? No
j) Could the study induce psychological stress or anxiety or cause harm or 
negative consequences beyond the risks encountered in normal life? No
k) Will the study involve prolonged or repetitive testing? Yes
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I) Will financial inducements (other than reasonable expenses and compensation 
for time) be offered to participants? No
Research Ethics Application Form 
version 4.1 5
C2)
a) Will the study seek written, Informed consent? Yes
b) Will participants be informed that their participation is voluntary?
Yes
c) Will participants be informed that they are free to withdraw at any time?
Yes
d) Will participants be informed of aspects relevant to their continued 
participation in the study? Yes
e) Will participants’ data remain confidential? Yes
f) Will participants be debriefed?
Yes
If you have answered ‘no’ to all items in SECTION C1 and 'yes’ to all questions in SECTION C2 the 
application will be processed through expedited review.
If you have answered “Yes” to one or more questions in Section C1, or ’’No" to one or more questions in 
Section C2, but wish to apply for expedited review, please make the case below. See research ethics 
website for an example “case for expedited review”.
C3) Case for Expedited Review - To be used if asking for expedited review despite answering YES to 
questions in C1 or NO to answers in C2.
The level of potential risk of harm to subjects is minimal as the collection methods described are 
oral swabbing techniques. The subjects will be monitored by approved staff at all times.
SECTION D ■ PARTICIPANT DETAILS
D1) How many participants will be recruited?
20
D2) How was the number of participants decided upon?
The number was decided to account for number of swabbing methods tested. This will also lower 
chances of sample variability caused by collecting from a smaller cohort.
D3)
a) Describe how potential participants in the study will be identified, approached and 
recruited.
Invitation for participation in the study will be posted on the University network, Sydney Jones 
Library, Harold Cohen Library and University Guild of students.
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b) Inclusion criteria:
The inclusion criteria will be healthy volunteers aged 18-30. All volunteers will be assessed by The 
student (Abadur Rohman) for norma! oral health (Primary teeth should be white and opaque with 
smooth surfaces on front teeth and grooved surfaces for back or posterior teeth, Permanent teeth 
should appear creamier in color and larger than primary teeth, Lips and tongue should be soft, 
pink, and moist tissues under the lip should appear pink or brown (depending on skin colour). The 
palate or upper groove of the mouth should be soft, pink and moist and skins and tissues of the 
face should not be bruised, swollen, or tender).A second opinion would be sought from Dr.
Bhavish Patel if conclusions are not accurately made. Any issues regarding oral health can be 
sought from Dr. Bhavish Patel.
c) Exclusion criteria:
Exclusion criteria will be assesed on oral health of individuals by the student (Abadur Rohman) 
and Dr. Bhavish Patel.
d) Are any specific groups to be excluded from this study? if so please list them and 
explain why:
No individuals will be excluded with regards to ethnicity/gender.
e) Give details for cases and controls separately if appropriate:
N/A
f) Give details of any advertisements:
Invitation for participation in the study wi!l be posted on the University network, Sydney Jones 
Library, Harold Cohen Library and University Guild of students.
D4)
a) State the numbers of participants from any of the following vulnerable groups and justify 
their inclusion
Children under 16 years of age; 0
Adults with learning disabilities: 0
Adults with dementia: 0
Prisoners: 0
Young Offenders: 0
Adults who are unable to consent for 
themselves:
0
Those who could be considered to have a 
particularly dependent relationship with the 
investigator, e.g. those in care homes, 
students of the PI or Co-applicants:
0
Other vulnerable groups (please list): 0
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b) State the numbers of healthy volunteer participants:
| Healthy Volunteers 20
D5)
a) Describe the arrangements for gaining informed consent from the research 
participants.
Information sheets and consent forms will be available both in electronic and paper form.
b) If participants are to be recruited from any of the potentially vulnerable groups listed 
above) give details of extra steps taken to assure their protection, including 
arrangements to obtain consent from a legal, political or other appropriate 
representative in addition to the consent of the participant (e.g. HM Prison Service for 
research with young offenders. Head Teachers for research with children etc.).
c) if participants might not adequately understand verbal explanations or written
information given in English, describe the arrangements for those participants (e.g. 
translation, use of interpreters etc.)
Arrangements will be made to help translate the documentation in various languages and where 
needed Involvement of interpreters will be sort.
d) Where informed consent is not to be obtained (including the deception of 
participants) please explain why.
D6) What is the potential for benefit to research participants, if any?
The Benefits for the research are to assess the different whole saliva swabbing methods and 
how effective they are collecting whole saliva for subsequent testing.
D7) State any fees, reimbursements for time and inconvenience, or other forms of compensation 
that individual research participants may receive. Include direct payments, reimbursement of 
expenses or any other benefits of taking part in the research?
Fees for time and Inconvieniance caused during the study will be via direct payment of £10 per 
individual.
SECTION E - RISKS AND THEIR MANAGEMENT
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E1) Describe in detail the potential physical or psychological adverse effects, risks or hazards 
(minimal, moderate, high or severe) of involvement in the research for research participants.
The risks associated with the procedure are minimal, There are no adverse effects associated 
that are either physical or psychological. The procedure detailed previously will involve natural 
biting mechanism, any subsequent discomfort will be addressed. The procedures implemented 
express negligible adverse effects.
E2) Explain how the potential benefits of the research outweigh any risks to the participants.
The potential benefits of the research outweigh the risks, as the methods used involve minimal 
risk. The potential benefits of conducting the research illustrate the promotion of whole saliva and 
its implications to be used as effective diagnostic medium for the assessment and treatment of 
disease states.
E3) Describe in detail the potential adverse effects, risks or hazards (minimal, moderate, high or 
severe) of involvement in the research for the researchers.
The risk and hazards to the researchers are minimal. The policies directed in the university code 
of research practice will be adhered to strictly.Both informed consent and safe tissue disposal in 
accordance to the human tissue act will be adhered to.AII Samples will be placed in to 
preservative post collection to prevent bacterial growth.AII Samples will be handled in a class II 
cabinet during testing.
E4) Will individual or group Interviews/questionnaires discuss any topics or issues that might be 
sensitive, embarrassing or upsetting, or is It possible that criminal or other disclosures 
requiring action could take place during the study (e.g. during interviews/group discussions, 
or use of screening tests for drugs)?
YES □ NO El
> /f Yes, give details of procedures In place to deal with these Issues.
E5) Describe the measures in place in the event of any unexpected outcomes or adverse events 
to participants arising from their involvement in the project
The measures in place will adhere to university of Liverpool regulations of reporting serious 
adverse events. These will be stipulated on both consent forms and questionnaires. The 
research will be halted by the principal investigator and the event reported and logged to the 
CORE, Sub-committee or departmental ethics board (research governance officer within 24 
hours of the incidence).
E6) Explain how the conduct of the project will be monitored to ensure that it conforms with the 
study plan and relevant University policies and guidance,
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The research will be monitored using the university code of research practice.
SECTION F • DATA ACCESS AND STORAGE
F1) Where the research involves any of the following activities at any stage (including
identification of potential research participants), state what measures have been put in place 
to ensure confidentiality of personal data (e.g. encryption or other anonymisation procedures 
will be used)
Electronic transfer of data by magnetic or 
optical media, e*mail or computer networks
Anonymisation
Sharing of data with other organisations N/A
Export of data outside the European Union N/A
Use of personal addresses, postcodes, 
faxes, e-mails or telephone numbers
N/A
Publication of direct quotations from 
respondents
N/A
Publication of data that might allow 
identification of individuals
N/A
Use of audio/visual recording devices N/A
Storage of personal data on any of the 
following:
Manual files N/A
Home or other personal computers N/A
University computers Anonymisation/Encryption
Private company computers N/A
Laptop computers N/A
F2) Who will have control of and act as the custodian for the data generated by the study?
The custodian for all data generated will be both the principal investigator Dr. Stuart Marshail- 
Clarke.
F3) Who will have access to the data generated by the study?
Access to the data will be available to Dr. Stuart Marshall-Clarke, Abadur Rohman.
F4) For how long will data from the study be stored?
Data and tissues will be stored in compliance with the human tissue act.
SECTION G - PEER REVIEW
Research Ethics Application Form 
Version 4.1 5
11/1/11
231
G1)
a) Has the project undergone peer review?
YES □ NO S
b) If yes, by whom was this carried out? (please enclose evidence if available)
SECTION G ■ CHECKLIST OF ENCLOSURES
Study Plan / Protocol
Recruitment advertisement
Participant information sheet
Participant Consent form
Research Participant Advocate Consent form
Evidence of external approvals
Questionnaires on sensitive topics
Interview schedule
Debriefing material
Other (please specify)
Evidence of peer review (If G1 = Yes)
Yes
Yes
Yes
Yes_
N/A
N/A
N/A
N/A
N/A
N/A
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Appendix B
Materials
Chemicals and Biological compounds
All chemicals and Biological compounds used were of analytical 
grade. Purchased from Sigma Aldrich (UK).
Elisa Test Kits
Human IgG Elisa Quantitation Kit Bethyl Laboratories Inc
(Montgomery, USA)
Human IgA Elisa quantitation Kit Bethyl Laboratories Inc
(Montgomery, USA)
Human IgM Elisa quantitation Kit Bethyl Laboratories Inc
(Montgomery, USA)
Human albumin Elisa quantitation kit Bethyl Laboratories Inc 
(Montgomery, USA)
Salivary alpha amylase detection kit (Salimetrics Europe,
Suffolk,UK),
Human salivary cortisol detection kit (Salimetrics Europe,
Suffolk,UK),
Human Salivary cotinine detection kit (Salimetrics Europe,
Suffolk,UK).
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Oral fluid collection materials
All biomaterials tested and utilised for the Seradate were acquired 
from
Filtrona Inc (Filtrona Fibertec GmbH.Reinbeck, Germany)
Forex Technologies (Forex Technologies GmbH, Aachen, Germany) 
Oral fluid collection devices
Prototype collection Device Seradate
Seradate is an oral fluid swab prototype (University of Liverpool). It is 
made of two hydrophilic material surfaces supplied by Filtrona 
Fibertec. (Germany).
Orasure
Orasure oral fluid collection device (Orasure Technologies Inc, 
Bethlehem, Pennsylvania) is an absorbent cotton pad affixed to a 
nylon stick. The pad was treated with a buffered salt solution (0.1% 
gelatine, 3.5% sodium chloride, 0.3% citric acid, 0.1% potassium 
sorbate, 0.1% sodium benzoate pH 7.2). It has its own preservative 
solution (0.8 ml aqueous antimicrobial preservative solution 0.5% 
Tween-20, 0.01% chlorohexidine digluconate)
Salivette
Salivette saliva collector (Sarstedt Numbrecht, Germany) is a plain 
cylindrical cotton swab designed specifically to collect saliva.
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Oracol
Oracol oral fluid collector (Malvern Medical Developments, 
Worcester, UK) is a hydrophilic foam pad affixed to a nylon handle). 
It targets a mixture of OMT and saliva.
Concateno Certus
Certus oral fluid collector (Concateno global drug testing services, 
London UK) is made of a hydrophilic cylindrical polymer affixed to a 
ergonomic handle with incorporated volume adequacy indicator 
(white to blue once sufficient fluid has been collected £lml)
Solution and Buffers
For Human IgG, IgA, IgM Elisa Assay
Phosphate Buffered Saline X10
NaCI 
KCI
Na2HP04 
KH2PO4
Coating Buffer
0.05 M Carbonate-Bicarbonate, pH 9.6, dissolved capsule in 100ml 
of distilled water
1L
80g
2g
14.4g
2.4g
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Wash Solution
Phosphate buffered saline, 0.05% Tween 20, pH 8.0, 10X PBS (1:10 
dilution of Stock) and 500pl of Tween 20. Final volume 1L.
Blocking (postcoat) Solution
Phosphate buffered saline, 1% BSA, pH 8.0, PBS (1:10 dilution of 
Stock) 10g BSA. Final volume 1 L
Sample/Conjugate Diluent
Phosphate buffered saline 1 % BSA, 0.05% Tween 20, pH 8.0, PBS 
(1:10 dilution of Stock) 10g BSA, 500ul of Tween 20. Final volume 
1 L
Enzyme Substrate
Tetra-methyl benzidine (TMB). Use Neat as directed by 
manufacturer’s instruction.
Stopping Solution
4M H2S04(1 part H2S04:4 parts H20)
Calibrator for standard curve
Human reference serum amount: 0.1 ml Concentration
236
A
nt
ib
od
ie
s 
us
ed
 in
 th
e 
te
st
in
g 
of
 O
FC
D
S
E
O)
E
1 m
g/
m
l
1 m
g/
m
l
1 £ £CO 0_03 E tj
3 03
x 03
CO "o CD
031 - ro—1— (0 03,± 03 3
£ .S, E?co c: Q _ >40 O .E T30 1= O
to CL Q_ 5 rS
0 a: X -Q C
CD x X < <
>1
ojQ
'-4—'c<
co
CJ
&0)r>
a
n:
o>
£
COD>p
'cTo
o
D_
az
x
CD
0) -i—' 
(0 O) Z3
'c*oo
n
X
o</)
't:oo
T30J
CO
CDZ3
‘E’O
o
O-
X
>.T3O
c
CO
CD,C
oo
TJOJ
to
CD
C3
E'oo
a.
x
x
>»■ao.a
c:
co
CD
.E
too
o
c
CO
3
,± >.
c
CO
03
TJ
CD
3a.
c
CO
E
3
X
■43 ^
C 
CO
c
t:
CO
03
TJ
CD
3Q.
C
5j=
CO
■O
CD
3a.
.&■
£
i
E
£
3
<
CO
E
3
X
"O
oJQ
£
CO
03
to
oo
V3
03
XJ
O
■Q
£
CO
O
t/3
'•E
oo
03.-t: cJT3 * f— r> .E 
CO -g 
X o
<
03
CD
03
£
E OC/3
3
X3 O
< O
23
7
2.3 Buffers for 2D gels
Buffers
Running Buffer (10x)
Add 800ml of distilled water into a 2 litre container. Add 29g Tris base, 144g glycine 
and 10g of SDS. Total volume 1 litre with distilled water. Stir solution using a 
magnetic stirrer.
Running Buffer (1X)
Add 100ml of 10X running buffer to 900ml distilled water.
Resolving Gel Buffer (3M Tris-HCL at pH 8.85)
Add 36.3g tris base to 50ml distilled water, stirred until dissolved. pH to 8.85 using 
concentrated HCi. Make up total volume to 100ml with distilled water.
Stacking Gel Buffer (1.25M Tris-HCL at pH 6.8)
Add 15.1g tris base to 50ml of distilled water, stir solution using a magnetic stirrer. 
pH to 6.8 with concentrated HCI. Make up the Total volume to 100ml with distilled 
water.
SDS 10%
Add 10g of SDS to 50ml of distilled water, total volume to 100ml with distilled water, 
solution is stirred by magnetic stirrer.
APS
Add 100mg of APS in 1ml distilled water.
Buffers for IEF
IEF Rehydration Solution (8M Urea 2M Thio urea)
4% Chaps,12g Urea, 3.8g of thiourea and 1g of Chaps. Total volume to 25ml. Rotate 
until fully dissolved, add 2 or 3 grains of bromophenol blue. Store at -20°C.
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Equilibration Buffer
43.47g of glycerol, 4ml of stacking gel buffer (1.25M Tris-HCI @ pH 6.8), 36.04g of 
urea and 2g of SDS. Make volume up to 100ml. When dissolved add 2 or 3 grains of 
bromophenol blue. Store at “20°C
Agarose Sealing Solution
Add 1g of agarose to 100ml of Running Buffer (1X), heat at 100°C until dissolved. 
Add 2 or 3 grains of bromophenol blue and store at room temperature (25°C)
Silver staining solutions
Fixing solution
25ml acetic acid, 100ml methanol, 125ml distilled water 
Sensitization solution
30ml methanol, 1.0g sodium thiosulphate, 6.8g sodium acetate, 66ml distilled water 
Silver stain solution
0.25g silver nitrate, 100 ml distilled water 
Development solution
2.50g sodium carbonate 100ml distilled water 40ul formaldehyde 
Stop solution
1.46g EDTA, 100ml distilled water
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Buffers for 1D page
5x Sample Buffer
10% w/v SDS 10nM Dithiothreitol 20% v/v Glycerol 0.2M Tris-HCL 0.05%w/v 
bromophenol.
Running Buffer (10x)
To 1000ml of distilled water add 29g tris base, 144g glycine and 10g of SDS. Stir 
until dissolved via magnetic stirrer.
Running Buffer (1X)
100ml of 10X running buffer to 900ml distilled water.
Resolving Gel Buffer (3M Tris-HCL pH 8.85)
To 100ml distilled water add 36.3g tris base, stir until dissolved. pH to 8.85 with 
concentrated HCL.
Stacking Gel Buffer (1.25M Tris-HCL pH 6.8)
To 100ml of distilled water add 15.1g tris base, stir until dissolved. pH to 6.8 with 
concentrated HCL.
SDS 10%
To 100ml of distilled water add 10g of SDS,
APS
Dissolve 100mg of APS in 1ml of distilled water.
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Appendix C
• GCF collection and feedback
• Feedback questionnaire for OFCDS
GCF Sample Collection
Volunteer Smoking status Site of collection Number of samples
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GCF Sample Collection
Volunteer Aesthetics Ease of Collection Comfort Overall
experience
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An aueesmont of different oral swabbing methods In the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box:
Cpental visits | Regular J | Fairty regular | Ocassionaly [ Hardly | Never
Feedback on swabbing methods (Scale 1-10 1« very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
Method 1
Method 2
Method 3
Method 4
Method 5
Method 6
Further Comments (please continue overleaf if required)
Version 3.0
244
^ewvJb.,^
UNIVERSITY OF
LIVERPOOL
An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box:
| Dental visits 1 Regula~ Fairty regular | Ocassionaly Never
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
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Further Comments (please continue overleaf if required)
Aesthetics Ease of collection Comfort Overall experience
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Method 7 NULL
Version 3.0
245
An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number .. ' “
Smoking Status
Please tick appropriate box:
Dental visits [Regular | Fairly regular | Ocassiona:y t '' Hai^ly | Never ~|
Feedback on swabbing methods (Scale M01= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
Method 1 \0 lc? to
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box:
1 Dental visits 1 Regular" Fairly regular Ocassionaly Hardly Never
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort
Overall experience
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number ----------------------------
Smoking Status
Please tick appropriate box:
I Dental visits Fairly regular | Ocassionaiy [ Hardly
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Never
Aesthetics Ease of collection Comfort Overall experience
Method 1 X 4 i
Method 2 5 r r
Method 3
r
Method 4 $ i
Method 5 f x X
Method 6
Method 7
Further Comments (please continue overleaf if required)
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status
yimin /o j/m
iicrTi hrnp fjO tvirryp
Please tick appropriate box:
Dental visits Regular ( Fairly regular Ocassionaly Hardly Never
Feedback on swabbing methods (Scale M01= very poor; 10= excellent)
Aesthetics Ease of collection Comfort
Overall experience
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box; 
1 Dental visits 1 Regular Fairly regular /1 Ocassionaly Hardly Never
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status ^■i
Please tick appropriate box:
| Dental visits' "RPOtilar y7 I Fa 'ly regular I OcassionalY [ MdiUy I Never
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
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Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box:
Dental visits | Regular rly regular) | Ocassionaly | Hardly Never
Feedback on swabbing methods (Scale 1*101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
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Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box: 
Dental visits (Regular Fairly regular | Qcassionaly I Hardly ncvui □
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
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Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box:
—L^jgLjZ^^ii£regt^ I Qcassionalv' ^HHard^' | Nevef 
Feedback on swabbing methods (Scale M01= very poor; 10= excellent)
Aesthetics Ease of collection Comfort
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status
Please tick appropriate box:
1 Dental visits 1 Regular^) | Fairly regular | Ocassionaly 1 Hardly [ Never
Feedback on swabbing methods ( Scale 1-10 1= very poor ; 10= excellent)
Aesthetics Ease of collection comfon Overall experience
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Feedback Questionnaire
ParticipantnumbeF
Smoking Status__
Please tick appropriate box. 
Dental visits Fairly regular | Ocassionalv^ 1 Hardly Never
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number
Smoking Status
t
Please tick appropriate box
[Dental visits [Regular 1 Fairly regular ! Ocassionaly ’Hardly TNever ]
Feedback on swabbing methods ( Scale 1-10 1= very poor, 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number 
Smoking Status
Please tick appropriate box:
[Denial visits TRegular " I Fairly regular f Ocassionaly ~THardly ~~ ~| Never ~ |
Feedback on swabbing methods (Scale 1-10very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
Method 1 0 L
Method 2 7 7 L 7*
Method 3 5 8 L K
Method 4 rj. 1 b
7
6
LMethod 5 7
Method 6 i 7- 7
Method 7 NULL
Further Comments (please continue overleaf if required)
Version 3.0
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
1 Participant number
[Smoking Status
Please tick appropriate box:
Dental visits 1 Regular [ Fairly regular [ Ocassionaly j Hardly | Never
Feedback on swabbing methods ( Scale 1-10 1= very poor; 10= excellent)
Aesthetics Ease of collection Comfod
Method 1 (o L ~Xr
Method 2 f ? 7 T
Method 3 1 / ~ ~r7 %
Method 4 1 / r7
Method 5 i & 7 c
Method 6 x S / 7
Method 7 NULL
(
Further Comments (please continue overleaf if required)
Version 3.0
ii n —
V./ fVoA^ rwjs loT
j n i v e p.sn Y OF
LIVERPOOL
An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
1 ParticipanTnumber
| Smoking Status
Please tick appropriate box
1 Den-1 v'sits—1 Regular  1 Fairly regular l~Ocassionaly [ Hardly [ Never ]
Feedback on swabbing methods ( Scale 1-10 1= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
Method 1 y7 1
Method 2 -A /;
Method 3
Method 4
Method 5 b 1 _
Method 6
Ji 0
Method 7 NULL
Further Comments (please continue overleaf if required)
Version 3 0
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An assessment of different oral swabbing methods in the collection of wnoie saliva
Feedback Questionnaire
Participant number 
Smoking Status_ _
Please tick appropriate box.
1 Dental visits 1 Regular | Fairi^regular : Ocassionaly ' Hardly
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
Method 1
Method 2 £ V
Method 3 t 7 f >
Method 4 7 ;
Method 3 i r
Method 6 7 > ______
Method 7
~r-
NULL
Further Comments (please continue overleaf if required)
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V LIVERPOOL
An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
j Participant number 
[ Smoking Status _
Please tick appropriate box:
[ Dental visits TReguiar | Fairly regular 1 Ocassionaly 1 Hardly Never
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
Method 1
c. 4 i
Method 2
-IJ 1
Method 3 -4—1
1
_____
Method 4 i 1
Method 5 > 4 1 —-------- 1______C
Method 6
^ j JL 2
Method 7 NULL
Further comments (please anlmue overleaf if required)
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An assessment of different oral swabbing methods in the collection of whole saliva
Feedback Questionnaire
Participant number 
Smoking Status 
Please tick appropriate box
roental visits { Regular | Fairly regular 1 Ocassionaly lHardly_ _ _ _ 1 NevSf
Feedback on swabbing methods (Scale 1-101= very poor; 10= excellent)
Aesthetics Ease of collection Comfort Overall experience
Method 1 Q e e e
Method 2 _ r 1 V
Method 3 1 a 3 Q
Method 4 b & 3 £
Method 0 8 1 e ---- Vi---- ---
Method 6 3 3 n.
Method 7 NULL
Further Comments (please continue overleaf if required)
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All questionnaires beyond this point were done on a scale of 7- 
5. For purposes of the study all values were doubled to coincide 
with the 1-10 scale used.
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Participant
Age ££ 
Sex
Method
Comfort Ease of Use Looks Experience
Saliva 3 5 ] b
Salivette 1 3 Z
Device 1 i ( 1
■
Concateno 3 3 5 3
.
Oracol k 5 *
Orasure <0 *7
Key: rating 1-5 ( 5= Highest)
Further Comments
_Sh*^
Sexrf
Method
Comfort Ease of Use Looks Experience
Saliva h f
•: v - ■
.
Sallvette X
Device z 2
Concateno h 5
Oracol A 5 5 h
—-----------------
Orasure 2 5 4 3
Key: rating 1-5 ( 5= Highest)
Further Comments
Participant '<SHoK,e^
S6X £
Method
Comfort Ease of Use Looks Experience
Saliva §2 % ^ ^ 1
Salivette 3 5 3 ?-3>
Device 2. 3 2
Concateno
'+- 4- 4-
Oracol 4- s M'
: ■ - ' - . ’ ..
Orasure
M- 4- 3 4-
Key: rating 1-5 ( 5= Highest)
Further Comments
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Af+jQ 
Sex ^
Participant
J>wijur
Method i
Comfort Ease of Use Looks Experience
Saliva
h 5 f
- •
Salivette X 3
Device Z 2
Concateno 5 3 3
Oracol 5 5 4
. -
Orasure X
___________ \ 3
Key: rating 1-5 (5= Highest) 
Further Comments
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Age
Sex
Method
Comfort Ease of Use Looks Experience
Saliva r X 4
Salivette 5. * r 3
Device S /
Concateno 3. 3
Oracol lr 4- If
Orasure 2 % 3
Key: rating 1-5 ( 5= Highest)
Further Comments
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Participant
Age 21
^ Male.
Method
Comfort Ease of Use Looks Experience
Saliva a a A
Salivette i 3> 1
Device i 1 3 2.
1
—
Concateno %
. .
Oracol
2 1 3> a
erasure 3 JlJ l
Key: rating 1-5 ( 5= Highest)
Further Comments
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Participant
*» 50 /eavS •
s*« Wv •
Method
Comfort Ease of Use Looks Experience
Saliva
Salivette
hcr\k/\$
Cb^vt
ehsjS) ($)
Device
<£> © ©
Concatpnn 2> © &
Oracol
&> rw
. ..
Orasure <iS s> © ©
Key: rating 1-5 {5= Highest)
Further Comments
- vs>
" <^CK^vXs^W^ v^V (o
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Participant
Age
Sex - /via* SrMok#./
Method
Comfort Ease of Use Looks Experience
^oXc.lu UsjoJsi/ 7aUao
cx uoUic to getSaliva 2 :
S' 3* 3
Salivette r r 4
Device 33r 3 3 <3^, t CoUcT do o^. cv co^o/1
Co proteci:
Concateno
S' s' s' / iKC. ~ft\c£ i/'efij CjO to^" to MO-
Oracol < 4- £
Orasure 3
- . -
4- 4- 2 Qio^A i^sbrv-cJc/o^i) o*^pacK^v^/'/Oj
Key: rating 1-5 (5= Highest)
Further Comments
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Participant
Afe 2-2—
Sex ^U:
Comfort Looks Experience
Salivette
Device
Concateno
Oracol
Orasure
Key: rating 1-5 ( 5= Highest) 
Further Comments
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Participant
A*e *1/ £ /VA7 -
Sea yCy
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Participant
Age —
Sex
■■ ■■■
Method
Comfort Ease of Use Looks Experience
Saliva
5 5 5 Jr
jy, ,
Salivette 3 3
■7‘ ijlTlIi'X"''V 'j' "
Device 3 3
Concateno At
'
Oracol 3 2-
Orasure 3 Z 3 2_
Key: rating 1-5 (5= Highest)
Further Comments
275
Participant
*« §0 /ecwS •
S« •
Method
Comfort Ease of Use Looks Experience
Saliva
— ----------^
Salivette
netwW ec&fs) CD
Device
& © <©)
concatenn (D ©
Oracol
db
Orasure & & © ©
Key: rating 1-5 {5= Highest)
Further Comments
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Participant
Age ££ 
56,1
Method
Comfort Ease of Use Looks Experience
Saliva 3 1 X/
Salivette t k 3 z
... ,
Device 1 1 ( 1
Concateno 3 3 5
Oracol 4 5 5
Orasure 5
Key: rating 1-5 ( 5= Highest) 
Further Comments
277
Participant
Age 2J
S Moks-ir'
Method
Comfort Ease of Use Looks Experience
Saliva z 3 3
1 HIIX* .
Salivette \ 3 2 2.
—i.-— v*1»‘"rr«m
Device \ 1 1 (
Concateno
mu—**
3> 4* 3 3
...
Oracol S 4T 4-
Orasure 4- 4- 4-
Key: rating 1-5 (5= Highest)
Further Comments
Participant
Aee ^ £U10I&Z
Method
Comfort Edse of Use Looks Experience
Saliva <r c w//t . r'
—
Salivette 4 2 2
Device / / 1 /
SSPS7!
Concateno i 4 4 4
—-------—
Oracol 3 3
-- '
Orasure &\ 3
------------- --
Z
--------------
2
Key: rating 1-5 ( 5= Highest)
Further Comments
279
